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ADAM10 is a ubiquitously-expressed ‘molecular scissor’ that regulates a variety of 
important transmembrane proteins by proteolytically cleaving their extracellular regions. 
The cellular localisation and substrate specificity of ADAM10 is regulated by one of six 
tetraspanin membrane proteins, termed TspanC8s, comprising Tspan5, 10, 14, 15, 17 and 
33. This has led to the hypothesis that ADAM10 exists as six different scissors, depending 
on its interacting TspanC8. This thesis investigates the function of Tspan15, which is of 
interest due to its recent implication in cancer, deep vein thrombosis and bacterial 
infection. The new discoveries of this study are as follows. (1) Tspan15 expression is 
dependent on ADAM10. (2) Tspan15 is required for cleavage of neural-, epithelial- and 
vascular endothelial-cadherin in cell lines. (3) Two of four newly-generated anti-Tspan15 
monoclonal antibodies have inhibitory activity directed against ADAM10-mediated 
cleavage of VE-cadherin, which cannot be explained by recognition of different epitopes 
or differential effects on Tspan15 internalisation or ADAM10 expression. (4) Loss of 
ADAM10 in human endothelial cells promotes migration, increases proliferation and 
impairs network formation, but loss of Tspan15 has no effect. These findings support the 
six-scissor hypothesis, suggest that the major function of Tspan15 is to regulate ADAM10, 
and demonstrate the therapeutic potential of TspanC8 monoclonal antibodies. 
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1.1 A disintegrin and metalloproteases 
(ADAMs) 
 
1.1.1 Shedding overview 
 
The landscape of proteases on the cell surface adds variety to the repertoire of surface 
proteins and their functions. Indeed, membrane proteases contribute towards the activation 
or inhibition of signalling cascades, and also form a part of the degradation machinery for 
unwanted proteins to maintain proper physiological function (Lopez-Otin and Bond, 
2008). Thus, proteolytic release of the ectodomains, or ‘shedding’, of membrane proteins 
emerges as an essential mechanism in controlling various biological events including 
embryonic development, cell adhesion, migration and differentiation, necessary for the life 
of all organisms (Weber and Saftig, 2012). Dysregulation of proteolytic systems is 
associated with many pathological conditions like cancer, neurodegenerative disorders, 
inflammatory and cardiovascular diseases (Giebeler and Zigrino, 2016). The shedding 
process is directed towards membrane-tethered proteins. Proteolytic shedding occurs at the 
juxtamembrane site, freeing a soluble ectodomain and leaving a membrane-associated 





In the shedding of cytokines or growth factors, like tumour necrosis factor α (TNF), 
transmembrane chemokine (CX3CL1), and the epidermal growth factor (EGF) family, the 
released extracellular fragment is biologically active and capable of initiating paracrine 
signalling (Lopez-Otin and Bond, 2008, Clark, 2014). The cleavage is also a prerequisite 
for intracellular signalling, which is mediated by intracellular protein domain release from 
the membrane through the action of -secretase. This process is known as regulated 
intramembrane proteolysis (RIP) and has a role in signal transduction and also contributes 
to the degradation of proteins (Lichtenthaler et al., 2011). A few proteins are known to be 
subjected to this double cleavage, among them Notch receptors (van Tetering et al., 2009), 
APP- (Postina et al., 2004), heparin binding (HB)-EGF (Nanba et al., 2003), the cadherin 
family of cell-cell ahesion proteins (Maretzky et al., 2005, Reiss et al., 2005, Schulz et al., 
2008), the adhesion protein CD44 (Nagano et al., 2004) and a disintegrin and 
metalloproteases (ADAMs) themselves (Tousseyn et al., 2009). Besides the signalling role, 
the proteolysis can abolish the function of proteins at the cell surface. This downregulation 
most commonly happens in cis, on the same cell, such as for endothelial adhesion 
molecule VE-cadherin (Shultz et al., 2008) or growth factor receptor VEGFR2 (Donners et 
al., 2010), that results in cell detachment or inhibition of signalling, respectively. In one 
case it has been reported on opposite cells, in trans, for ADAM10 cleavage of ephrin-A5 
following engagement with its Eph-A3 receptor on an adjacent cell, a process which 
enables termination of signalling and the contact repulsion of neuronal cells (Janes et al., 





1.1.2 ADAM family 
 
The ADAMs belong to an evolutionarily conserved superfamily of Zn
2+
-dependent 
metalloproteinases. They are type I transmembrane glycoproteins of about 750-900 amino 
acids in length and identified in a broad range of animal classes including nematodes, sea 
urchins, fruit flies, frogs, birds and mammals (Weber and Saftig, 2012). 22 ADAM 
members have been identified in human and 12 of them (ADAM 8, 9, 10, 12, 15, 17, 19, 
20, 21, 28, 30 and 33) are found to be enzymatically active. Over the years, studies have 
highlighted their roles as sheddases and modulators of cell-cell adhesion and cell-matrix 
interactions, with some variations in substrate specificity (Endres and Deller, 2017). 
Expression profiles of the ADAMs can vary considerably. ADAM9, 10, 15 and 17 are 
ubiquitous, whereas other ADAMs are expressed in a tissue-type restricted manner like 
ADAM12 and 19 in muscle, ADAM22 in the brain and ADAM23 in the heart and the 
brain (Hartmann et al., 2013, Edwards et al., 2008). ADAMs are involved in the shedding 
of a plethora of transmembrane proteins like growth factors and their receptors, adhesion 
molecules, as well as cell cytokines, among others (Reiss and Saftig, 2009). 
 
The uniqueness of the structural organisation of ADAMs allows them to exhibit proteolytic 
activity towards their substrates on the cell surface. Typical ADAM structure shares a 
modular topology (Figure 1.1). Starting from the N-terminal signal sequence that directs 
the enzyme through secretory pathways, the first domain is a pro-domain (in the immature 
form of the protein, which controls enzyme latency and correct folding). This is followed 









disintegrin domain and cysteine-rich region that together contribute to substrate 
recognition and ADAM catalytic activity (Janes et al., 2005). This is followed by an EGF 
domain, except for ADAM10 and 17. This region has been thought to contribute to the 
regulation of substrate binding to the cysteine-rich domain. Lastly, there is a 
transmembrane region and cytoplasmic tail equipped with proline-rich motifs, recognising 
SH3 domain-containing proteins, and phosphorylation sites. The tail has been postulated to 





Figure 1.1 Schematic representation of modular domain organisation of ADAM 
family proteins.  N-glycosylation sites represented by ovals. 
 
 
Metalloproteases are produced as inactive proenzymes in the endoplasmic reticulum (ER). 
Their activation and subsequent maturation take place in the ER and Golgi network, where 




As a consequence, the active site within the metalloprotease domain is revealed, and the 
enzymes can exert their proteolytic activity (Wong et al., 2015).  
 
There is no consensus sequence that indicates the cleavage site in the substrates subjected 
to proteolysis by ADAMs. Nevertheless, the cleavage occurs close to the plasma 
membrane (Hogl et al., 2011). The proteomic identification of ADAM10 cleavage sites 
identified specificity for basic and aromatic amino acid residues like leucine, tyrosine and 
phenylalanine (Tucher et al., 2014). Additionally, other features like the substrate-binding 
pocket within the metalloprotease domain, the presence of non-catalytic domains and 
conformational change within the substrate may facilitate substrate recognition (Janes et 






1.2.1 Structure and function of ADAM10 
 
To date, ADAM10 (Kuzbanian orthologue in Drosophila), along with its close relative 
ADAM17 (TACE, tumour necrosis factor  (TNF) converting enzyme), is the best 
characterised ADAM. ADAM10 has a ubiquitous expression profile in mammalian cell 
types and a broad list of identified substrates (Hartmann et al., 2013). Additionally, genetic 
deficiency of the protease yields severe phenotypes during embryogenesis that have lethal 
consequences for both vertebrates and invertebrates (Dreymueller et al., 2015, Saftig and 
Lichtenthaler, 2015).  
 
ADAM17 is particularly important for inflammation, immunity and epithelial barrier 
integrity (Dreymueller et al., 2015). It is critically involved in first line of defence upon 
injury, by mediating proteolysis of TNF to stimulate the immune system, and EGFR-
ligands to promote epithelial cell proliferation and repair (Le Gall et al., 2010). Indeed, 
ADAM17-knockout mice die perinatally with defects in eyes, hair and in morphogenesis 
of multiple organs (heart, lung and skin), strikingly resembling phenotypes observed in 
EGF/transforming growth factor α (TGFα)/HB-EGF-deficient mice (Chalaris et al., 2010, 
Franzke et al., 2012, Jackson et al., 2003, Sternlicht et al., 2005). Mice with tissue specific 
deletion of ADAM17 are protected from endotoxin-induced septic shock and have reduced 





Rooke et al showed that a loss-of-function mutation in ADAM10 in Drosophila was 
critical for neuronal cell fate decisions (Rooke et al., 1996). These results were in line with 
those caused by mutations in Notch. In ADAM10-deficient fruit flies, the Notch receptor 
cannot be shed, which leads to abolished signalling and severe developmental defects 
(Sotillos et al., 1997). The mechanism underlying Notch signalling and its proteolytic 
processing is conserved in all multicellular organisms ranging from sea urchins to humans. 
ADAM10 is responsible for ligand-induced cleavage at the plasma membrane that enables 
intramembrane proteolysis by -secretase, release of the Notch intracellular domain and 
ultimately gene transcription in the nucleus (van Tetering et al., 2009).  
 
The importance of the protease is emphasized by the fact that ADAM10-deficient mice die 
at embryonic day 9.5 due to numerous defects in somite, cardiovascular and neuronal 
systems. This is similar to phenotypes observed in Notch1 and 4 double-knockout mice 
(Hartmann et al., 2002). Also, conditional deletion of ADAM10 in endothelial cells 
induces vascular abnormalities like those caused by interference with Notch signalling 
(Glomski et al., 2011). 
 
A recent discovery based on the first crystal structure of the ADAM10 ectodomain brought 
new insight into the architecture and domain organisation (Figure 1.2). Interestingly, the 
protease favours a closed “auto-inhibitory” conformation, where the cysteine-rich domain 
partially masks the active site within the metalloprotease domain. Therefore, access of the 
enzyme to substrates is restricted, although the catalytic site is in position to cleave the 
substrates close to the plasma membrane, presumably following a conformational change 






Figure 1.2 ADAM10 ectodomain structure.  On the left is the crystal structure of the 
ADAM10 ectodomain (Seegar et al., 2017) modelled onto the transmembrane region; on 





1.2.2 Regulation of ADAM10 
  
ADAM10 contributes to a broad range of cellular functions; therefore, its spatial-temporal 
regulation is of pivotal importance. The activity of the protease can be controlled by 
several mechanisms including regulation of gene expression, post-translational 
modifications, compartmentalisation at the plasma membrane and protein-protein 
interactions (Endres and Deller, 2017). The human ADAM10 gene is evolutionarily 
conserved, contains 16 exons and spans a total of 154 kb. The promoter region does not 
comprise a TATA box but has several transcription factors binding sites. The interactions 
with factors like specificity protein 1 (SP1), upstream stimulatory factor (USF), X-box 
binding protein-1 (XBP-1) and retinoic acid were found to be important to induce 
ADAM10 transcription and its availability within the cell, especially during Alzheimer’s 
pathogenesis (Peron et al., 2018). Upregulation of ADAM10 mRNA levels by retinoic acid 
receptor (RAR) was found to induce ADAM10 -secretase processing of amyloid 
precursor protein (APP), so decreasing amyloid- formation in vitro (Lee et al., 2014) and 
in vivo (Tippmann et al., 2009). Translational regulation of ADAM10 includes the 
interaction of microRNAs (miRNA) with the 3’ untranslated region (UTR) of ADAM10 
mRNA, and the presence of a GC-rich sequence in the ADAM10 5’ UTR region that forms 
G-quadruplex RNA secondary structures. Both factors act as negative regulators of 
ADAM10 genes, contributing to the suppression of ADAM10 protein levels (Endres and 
Deller, 2017, Peron et al., 2018). Depletion of endogenous ADAM10-targeting miR-122 in 
human hepatic cancer cells promoted a tumorigenic phenotype of the cells (Bai et al., 
2009), while destabilisation of the G-quadruplex dysregulated ADAM10-mediated APP 





ADAM10 is synthesised in the endoplasmic reticulum (ER) as an 85 kDa auto-inhibited 
pro-enzyme (Anders et al., 2001). After enzymatic removal of the prodomain in the Golgi, 
a 65 kDa mature and active form of ADAM10 is transported to the cell surface. ADAM10 
itself can be proteolytically processed by ADAM9, 15 and -secretase, leaving a 
membrane-bound C-terminal fragment (10 kDa) and releasing a soluble ectodomain of 55 
kDa and cytoplasmic fragment (7 kDa) (Tousseyn et al., 2009). However, the 
physiological relevance of this cleavage is unknown.  
 
Cellular compartmentalisation is thought to be important for ADAM10 regulation and 
activity. The mature ADAM10 is found to be associated with cellular trafficking 
regulators. For example, the cytosolic tail of the protease, via a proline-rich motif, binds to 
the SH3 domain of synaptic proteins like synapse-associated protein 97 (SAP97) (Saraceno 
et al., 2014) and adaptor protein 2 (AP2) (Marcello et al., 2013), that control transport to 
the plasma membrane and internalisation, respectively. Rab14 and its effector FAM116 
also have been suggested to promote ADAM10 trafficking and surface localisation 
(Linford et al., 2012). Additionally, ADAM10 was found to interact with tetraspanin 
trafficking proteins (Arduise et al., 2008), and this association is the only one to known to 
affect ADAM10 maturation and activity (Saint-Pol et al., 2017b); this is the focus of this 
thesis and will be introduced later.  
 
The composition of the plasma membrane is another crucial feature in ADAM10 
regulation. The association of ADAM10 within cholesterol-rich regions contributes to the 




increase in cholesterol levels, which often occurs in patients with Alzheimer’s disease, 
reduces the expression of ADAM10 (Sathya et al., 2017). The aforementioned may be one 
of the factors that prevent the production of a neuroprotective form of APP, instead 
generating toxic and insoluble Aβ peptides. This has crucial consequences for the 
progression of a disease state like Alzheimer’s disease, where the formation of amyloid 
plaques is elevated (Sathya et al., 2017). In contrast, cholesterol depletion may affect 
membrane fluidity and disassembly of membrane micro-platforms, which enhances 
substrate accessibility and ADAM10 mediated cleavage (Kojro et al., 2010, Peron et al., 
2018).  
 
ADAM functions have been shown to be controlled by various inhibitors and stimuli. The 
naturally occurring inhibitors are the ADAM10 prodomain (Moss et al., 2007) and 
endogenous tissue inhibitor of metalloproteases (TIMP-1 and -3) (Amour et al., 2000, 
Murphy, 2011). The synthetic inhibitor GI254023X binds the Zn
2+
 ion within the active 
site cleft of the metalloprotease domain and blocks its activity (Seegar et al., 2017). 
Although a broad inhibition of the protease is detrimental, as indicated by the lethal 
phenotype of the ADAM10-knockout mice, it is thought that a well-controlled dose of 
inhibitor may be useful for disease treatment (Ludwig et al., 2005).  
ADAM10 activity is enhanced by Ca
2+
 ionophores (Sanderson et al., 2005, Maretzky et al., 
2005), the alkylating agent N-ethylmaleimide (NEM) (Facey et al., 2016), or growth 
factors such as vascular endothelial growth factor (VEGF) (Donners et al., 2010). 
However, the exact mechanisms of their actions remain unknown. Donners et al 
demonstrated the increase in both the expression and activity of ADAM10 upon VEGF 




and VEGFR2 (Donners et al., 2010). In the aforementioned, ADAM10-mediated cleavage 
may further depend on activated extracellular signal-regulated kinase (ERK) 1/2 and 
phosphoinositide 3-kinase (PI3K) signalling pathways. Moreover, the agonists can 
modulate ADAM10 substrate selectivity. Ionomycin but not phorbol 12-myristate 13-
acetate (PMA) may stimulate the activity of ADAM10 towards TNF, TGF and L-
selectin in the absence of their principal sheddase, ADAM17 (Le Gall et al., 2009). The 
mechanism behind the inducible shedding is not well understood, but it may depend on the 
structural domains. Maretzky et al showed that the cytoplasmic domain negatively 
contributes to the constitutive activity of ADAM10 via an ER retention motif, but it is 
dispensable for rapid activation of the protease by NEM and ionomycin towards 
betacellulin. Instead, the authors emphasised the importance of the transmembrane region 
in this process (Maretzky et al., 2015). The results were in line with those previously 
reported by Horiuchi et al. The authors have shown that expression of an ADAM10 mutant 
with a truncated cytoplasmic domain partially rescue Ca
2+
-stimulated shedding of BTC in 
ADAM10-deficient cells (Horiuchi et al., 2007). This suggests that regulation may occur 
on the plasma membrane through interactions with putative ADAM10 binding partners and 





1.2.3 ADAM10 substrates 
 
1.2.3.1 Overview of ADAM10 substrates 
 
ADAM10 is a primary sheddase for more than 40 substrates; many of which have an 
impact on health and disease. These include the Notch cell fate regulator (van Tetering et 
al., 2009), junctional adhesion molecule VE-cadherin (Schulz et al., 2008), transmembrane 
chemokines CX3CL1 and CXCL16 (Hundhausen et al., 2007), APP (Postina et al., 2004); 
glycoprotein VI (GPVI) (Bender et al., 2010, Gardiner et al., 2007), EGF receptor (EGFR) 
ligands betacellulin and EGF (Yan et al., 2002, Sahin et al., 2004, Sanderson et al., 2005, 
Blobel, 2005), cellular prion protein (Altmeppen et al., 2015), cadherin and CD44 adhesion 
molecules (Nagano et al., 2004, Reiss et al., 2005, Schulz et al., 2008), the low affinity 
immunoglobulin E receptor CD23 (Lemieux et al., 2007), vascular endothelial growth 
factor receptor 2 (VEGFR2) (Donners et al., 2010) and many others. The ubiquitous 
expression and the substrate repertoire of ADAM10 contribute to a variety of biological 
processes, including cell fate and differentiation, chemotaxis, receptor-ligand signalling, 
vascular permeability, migration, proliferation and immunity (Pruessmeyer and Ludwig, 
2009, van der Vorst et al., 2012). Due to the biological importance of substrates cleaved by 
ADAM10, dysregulation of ADAM activity has been associated with pathologies such as 
cancer, cardiovascular disease, inflammation and neurodegeneration. Thus, targeting 
ADAM10 could have therapeutic potential (Wetzel et al., 2017). Many conditions, 
including cancer, inflammation, asthma and skin disorders, could potentially benefit from 
the inhibition of ADAM10 activity (Saftig and Lichtenthaler, 2015). For example, some 
breast tumours are characterised by an increased level of ADAM10, which contributes to 




inactivation of ADAM10 reduces breast cancer cell migration and invasion in vitro. 
Therefore, downregulation may be regarded as an approach that carries therapeutic benefit 
(Mullooly et al., 2015). In contrast, many disorders can benefit from induction of 
ADAM10 activity. These include Alzheimer’s disease, heart attack and stroke caused by 
thrombosis (Saftig and Lichtenthaler, 2015, Induruwa et al., 2016). For example, in an 
Alzheimer’s disease mouse model, the neuronal overexpression of ADAM10 was 
associated with a reduction of the pathologies associated with deposition of the 




One of the most important and well-studied ADAM10 substrates is Notch, for which there 
are four family members, Notch 1-4. Notch signalling is evolutionarily conserved within 
the animal kingdom, is involved in cell fate decisions and is a crucial developmental 
process (Weber and Saftig, 2012). Upon binding of a Notch ligand (for example Delta-like 
ligand 1) to the Notch receptor, ADAM10 liberates the Notch ectodomain. The remaining 
membrane-anchored fragment is processed by the -secretase complex that releases a 
Notch intracellular domain (NICD). The NICD fragment translocate to the nucleus where 
it is involved in transcription of Notch target genes (Kopan and Ilagan, 2009). Global 
ADAM10 inactivation is lethal at the embryonic stage (E9.5) in mice due to developmental 
defects in the neuronal and cardiovascular system (Hartmann et al., 2002), which is 
comparable to the features observed in Notch1 and 4 double-knockout mice (Krebs et al., 
2000). In angiogenesis, vessel sprouting and branching, as well as tip and stalk cell 




2011). Indeed, in mice with ADAM10-deficient endothelial cells, vascular integrity is 
impaired through hyper-sprouting of poorly perfused vessels and increased numbers of 
endothelial cells and cells displaying tip cell characteristics (Glomski et al., 2011, Caolo et 
al., 2015).  This is consistent with the findings of Lucitti et al where an increased number 
of collateral vessel formations was observed in mice with ADAM10-deficient endothelial 
cells, due to aberrant sprouting and branching (Lucitti et al., 2012). Indeed, expression of 
Notch target genes (the Snail transcriptional factor and bone morphogenetic protein 2 
(Bmp2)) is impaired in ADAM10-deficient endothelial cells, supporting the notion of 
ADAM10 involvement in Notch signalling (Zhang et al., 2010).  
 
1.2.3.3 Amyloid precursor protein (APP) 
 
Two alternative proteases mediate APP proteolytic processing: ADAM10 (-secretase) or 
-secretase (BACE 1), which lead to soluble APP (sAPP) or A peptide, respectively. 
The ectodomain cleavage leaves a membrane-tethered fragment that is further processed 
by -secretase, releasing an APP intracellular domain (Kogel et al., 2012). However, its 
exact role is still under discussion. Pathogenesis of Alzheimer’s disease is associated with 
the accumulation of toxic amyloidogenic A peptides in the cerebral cortex, which can be 
prevented by enhanced cleavage by ADAM10 and the subsequent generation of the 
neuroprotective sAPP (Marcello et al., 2017). Consistent with this, overexpression of 
ADAM10 in an Alzheimer’s disease mouse model reduced memory loss and 
neurodegeneration (Postina et al., 2004). Besides its well-established role in the brain, APP 
is abundantly expressed on platelets, where it limits venous thrombosis by inhibiting the 








Vascular permeability, integrity and migration are the crucial characteristics of the blood 
vessel endothelium. To uphold function of the vascular barrier these features must be 
finely tuned at the right time and place. Endothelial guardians for the aforementioned 
functions are present within the cadherin superfamily of Ca
2+
-dependent adhesion 
molecules (Figure 1.3) (Dejana and Orsenigo, 2013). 
Cadherins are type 1 single-pass transmembrane proteins which mediate cell-cell adhesion 
via trans-homodimerization and through cis-clustering of the cadherins at the cell 
junctions. While the extracellular domain drives adhesion from outside the cell, the 
intracellular domain mediates interaction with the actin cytoskeleton which induces 
changes to cell migration and morphology. To support the aforementioned functions, 
interaction between the cadherin intracellular domain and cytoplasmic binding partner 
proteins, p120-catenin and -catenin, is essential (Gartner et al., 2015). The interaction of 
p120 with the membrane-proximal region of the cadherin is required for stabilising 
cadherins at the cell surface, which enhances their adhesion strength and prevents 
endocytosis. Also, p120 was found to interact with Rho GTPases, which affects actin 
assembly and dynamics (Shapiro and Weis, 2009). As a component of adherens junctions, 
the adaptor -catenin has a dual function: it directly links cadherins to the cytoskeleton via 
-catenin, and also regulates gene transcription on the Wnt signalling pathway, when 




VE-cadherin is a crucial component of endothelial adherens junctions that mediates 
homotypic interactions and adhesion between endothelial cells. Therefore, it is required for 
the establishment of a stable vascular network by inducing contact inhibition of growth, 
regulation of endothelial permeability and leukocyte transmigration (Giannotta et al., 
2013). In vivo, intravenous administration of anti-VE-cadherin antibody induced 
redistribution of the protein from cell-cell junctions and increased permeability of the 
vascular layer (Corada et al., 1999). VE-cadherin gene deletion (or mutation) do not affect 
the early stages of de novo formation of blood vessels. However, the consequence is 
lethality at embryonic day 9.5, due to impaired maintenance and remodelling of 
endothelial cells into vascular structures (Carmeliet et al., 1999, Crosby et al., 2005).  
 
VE-cadherin function and expression at the cell surface are regulated through 
permeability-increasing agents (inflammatory cytokines, histamine, thrombin and VEGF). 
The VEGF/VEGFR2-activated signalling pathways promote uncoupling of the 
VEGFR2/VE-cadherin complex at the cell surface. Subsequent phosphorylation of the 
constituents and endocytosis of VE-cadherin contribute to the disruption of the cell-cell 
contacts and increased permeability of the vasculature (Gavard and Gutkind, 2006). Also, 
VEGF-induced endothelial cell survival requires formation of the complex between VE-
cadherin, catenin and VEGFR2. Carmeliet et al showed that deficiency of the cadherin 
gene, or truncation of its cytosolic domain in mice, impairs cell survival and induces 
apoptosis which in turn prevents angiogenesis (Carmeliet et al., 1999). VE-cadherin 
clustering induces contact inhibition of endothelial cells and subsequently blocks 
proliferation. Therefore, confluent cells poorly respond to VEGF signalling via the 





Shulz et al showed that VE-cadherin is shed by ADAM10, and that thrombin-induced 
ADAM10 shedding of VE-cadherin contributes to endothelial cell dissociation. 
Furthermore, siRNA knockdown of ADAM10 on endothelial cells increased VE-cadherin 
expression and decreased permeability of the endothelial barrier. In fact, elevated levels of 
soluble VE-cadherin and increased vessel leakage accompany vascular disorders like 
atherosclerosis and diabetic retinopathy (Schulz et al., 2008). Following up the Schulz 
publication, Donners et al demonstrated VEGF-induced VE-cadherin shedding by 
ADAM10, and its requirement for endothelial cell migration and vascular permeability 
(Donners et al., 2010). In vitro and in vivo studies also investigated histamine as an inducer 
of vascular permeability. This was effected by phosphorylation and delocalisation of VE-
cadherin, activation of protein kinase C (PKC) signalling pathways and cytoskeletal 
rearrangements (Ashina et al., 2015). In sepsis, increased levels of soluble VE-cadherin are 
associated with inflammation-induced endothelial barrier breakdown through the 
interference with binding affinities of endogenous VE-cadherin. The application of an 
ADAM10 inhibitor confirmed the proteolytic origin of the released fragment, and impaired 





A second cadherin expressed on endothelial cells is N-cadherin, but it is best characterised 
on other cell types such as epithelial cells, fibroblasts, neurons and cardiac myocytes 




maintains barrier function and as a positive regulator of proliferation, migration and 
invasion (Wheelock et al., 2008, Hazan et al., 2000, Vassilev et al., 2012). N- and VE-
cadherin share 38% amino acid sequence identity, and the cytoplasmic regions are most 
similar, at over 47% (Ferreri et al., 2008). Despite the close homology, N-cadherin differs 
in having diffuse distribution along the endothelium and mediating heterotypic interactions 
between endothelial cells and mural cells (Figure 1.3) (Salomon et al., 1992, Giampietro et 
al., 2012). The interruption of the heterotypic interactions between endothelial cells and 
pericytes, for example, leads to poor pericyte adhesion to endothelium, disturbed vascular 
morphogenesis and vessel elongation (Gerhardt et al., 2000). Previous work has shown that 
VE-cadherin’s presence at the junctions excludes N-cadherin from these sites, due to its 
higher affinity for p120-catenin (Navarro et al., 1998, Giampietro et al., 2012). However, 
in a separate study, N-cadherin was portrayed as a significant modulator of endothelial cell 
function and behaviour that localises to endothelial junctions. Indeed, endothelial cell-
specific inactivation of the N-cadherin gene causes embryonic lethality at day 9.5 in mice 
due to severe vascular defects including abnormal vessel organisation, endothelial cell 
death and impaired development of the heart (Radice et al., 1997, Luo and Radice, 2005). 
This, in fact, corresponds to the phenotype seen in VE-cadherin-deficient mice (Carmeliet 
et al., 1999). Interestingly, embryonic death happened before engagement of pericytes in 
the vasculature, implying that besides the role in vessel maturation, N-cadherin has a direct 
role in endothelial function (Luo and Radice, 2005, Ferreri et al., 2008). Luo and Radice et 
al concluded that N-cadherin regulates angiogenesis upstream of VE-cadherin, as N-
cadherin loss significantly reduced VE-cadherin and p120 surface expression (Luo and 
Radice, 2005). In the same study, the inactivation of N-cadherin by siRNA resulted in cell 




expression. Similar to promoting cell motility on endothelial cells, N-cadherin can 
stimulate epithelial cell behaviour. The cadherin switching (cadherin isoform switching) 
that occurs during epithelial-mesenchymal transition (EMT) contributes to upregulation of 
N-cadherin, that in turn modulates many aspects of epithelial cell behaviour in 
physiopathology (Wheelock et al., 2008). Finally, N-cadherin is functional on neuronal 
cells (Radice et al., 1997), and has a role in neuro-epithelial cell-cell adhesion, regulation 
of synaptic development, axonal extension and polarity (Huntley, 2002, Gartner et al., 
2015). 
Reiss et al have identified ADAM10 as the specific sheddase for N-cadherin (Reiss et al., 
2005), but the importance of N-cadherin shedding remains poorly understood. In 
fibroblasts and neuronal cells, N-cadherin processing by ADAM10 is thought to play a role 
in cell adhesion, migration and signalling. ADAM10-deficient fibroblasts showed 
upregulated adhesive behaviour and impaired β-catenin-dependent signalling due to the 
accumulation of full-length cadherin and β-catenin in intact adherent junctions. As a result, 
-catenin was inaccessible for Wnt signalling which is essential for proliferation and cell 
survival (Reiss et al., 2005). Not only full-length, but also shed N-terminal fragments of 
the cadherin, retain biological activities. Derycke et al reported that the cleaved, soluble 
fragment of N-cadherin promotes angiogenesis in vivo and wound healing in vitro, through 
N-cadherin/fibroblast growth factor (FGF)-receptor complex activation. Upon binding of 
the soluble fragment to the complex, expression of matrix metalloproteases (MMPs) and 
plasmin was upregulated, which in return induced angiogenesis (Derycke et al., 2006). 
Likewise, another study showed that N-cadherin expression induces cell motility by 
maintaining a high level of FGF signalling, leading to upregulation of migration-related 




1.2.3.6 E-cadherin   
 
E-cadherin has been identified as one of the most important ADAM10 substrates involved 
in epithelial morphogenesis, repair and integrity. E-cadherin is exclusively expressed on 
epithelial tissues. Mice with global E-cadherin deletion are embryonic lethal, highlighting 
its importance in development and tissue homeostasis. Also, tissue and organ-specific loss 
of the protein leads to early death due to aberrant cell morphology, increased permeability 
and tissue damage (Schneider and Kolligs, 2015, Schnoor, 2015). E-cadherin is cleaved 
specifically by ADAM10. E-cadherin shedding is associated with loss of cell adhesion and 
increased cell migration and proliferation in vitro and in vivo. Moreover, E-cadherin 
processing by ADAM10, and then -secretase, results in translocation of -catenin to the 
nucleus to activate Wnt signalling. This contributes to epithelial-mesenchymal transition 
(EMT) and invasive behaviour of tumour cells (Maretzky et al., 2005). Sorting and 
compartmentalisation of cells in epithelial tissue relies on strong adhesion between them. 
ADAM10-mediated shedding of E-cadherin influence asymmetric localisation of the 
protein and restricted boundary formation caused by scattered cells. This dispositioning of 
cells carries important consequences for tissue morphogenesis and homeostasis (Solanas et 
al., 2011). E-cadherin is known as a tumour suppressor gene, as mutations are associated 
with gastric, breast, collateral, thyroid and ovarian cancers (Pecina-Slaus, 2003). The loss 
of function or downregulation of E-cadherin is also associated with poor outcomes and 
survival in patients. Conversely, upregulation of E-cadherin on cells prevents 
carcinogenesis due to growth inhibition, cell cycle arrest and reduced invasiveness (Wong 
et al., 2018). Additionally, elevated levels of the soluble E-cadherin are a vital diagnostic 




-catenin, by keeping the junctions intact and stopping -catenin entering the nucleus to 
affect gene expression. Upon pro-inflammatory stimuli, such as TGF and cytokines, the 
areas affected by eczema lesions show upregulation of active ADAM10 and 
downregulation of E-cadherin, which correlates with impaired keratinocyte cohesion 
(Maretzky et al., 2008). 
Tissue integrity shaped by homotypic interactions between the cadherins on neighbouring 
cells is essential to hinder spread of pathogens such as bacteria. Identification of ADAM10 
as a receptor for Staphylococcus aureus -toxin raised significant interest in exploiting its 
activity as a therapeutic target. ADAM10-bound -toxin forms pores in the plasma 
membrane to induce Ca
2+
 influx and activate ADAM10. Subsequent E-cadherin shedding 
compromises the epithelial barrier allowing the bacteria to spread (Berube and Bubeck 
Wardenburg, 2013, Virreira Winter et al., 2016). Indeed, mice with conditional deletion of 
ADAM10 in respiratory epithelium were resistant to lethal pneumonia (Inoshima et al., 
2011). A similar process can occur on endothelial cells, but in this case -toxin induces 
ADAM10 shedding of VE-cadherin and subsequent breakdown of endothelial barrier 








Figure 1.3 Schematic representation of VE-cadherin and N-cadherin regulation of 
homotypic and heterotypic interactions on endothelial cells, respectively.  VE-cadherin 
is localised at adherens junctions between adjacent endothelial cells and mediates 
homotypic cell interactions. N-cadherin is dispersed along the endothelial surface and 
facilities heterotypic interactions between endothelial cells and pericytes. The mature 
cadherin forms Ca
2+
-dependent trans dimers between two adjacent cells via the 
extracellular domains. The highly conserved cytoplasmic domain forms a complex with 
armadillo family proteins (-catenin, plakoglobin, p120) that link to the actin filaments via 
-catenin. These structural units together contribute to the core functions of the cadherins, 






1.3 Tetraspanins as plasma membrane 
‘organisers’ 
 
1.3.1 Function and structure of tetraspanins 
 
Tetraspanins form a superfamily of evolutionary conserved transmembrane proteins with 
four transmembrane domains and a characteristic structure that will be discussed later 
(Figure 1.4). They are commonly expressed across animal and plant kingdoms with 33 
expressed in humans. Many tetraspanins are widely expressed, like CD9 and CD81. 
However, a number of them have a tissue or cell-specific expression, like CD37 and CD53 
on leukocytes, uroplakin (UP) 1a and UP1b on urothelium, or peripherin and ROM-1 on 
the retina (Hemler, 2005). Tetraspanins contribute to plasma membrane organisation 
through the ability to associate with one another and with interacting ‘partner’ proteins to 
form nanoclusters (Charrin et al., 2014). The current notion states that separate 
nanoclusters are devoted to a single type of tetraspanin. However, they can share recruited 
partner proteins like immunoglobulin superfamily members, integrins, proteases and 
intracellular signalling proteins (Zuidscherwoude et al., 2015). This spatial organization 
generates a dynamic network of interactions across the plasma membrane through which 
tetraspanins are believed to facilitate intracellular trafficking, signalling, clustering, lateral 
mobility and membrane compartmentalization of their partners. This can lead to the 
regulation of vital cellular events like adhesion, spreading, migration, fusion and signalling 





A relatively well-studied example of tetraspanin function is CD151 regulation of laminin-
binding integrins (31, 61, 64 and α7β1) (Sterk et al., 2002, Hemler, 2014). Indeed, 
CD151 restricts integrin diffusion mode to random-confined movements that facilitate 
integrin outside-in signalling and the availability to participate in cell adhesion and 
spreading functions (Yang et al., 2012). Loss of CD151 also decreases the adhesion 
strengthening towards laminins by an altered dynamic of integrin clustering (Lammerding 
et al., 2003). In addition, CD151 knockdown causes a reduction in integrin clustering that 
accompanies the effects on lateral diffusion (Yang et al., 2012), along with impaired 
recycling and redistribution of integrins away from the tetraspanin microdomains during 
cell migration (Winterwood et al., 2006, Yang et al., 2008). CD151-knockout mice have 
phenotypes consistent with impaired function of laminin-binding integrins, including 
kidney failure due to defective epithelial cell binding to basement membrane (Sachs et al., 
2006). Similarly, CD151 deficiency in humans leads to kidney dysfunction and skin 
blistering disease (Karamatic Crew et al., 2004). 
 
A second relatively well-studied tetraspanin is CD81, one function of which is to complex 
with B-cell co-receptor CD19 to regulate its glycosylation profile and trafficking from the 
ER to the cell surface. CD81-knockout mice, and a human patient with loss of CD81 due 
to a mutation, show reduced surface expression of CD19 (Shoham et al., 2003, Levy, 
2014). As a result, B cell receptor signalling is impaired and the mice and human have 






A third example of tetraspanin function is Tspan12 regulation of Wnt receptor Frizzled-4 
clustering and signalling via the Norrin ligand. Tspan12 is relatively highly expressed by 
endothelial cells in the retina, and loss of Tspan12 in mice results in impaired vascular 
development in the retina, which phenocopies deletion of Frizzled-4 (Junge et al., 2009). 
Moreover, in a mouse model of vasoproliferative retinopathy, anti-Tspan12 mAbs inhibit 
Frizzled-4/Tspan12-mediated -catenin signalling and prevent abnormal vessel growth 
(Bucher et al., 2018). In humans, mutations in Tspan12 and Frizzled-4 lead to the human 
disease familial exudative vitreoretinopathy, characterised by defective retinal vasculature 
and ultimately blindness (Poulter et al., 2010). 
 
An additional aspect of tetraspanins is that several of them are utilised by infectious 
pathogens to promote disease dissemination. Some pathogens interact directly with 
tetraspanins and use them as a means of spreading infections, while others exploit the 
cellular processes that tetraspanins are involved in, like exosome release, vesicle 
trafficking, internalisation and adhesion (Hemler, 2008, Monk and Partridge, 2012). For 
example, CD81-dependent entry and trafficking of the hepatitis C virus into hepatocytes 
has been well-studied. The virus entry is a multistage process and involves many proteins, 
including scavenger receptor class B type I (SR-BI), CD81, claudin-1 and occludins 
(Feneant et al., 2014). Furthermore, CD81 is a co-receptor for the protozoan Plasmodium 
(which is responsible for malaria), and is required for hepatocyte invasion in their 
sporozoite form, which sustains malaria infection. CD81 is crucial for the formation of 
parasitophorous vacuole, where the parasite acquires its exoerythrocytic form necessary for 
the disease (Silvie et al., 2003). Finally, adhesion of Neisseria meningitidis, 




epithelial cells involves their interaction with CD9, CD63 and CD151, and Salmonella 
typhimurium binding to macrophages involves CD63 (Green et al., 2011, Hassuna et al., 
2017). Tetraspanin knockdown, or pre-treatment of the epithelial cells with tetraspanin 
mAbs or recombinant forms of the major extracellular regions of tetraspanins, reduced 
adhesion of the bacteria (Green et al., 2011). More recently, peptides from the major 
extracellular region of CD9 were shown to inhibit S. aureus binding to keratinocytes 
(Ventress et al., 2016). The mechanism of action behind this striking finding remains 
unclear, but the data suggest that tetraspanin targeting has great potential as an anti-
bacterial therapeutic strategy. 
 
 
1.3.2 Structure of tetraspanins 
 
Tetraspanins are small molecules of 204 - 355 amino acids long with only a 5 nm 
projection over the plasma membrane. Tetraspanin structure comprises four 
transmembrane regions, two extracellular loops that are distinct in size, one inner loop, and 
N- and C- cytoplasmic tails (Figure 1.4). The structure of the tetraspanins supports 
intramolecular interactions mediated by features in the large extracellular loop and 
transmembrane regions. The large extracellular loop holds structurally essential cysteine 
residues (between 4 to 8), including a characteristic CCG motif, and disulphide bridges - a 
hallmark of the group. It is also the most diverse domain in the family and is where the 
functionally important variable region is located. The transmembrane domains include 
conserved polar and hydrophobic residues and are important for proper packaging and 




that tetraspanins with mutations in the transmembranes were unable to exit the ER and had 
impaired folding of the extracellular regions (Kovalenko et al., 2005). The intracellular 
events and protein organisation below the plasma membrane are believed to be regulated 
by the tetraspanin cytoplasmic tails, which are diverse in size and sequence homology. The 
C-terminus tail holds the YXX and/or PZD-binding motifs in some tetraspanins, 
responsible for endocytosis, signalling and intracellular localisation of certain cytoplasmic 
proteins (Stipp et al., 2003). This aspect of tetraspanins remains understudied, but 
interactions between the N-terminal tail of CD53 and PKC-β (Zuidscherwoude et al., 
2017), or C-terminal tail of CD81 and Rac (Tejera et al., 2013), have been noted. In 
addition, tetraspanins are subjected to post-translational modification, such as 
palmitoylation of cytosolic membrane-proximal cysteine residues, N-glycosylation in the 
large extracellular region and ubiquitination at cytoplasmic tails (van Deventer et al., 
2017). In particular, palmitoylation was shown to contribute to tetraspanin-tetraspanin 
interactions and tetraspanin web formation as a whole (Israels and McMillan-Ward, 2010), 
whereas N-glycosylation contributes to tetraspanin-partner protein interactions (Yoshida et 
al., 2009).  
 
Recently the structure of the first full length tetraspanin was solved, for CD81, which 
revealed a cone-like architecture where the large extracellular loop overshadows the four 
transmembrane domains arranged as separate pairs of helices, forming an 
intramembranous ligand-binding cavity (Figure 1.4). The study suggests that the lipid 
composition of the plasma membrane, in particular cholesterol, modulates dynamic 




cholesterol is not bound within the cavity. This, in turn, appears to affect tetraspanin 





Figure 1.4 Tetraspanin structure: an ice cream cone with a cavity.  A schematic 
representation of human tetraspanin CD81 (left panel) based on the CD81 crystal structure 
(right panel, Zimmerman et al., 2016). 




1.4 The TspanC8 tetraspanins and 
ADAM10 
 
1.4.1 ‘Six scissors’: TspanC8s regulate 
ADAM10 
 
ADAM10 has been shown to interact specifically with six different tetraspanins, as 
determined by co-immunoprecipitation under stringent lysis conditions like 1% digitonin 
(Dornier et al., 2012, Haining et al., 2012, Prox et al., 2012). These six tetraspanins have 
been named the TspanC8s, which form a subgroup of evolutionary conserved tetraspanins 
comprising Tspan5, 10, 14, 15, 17, and 33. Each of them contain eight cysteine residues in 
the large extracellular loop, a hallmark of the group. Various experimental approaches 
have shown that these tetraspanins are important for ADAM10 function through regulation 
of its maturation, trafficking, surface expression, lateral mobility and its activity towards 
several substrates (Figure 1.5). The findings are consistent in Drosophila, primary human 
endothelial cells, and in mice (Matthews et al., 2017b, Saint-Pol et al., 2017b, Matthews et 






Figure 1.5 Different TspanC8s promote shedding of specific ADAM10 substrates.   
ADAM10 is synthesised as an inactive precursor in the ER. TspanC8s are required for 
ADAM10 ER exit and its subsequent maturation in the Golgi, via removal of the inhibitory 
prodomain. The mature form of ADAM10 is transported to the plasma membrane or 
intracellular compartments. Emerging evidence suggests that different TspanC8/ADAM10 
complexes cleave different substrates such as Notch cell fate regulators, cadherin adhesion 
molecules and the platelet collagen receptor GPVI. 
 
The depletion of all three TspanC8 gene orthologs (Tsp3A, Tsp86D and Tsp26D) in 
Drosophila resulted in developmental defects that phenocopied ADAM10 and Notch 
deletion. Weaker effects in single knockdowns suggested functional redundancy amongst 
these three TspanC8s (Dornier et al., 2012). Moreover, in human cell line models, Tspan5 
and Tspan14 were identified as positive regulators of ADAM10-mediated Notch 
activation, while Tspan15 and Tspan33 appeared to be negative regulators (Dornier et al., 




with Tspan5/14 for ADAM10. In osteoclasts, Zhou et al have shown that loss of Tspan5 or 
Tspan10 expression reduced ADAM10 maturation and consequent Notch2 activity (Zhou 
et al., 2014). These data suggest that Tspan5, 10 and 14 can each promote ADAM10-
mediated Notch activation, but their relative importance will likely depend on expression 
levels in different cell types. Indeed, different cell types have different TspanC8 
repertoires (Haining et al., 2012, Noy et al., 2016, Matthews et al., 2017b, Matthews et al., 
2018). 
The most definitive example of a TspanC8 specifically promoting shedding of a particular 
substrate is Tspan15 and N-cadherin, because it has been shown by three different groups 
(Noy et al., 2016; Jouannet et al., 2016; Prox et al., 2012). This will be covered in the next 
section on Tspan15. However, other examples are Tspan15/33 and the platelet collagen 
receptor GPVI (Matthews and Tomlinson, unpublished), and Tspan5/17 and VE-cadherin 
(Reyat et al., 2017). In the HEK-293T cell line, Tspan14 over-expression appeared to 
protect GPVI from ADAM10-mediated cleavage, but the other TspanC8s did not have this 
effect (Noy et al., 2016). More recent data from the Tomlinson lab, using CRISPR/Cas9 
knockout megakaryocyte-like cell lines, has shown that Tspan15/ADAM10 and 
Tspan33/ADAM10 can each promote GPVI cleavage, but Tspan14/ADAM10 and other 
complexes cannot (Matthews and Tomlinson unpublished). The apparent protection by 
Tspan14 in the over-expression system was likely due to competition with Tspan15/33 for 
ADAM10 interaction. For VE-cadherin, our study in HUVECs using combination 
TspanC8 siRNA knockdowns, showed that Tspan5 and Tspan17, which are the two most 
highly-related TspanC8s at 72% amino acid identity, limit VE-cadherin expression and 
promote lymphocyte transmigration, but it was not proven that this was via actual 




As previously mentioned, different cell types show different expression patterns of 
TspanC8s (Haining et al., 2012, Noy et al., 2016, Matthews et al., 2017b, Matthews et al., 
2018). For instance, primary HUVECs and the A549 lung epithelial cell line express most 
of the TspanC8s, although with substantial variation in the relative levels (Haining et al., 
2012). In contrast, primary mouse erythroblasts and megakaryocytes express mainly 
Tspan33 and Tspan14, respectively (Haining et al., 2012). Erythrocytes from Tspan33-
knockout mice showed almost a complete loss of ADAM10 surface expression (Haining et 
al., 2012), that was accomplished by defects in red blood cell development (Heikens et al., 
2007), but it is not clear that these are linked. Knockdown of Tspan14, the most highly 
expressed TspanC8 in HUVECs, was sufficient to reduce ADAM10 surface expression 
and activity towards VE-cadherin (Haining et al., 2012). TspanC8s also have different 
subcellular localisations. In the present absence of antibodies to most TspanC8s, this has 
been investigated using transfected GFP-tagged TspanC8s. For example, Tspan5, 14, 15 
and 33 are located mainly at the plasma membrane, whereas Tspan10 and 17 have more 
intracellular localization (Dornier et al., 2012). However, the mechanism underlying these 
different localisation patterns is not known. 
 
The mechanisms by which different TspanC8s differentially regulate ADAM10 substrate 
specificity are not known. It seems likely that TspanC8s exert their functions by 
trafficking ADAM10 into proximity with substrates and/or by constraining ADAM10 into 
distinct conformations that favour cleavage of certain substrates. As mentioned in the 
previous paragraph, TspanC8s do differentially localise ADAM10. Moreover, TspanC8s 




measured by single particle tracking of ADAM10 in Tspan5- or Tspan15-over-expressing 
cells, in which mobility in the membrane increased by 55% in the presence of Tspan15 
versus Tspan5 or control cells (Dornier et al., 2012, Jouannet et al., 2016). GFP-tagged 
Tspan5 and Tspan15 were also shown to co-immunoprecipitate overlapping but somewhat 
different proteins in 1% Brij97, as detected by mass spectrometry, suggesting that they 
reside in different membrane microdomain environments (Jouannet et al., 2016). There is 
also evidence that ADAM10 may adopt distinct conformations in complex with different 
TspanC8s (Figure 1.6) that in turn could impact the substrate specificity and cellular 
localization (Jouannet et al., 2016, Noy et al., 2016). Binding regions were mapped using 
chimeric approaches for both TspanC8s and ADAM10, and the extracellular regions of the 
two interacting partners seemed to play the most important role (Noy et al., 2016). Indeed, 
the variable region in the large extracellular region of TspanC8s was necessary but not 
sufficient to mediate interactions with ADAM10. Furthermore, just the 26 amino acid 
membrane-proximal stalk region of ADAM10 appeared sufficient for interaction with 
Tspan15. In contrast, the stalk, cysteine-rich and disintegrin domain were required for 
interactions with Tspan5, 10, 14 and 33, whereas Tspan17 interaction was impaired by 
inclusion of the disintegrin domain (Noy et al., 2016). Since there are no specific amino 
acid sequence motifs identified as an ADAM10 cleavage site, and since the shedding 
happens at different heights above the plasma membrane (5-15 amino acids for different 
substrates), it is possible that different TspanC8s ‘lock’ ADAM10 in a conformation that 
favours cleavage of certain substrates. However, the data underlying these speculations 
were based entirely on co-immunoprecipitation of over-expressed mutant proteins, and so 





Taking together the data that has emerged in the last six years on TspanC8s, the 
Tomlinson group have proposed the ‘six scissors’ hypothesis, in which ADAM10 can be 
regarded as six different molecular scissors, depending upon which TspanC8 it is 
partnered with (Matthews et al., 2017, Mathews et al., 2018). A better understanding of 
the regulation of ADAM10 by TspanC8s could enable a new avenue of therapy for human 




Figure 1.6 'Six scissors' hypothesis.  ADAM10 in a complex with different TspanC8 
tetraspanins may adopt distinct conformations, which could impact substrate specificity 
and cellular localization. Therefore, ADAM10 is regarded as six different proteases. Figure 
taken from Noy et al., 2016.  
  





1.4.2 Tspan15  
 
Tspan15 became the model TspanC8 of focus for this thesis because the Tomlinson group 
generated the first mAbs to this protein (Noy, unpublished), and because Tspan15 was 
definitively shown to specifically promote ADAM10 cleavage of N-cadherin (Jouannet et 
al., 2016, Prox et al., 2012, Noy et al., 2016). Through the generation of a polyclonal 
antibody to Tspan15, the Saftig group demonstrated Tspan15 expression in most mouse 
tissues (Seipold et al., 2018). The examination of its expression within the Human Protein 
Atlas RNA-Seq data indicated that Tspan15 has a relatively restricted expression in 
epithelial and endothelial cells, and is an unfavourable prognostic marker in liver and 
kidney cancers (Uhlén et al., 2015). In the Gene Expression Profiling Interactive Analysis 
(GEPIA) data, Tspan15 is found to be approximately 50-fold, 16-fold and 13-fold 
upregulated in cholangio carcinoma, ovarian serous cystadenocarcinoma and pancreatic 
adenocarcinoma, respectively, but not substantially upregulated in most other cancers 
(Tang, 2017). Furthermore, overexpression of Tspan15 was recently reported in clinical 
oesophageal squamous cell carcinoma, which correlated with cancer metastasis and poor 
survival. Further studies suggested an importance of Tspan15 in cancer initiation and 
development and the possibility of using it as a therapeutic marker (Zhang et al., 2018). 
Indeed, Tspan15 over-expression in two oesophageal cancer cell lines substantially 
increased cell migration in vitro and promoted tumour formation in nude mouse lungs by 
3-fold following intravenous injection of the cells. Consistent with this, Tspan15 
knockdown reduced in vivo tumour formation by 75% (Zhang et al., 2018). To understand 
mechanism, the authors showed a co-immunoprecipitation of beta-transducin repeat 




of the transcription factor nuclear factor-κB (NF-κB), by targeting the IκB inhibitory 
proteins for degradation via ubiquitination. Moreover, knockdown of BTRC, or chemical 
inhibition of the NF-κB pathway, inhibited the in vitro and in vivo oncogenic effects of 
Tspan15 (Zhang et al., 2018). However, the co-immunoprecipitation was not fully 
controlled, for example knockdown cell lines could have been used as negative controls to 
check antibody specificity, and the BTRC functional effects could be merely downstream 
effects on signalling induced by Tspan15/ADAM10 activity. The authors acknowledge 
that ADAM10 presents a mechanistic possibility that they had not investigated and that 
further study is required to provide a complete understanding (Zhang et al., 2018).  
 
Tspan15 was first identified by Prox et al as a specific binding partner of ADAM10 in 
mammalian cell line models. Furthermore, the overexpression of Tspan15 was found to 
increase surface levels of ADAM10 and its shedding activity towards N-cadherin. Further 
data showed that Tspan15 knockdown substantially reduced N-cadherin shedding (Prox et 
al., 2012). Using over-expression and knockdown in different cell line models, our group 
and the Rubinstein group confirmed the above findings, and extended them to show that 
the other five TspanC8s could not promote N-cadherin cleavage (Noy et al., 2016, 
Jouannet et al., 2016). Analysis of Tspan15-knockout mice agreed with these cell line 
studies by showing 75-85% decreased N-cadherin cleavage in the brains of Tspan15-
knockout mice, an effect that increased with age, and a subtler 25-50% decrease in the 
percentage of mature ADAM10 (Seipold et al., 2018). A 50-60% decrease in cleavage of 
cellular prion protein was also observed, but APP cleavage was unaffected. Yet, Tspan15-
knockout mice had no obvious functional impairments when compared to wide-type 




which are important for memory and learning, were also normal (Seipold et al., 2018), but 
it may be interesting in future to perform more detailed functional analysis of the brains of 
these mice or to cross them to a model for prion disease. 
 
In the Seipold study, Tspan15 protein expression levels were shown to be elevated by 25% 
in the brains of a mouse Alzheimer’s disease model, and by 70% in the brains of human 
Alzheimer’s disease patients, as assessed from six patient samples. However, the 
relevance of these changes is not known. Tspan15 has also been implicated in deep vein 
thrombosis in a genome-wide association study (Germain et al., 2015). A single nucleotide 
polymorphism (SNP) in a Tspan15 intron was one of two SNPs identified in this study as 
being linked to disease susceptibility, but it is not yet known whether this truly impacts on 
the disease (Germain et al., 2015). More recently, Tspan15 was implicated in 
Streptococcus pneumoniae infection (Salas et al., 2018). Whole exome sequencing of 
eight patients with complicated cases of pneumococcal pneumonia identified a SNP in the 
3’ UTR of Tspan15 as the second-best candidate. Although the relevance to the disease is 
again unknown (Salas et al., 2018), it is interesting that ADAM10-cleavage of cadherins, 
following activation by the S. pneumoniae virulence factor pneumolysin, has been 
implicated in bacterial spread (Inoshima et al., 2011). This will be discussed later in the 









Endothelial cells became the cells of choice for functional studies of ADAM10 and 
Tspan15 in this thesis. Endothelial cells are the building blocks of all blood vessels. 
Collectively they form a thin monolayer called the endothelium that lines the interior of the 
entire cardiovascular system (Eelen et al., 2015). The endothelium is heterogenic in both 
phenotype and functions. This is a consequence of the diversity of endothelial cells that are 
present in different parts of the vascular system. Thus, it has the capacity to adapt its 
number and organisation to suit the local environment (Aird, 2012). The endothelium acts 
not only as a physical barrier between vessel lumen and underlying tissue, but also actively 
participates in cardiovascular regulation. It maintains vessel integrity and homeostasis by 
regulating the balance between pro-thrombogenic and fibrinolytic substance release and 
generating the anti-thrombogenic surface allowing blood to flow freely. Further, it controls 
vascular tone by releasing vasoactive factors, like nitric oxide, that constrict and dilate the 
vessels. The endothelium is also an active participant in inflammatory processes via 
recruiting and regulating transmigration of leukocytes through the vessel wall. It is also 
playing a necessary role in the regulation of vessel permeability by controlling the crossing 
of macromolecules back and forth between the bloodstream and tissues (Galley and 
Webster, 2004). 
The industrialisation and globalisation of everyday life contribute to the development and 




diseases, blindness, diabetes, obesity, cardiovascular diseases among others. In the last 
decade, scientists have linked these conditions to the vascular endothelium and blood 
vessels (Mensah, 2007). Indeed, the homeostasis established by blood vessel integrity is 
crucial for life, and its dysregulation can be fatal. Abnormalities of blood vessels are 
present in the majority of malignant, ischemic, inflammatory, infectious and immune 
conditions (Carmeliet, 2005a). Vascular disorders are hence often reported as the leading 
cause of death worldwide (WHO, 2007). Angiogenesis, the formation of new blood vessels 
from existing vasculature, is a major current research focus. The development of 
angiogenesis-targeting therapies, using suppressors or activators of the vascular beds, 
could provide a new avenue in combating these diseases (Chu and Wang, 2012). Before 
developing these therapies, however, more detailed understanding of the vascular system is 
required.   
  
1.5.2 Endothelial cells in sprouting 
angiogenesis 
 
In order to grow and survive, any single cell or multicellular entity will require new blood 
vessels to satisfy constant metabolic demands. Thus, the primitive vascular plexus that was 
once established during embryogenesis undergoes reorganisation, expansion and 
maturation into a functional circuit in a process called sprouting angiogenesis (Adair and 
Montani, 2010). This multi-step process is strictly regulated by a number of pro- and anti-
angiogenic molecules (Table 1). The complex interactions between these factors affect the 




Table 1 List of activators and inhibitors of angiogenesis and their function. 
 
ACTIVATORS FUNCTION INHIBITORS FUNCTION 
 VEGF family members: stimulate 
angiogenesis, permeability, leukocyte 
transmigration 
 
 VEGFR2, NRP-1: integrate 
angiogenic and survival signals 
 
 Angiopoetin1, Tie 2: stabilise vessels, 
inhibit permeability 
 
 PDGF and receptors: recruits 
pericytes, smooth muscle cells 
 
 TGF- and receptors: stimulate 
extracellular matrix production, recruit 
macrophages 
 
 Integrin: receptor for matrix 
macromolecules and proteinases 
 
 VE-cadherin, PECAM (CD31): 
endothelial junctional molecules 
 
 Plasminogen activators, MMPs: 
remodel extracellular matrix, release 
and activate growth factors 
 
 HIF-1: activate pro-angiogenic factors 
 VEGFR1: binds VEGF 
 
 Angiopoietin 2: agonists for 
Angiopoietin 1  
 
 Thrombospondin-1, -2: inhibit 
endothelial migration, growth, 
adhesion and survival 
 
 Angiostatins: suppress tumour 
angiogenesis 
 
 Endostatins: inhibit endothelial 
survival and migration 
 
 TIMPs: inhibit MMPs 
 
 IL-4, IL-12, IL-8, IFN-, -, -: inhibit 




In health, quiescent endothelial cells within blood vessels form monolayers on the 
basement membrane, connected through junctional molecules including VE-cadherin, 
JAMs, PECAM-1, ZO-1 and claudins. These are enclosed by contractile pericytes/smooth 
muscle cells. Since the vessels carry oxygen and blood, they are well-equipped with 




expression and consequent release of pro-angiogenic factors like VEGF, EGF, Ang2, FGF, 
TGF and chemokines. This triggers morphological and behavioural changes in the 
vessels, like pericyte detachment from vessel walls, loosening of the cell-cell junctions, 
vessel dilation and ultimately cell migration and sprouting (Welti et al., 2013).  
 
The individual steps of sprouting angiogenesis, together with key players, are shown in 
Figure 1.7. During the process of the sprout formation, cells do not move in masses. 
Specialized cells, called ‘tip cells’, lead the migration along a concentration gradient of the 
angiogenic stimuli towards hypoxic regions. These cells are equipped with filopodia and 
sensors to probe their local environment for guidance. In addition, they release matrix 
metalloproteases (MMPs) which enable the degradation of extracellular matrix 
components (laminins, collagens, proteoglycans). The cells that trail behind the tip cells 
are called ‘stalk cells. The differentiation and specification of stalk cells results in a highly 
proliferative phenotype that facilitates elongation and formation of the main body of the 
new vessel (Eilken and Adams, 2010). The selection and identity of the endothelial cells 
are controlled by the interplay between VEGF/VEGFR2 and Notch/DLL4 signalling. 
These signalling pathways control responsiveness of the cells to growth factors (Phng and 
Gerhardt, 2009). The tip-stalk cell phenotype is transient and may be reversed upon vessel 
fusion and cell-cell communication (Jakobsson et al., 2010). In the final phase of 
angiogenesis, nearby sprouts that invaded the tissue space anastomose with one another. In 
the newly formed vessel, the cell-cell contacts are re-established by VE-cadherin and Ang-
1; the basement membrane is laid down with the help of tissue inhibitors of 
metalloproteases (TIMPs), which prevent digestion of the extracellular matrix by plasmin. 




in response to TGF-, PDGFR/PDGF- and Ang-1. Blood starts to flow, bringing the 
oxygen level back to normal, the growth factor activity diminishes and the nascent vessel 





Figure 1.7 Vessel sprouting model.  The drawing represents the main steps in vascular 
morphogenesis: initial tip cell selection and guidance; stalk elongation and lumen 
formation; anastomosis, maturation and quiescence of the newly formed blood vessel.  




During postnatal development, the formation of new blood vessels from pre-existing 
capillaries occurs rarely and is limited to the menstrual cycle, placenta development, 
embryo implantation, wound healing, tissue growth and regeneration (Sherer and Abulafia, 
2001). However, in pathological conditions, deregulated angiogenesis contributes to 
sudden enlargement or regression of the existing capillary network. This includes, but is 
not limited to, cancers, cardiovascular diseases, blindness, arthritis, complications of AIDS 
(acquired immunodeficiency syndrome), diabetes and Alzheimer’s disease (Carmeliet and 
Jain, 2000). 
 
The early dogma proposed by Judah Folkman presented angiogenesis as an important 
target for cancer and other diseases (Folkman, 1971). The restriction of blood vessel 
availability within the whole affected area in the body therefore became a key approach to 
increase patient survival. Recent discoveries have brought into light the therapeutic 
potential of targeting angiogenesis whereby the process per se, and its driving factors, 
could be stimulated or inhibited to treat certain diseases (Ferrara and Kerbel, 2005). 
Indeed, many diseases, including neurodegenerative illnesses, heart attack, blood clots and 
limb fractures, could potentially benefit from the administration of pro-angiogenic agents 
that would stimulate blood vessel growth. In contrast, many disorders can benefit from 
blocking angiogenesis by introducing anti-angiogenic factors. These include retinal 
diseases, cancers, arthrosclerosis, obesity and endometriosis (Jain and Carmeliet, 2001). 




1.5.3 Crosstalk between VEGF and Notch 
signalling pathways in regulation  
of sprouting angiogenesis 
 
Vascular endothelial growth factors (VEGFs) include mammalian VEGFs A-D, and 
placental growth factor (PIGF), which regulate vasculogenesis, angiogenesis and 
lymphangiogenesis (Shibuya, 2013). In particular, VEGF-A is crucial for angiogenesis, as 
a 50% reduction in the level of the ligand is embryonically lethal and associated with 
various pathologies when bioavailability of VEGF-A decreases (Simons et al., 2016). 
VEGF and its receptors, the VEGFR1-4 receptor tyrosine kinases, are potent mediators of 
endothelial cell functions like migration, proliferation and differentiation. Vascular 
endothelial cells express VEGFR1 and 2, and mice deficient in VEGFR2 die in the uterus 
due to impaired blood-island formation and vasculogenesis (Shalaby et al., 1995). VEGF 
and Notch have been identified as crucial regulators of angiogenesis (Figure 1.8). Genetic 
deficiencies in these genes result in embryonic lethality due to impaired or lack of 
development of a vasculature (Hofmann and Iruela-Arispe, 2007, Carmeliet, 2005b). 
Although the two signalling cascades collectively unite through downstream effectors, they 
differ in temporal and spatial expression and regulation, but are both required for the 
differential responsiveness of endothelial cells to angiogenic stimuli and correct patterning 
and assembly of the vasculature (Martin and Murray, 2009). VEGF acts upstream, 
inducing and controlling expression of Notch signalling components, whereas Notch 
negatively modulates VEGF pathways. This dependence is coordinated by the feedback 
loops between expression of the VEGFR2/R1 receptors and activity of the Notch-DLL4 
complexes (Blanco and Gerhardt, 2013). In the developing vasculature, VEGF drives the 




to guide cell fate decision (arterial-venular and tip-stalk phenotype of endothelial cells) and 
sprouting, while restricting the angiogenic response to VEGF (Holderfield and Hughes, 
2008). 
 
VEGF and Notch/DLL4 are essential drivers of sprouting angiogenesis. Their engagement 
balances migratory tip cell and proliferating stalk cell phenotypes. Briefly, endothelial cells 
compete for a tip cell phenotype by over-expressing the VEGFR2/Nrp-1 receptor complex. 
Nrp-1 is co-receptor for VEGFR2 that is involved in enhancing its binding to VEGF. The 
absence of Nrp-1 results in embryonic lethality at day 10.5 as a result of impaired heart and 
blood vessel development and arterial-venous differentiation (Mehta et al., 2018). Hypoxia 
and binding of VEGF to VEGFR2/Nrp-1 upregulates DLL4 which binds to the Notch1 
receptor on a neighbouring cell. This initiates activation and proteolytic cleavages of Notch 
by ADAM10 and the -secretase complex. The resulting intracellular fragment of Notch, 
named the Notch intracellular domain (NICD), translocate to the nucleus where it interacts 
with CSL (CBF1/RBP-J, Su(H), Lag-1) transcription factors, which in turn initiates the 
transcription of Notch target genes. As a consequence, the gene expression profile is 
altered, including upregulation of VEGFR1, which acts as a VEGF ‘trap’ to inhibit VEGF 
activation of VEGFR2 and downregulation of VEGFR2/Nrp-1. As a result, endothelial 
stalk cells have impaired responsiveness to VEGF, limited filopodia formation and reduced 
migration. Conversely, locally high VEGF concentration favours signalling pathways that 
lead to proliferation and migration of the cells with elevated levels of the VEGFR2/Nrp-1 








Figure 1.8 VEGF and Notch in the fine-tuning of sprouting angiogenesis.  Interplay 
between VEGF and Notch signalling cascades facilitates vascular development and 





1.6 Thesis aims 
 
ADAM10 has been shown to be involved in a wide variety of processes including cell 
adhesion, migration, differentiation and vascular homeostasis, and is known to play an 
essential role in many pathophysiological conditions. Targeting ADAM10-TspanC8 
complexes is therefore a potential therapeutic strategy. Previous studies have made 
progress towards understanding the mechanism of ADAM10 involvement within these 
cellular processes, and several key substrates of ADAM10 have been identified. There is, 
however, still a lack of understanding in how ADAM10 is regulated by tetraspanins. This 
thesis therefore aims to investigate the regulation of ADAM10 by Tspan15 as a model 
TspanC8, and to understand how this interaction ultimately modulates cell function.  
 
The main aims of the thesis are as follows: 
 
1. To use four recently-generated anti-Tspan15 mAbs and ADAM10- and Tspan15-
knockout cell lines to determine the extent to which Tspan15 regulates cell surface 
ADAM10 expression, and whether ADAM10 regulates Tspan15 expression. 
 
2. To investigate whether Tspan15 is required for the ADAM10-mediated cleavage of N-, 
E- and VE-cadherin in cell lines, and whether the Tspan15 mAbs affect their cleavage. 
 
3. To epitope map the four Tspan15 mAbs and to determine their effects on Tspan15 





4. To establish a cell line model for Tspan15 structure/function analyses, by stably 
reconstituting Tspan15-knockout cells with Tspan15 mutant constructs.  
 
5. To determine whether siRNA knockdown of ADAM10 or Tspan15 in primary 








2.1. List of reagents and antibodies 
 
Table 2 List of reagents and antibodies 
 
Reagent Source 
Ampicillin Sigma-Aldrich (Poole, Dorset, UK) 
Acrylamide Geneflow (Lichfield, UK) 
Ammonium persulfate (APS) Sigma-Aldrich (Poole, Dorset, UK) 
Blasticidin Sigma-Aldrich (Poole, Dorset, UK) 
Bovine brain extract First Link (UK) Ltd. 
(Wolverhampton, UK) 
Gift from Dr V.Heath, UK 
Bromophenol Blue Bio-Rad (Hemel Hempstead, 
Hertfordshire, UK) 
Digitonin Merck Millipore (Watford, 
Hertfordshire, UK) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Poole, Dorset, UK) 
Dulbecco’s Modified Eagles Medium 
(DMEM) with 1000 mg/L glucose 




Ethanol Fisher Scientific (Loughborough, 
Leicestershire, UK) 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (Poole, Dorset, UK) 
10% heat activated fetal bovine serum (FBS) Gibco (Paisley, UK) 
Gelatin Sigma-Aldrich (Poole, Dorset, UK) 
Glycine Sigma-Aldrich (Poole, Dorset, UK) 
GI 254023X   Sigma-Aldrich (Poole, Dorset, UK) 
Heparin Sigma-Aldrich (Poole, Dorset, UK) 
L-Glutamine Gibco (Paisley, UK) 
Lipofectamine RNAiMAX 
 
Life Technologies Invitrogen 
Compounds (Paisley, UK) 
Marvel Premiere Foods (St Albans, 
Hertfordshire, UK) 
Matrigel BD Bioscience (Oxford, UK) 
Methanol Fisher Scientific (Loughborough, 
Leicestershire, UK) 
-mercaptoethanol Sigma-Aldrich (Poole, Dorset, UK) 
Mitomicin C Sigma-Aldrich (Poole, Dorset, UK) 
M119 medium Sigma-Aldrich (Poole, Dorset, UK) 
N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT) 
Sigma-Aldrich (Poole, Dorset, UK) 
  N-ethylmaleimide (NEM) Sigma-Aldrich (Poole, Dorset, UK) 
N, N, N’, N’-Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich (Poole, Dorset, UK) 
OptiMEM Gibco (Paisley, UK) 
Orange G loading buffer (6x) Fisher Scientific (Loughborough, 
Leicestershire, UK) 




Phosphate Buffer Saline (PBS) Sigma-Aldrich (Poole, Dorset, UK) 
Polyethylenimine (PEI) Sigma-Aldrich (Poole, Dorset, UK) 
Polyvinylidene fluoride (PVDF) membrane Immobilon-FL, Merck Millipore 
(Watford, Hertfordshire, UK) 
Protein G sepharose beads Generon (Berkshire, UK) 
Protease inhibitor cocktail Sigma-Aldrich (Poole, Dorset, UK) 
Protein marker (BLUEye
TM
) Geneflow (Lichfield, UK) 
Sodium azide (NaN3) Sigma-Aldrich (Poole, Dorset, UK) 
Sodium chloride (NaCl) Sigma-Aldrich (Poole, Dorset, UK) 
Sodium dodecyl sulphate (SDS) Fisher Scientific (Loughborough, 
Leicestershire, UK) 
SYBR Safe DNA gel stain Fisher Scientific (Loughborough, 
Leicestershire, UK) 
Tris Fisher Scientific (Loughborough, 
Leicestershire, UK) 
Triton X-100 lysis buffer Sigma-Aldrich (Poole, Dorset, UK) 
Trypsin-EDTA Sigma-Aldrich (Poole, Dorset, UK) 
Whatman filter paper (3MM) GE Healthcare (Amersham, 
Buckinghamshire, UK) 
Antibody Details and source 
Rabbit anti-HA (C29F4) Cat No.:3724, Cell Signaling 
Technology (Danvers, USA) 
Working dilution: 1:2000 (western 
blotting) 
Mouse anti-FLAG (M2) Cat No.: F9291, Sigma-Aldrich 
(Poole, Dorset, UK) 
Working concentration: 1 µg/ml 
(western blotting) 




(Poole, Dorset, UK) 
Working concentration: 1 µg/ml 
(western blotting) 
Rabbit anti-HA Cat No.: C29F4, Cell Signaling 
Technology (Massachusetts, USA) 
Working concentration: 1 µg/ml 
(western blotting) 
Mouse anti-human ADAM10 (11G2) Gift from Dr Eric Rubinstein, France 
Working concentration: 1 µg/ml 
(western blotting) 
Mouse anti-human ADAM10 FITC R&D Systems (Abingdon, UK) 
Working dilution: 1:50 (flow 
cytometry) 
Mouse anti-human ADAM10 APC R&D Systems (Abingdon, UK) 
Working dilution: 1:50 (flow 
cytometry) 
Mouse IgG (MOPC-21) Cat No.: 50327, MP Biomedicals 
Europe (Santa Ana, California, USA) 
Working concentration: 10µg/ml 
(flow cytometry) 
Mouse anti-human Tspan15 hybridoma tissue 
culture supernatant 
5F4 (IgG2b Kappa) 
5D4 (IgG1 Kappa) 
1C12 (IgG1 Kappa) 
4A4 (IgG1 Kappa) 
Abpro (Boston, Massachusetts, 
USA) 
Working volume: 50 µl (flow 
cytometry) * 
 
Mouse anti-human Tspan15 monoclonal 
antibodies: 
5F4 (IgG2b Kappa) 
5D4 (IgG1 Kappa) 
1C12 (IgG1 Kappa) 
4A4 (IgG1 Kappa) 
Abpro (Boston, Massachusetts, 
USA) 
Working concentration: 10 µg/ml 





Mouse anti-human Tspan5 (TS5-2) Gift from Dr Eric Rubinstein, France 
Working concentration: 10 µg/ml 
(flow cytometry) 
Rabbit VE-cadherin (D87F2) XP Cat No.: 2500, Cell Signaling 
Technology (Danvers, USA) 
Working dilution: 1:1000 (western 
blotting) 
Mouse anti-N-cadherin (13A9) Cat No.: 14215, Cell Signaling 
Technology (Danvers, USA) 
Working dilution: 1:1000 (western 
blotting) 
Rabbit anti-E-cadherin (24E10) Cat No.: 3195, Cell Signaling 
Technology (Danvers, USA) 
Working dilution: 1:1000 (western 
blotting) 
Goat anti-Mouse IgG IRDye 680RD & 800CW LI-COR (Cambridge, UK) 
Working dilution: 1:10000 (western 
blotting) 
Goat anti-Rabbit IgG IRDye 680RD & 800CW LI-COR (Cambridge, UK) 
Working dilution: 1:10000 (western 
blotting) 
Anti-mouse IgG2B-FITC Sigma-Aldrich (Poole, Dorset, UK) 
Working dilution: 1:50 (flow 
cytometry) 
Anti-mouse IgG2B-APC Sigma-Aldrich (Poole, Dorset, UK) 
Working dilution: 1:50 (flow 
cytometry) 
 
* mAb / hybridoma tissue culture supernatant was used at volume that gave saturating 






2.2 List of buffers 
 
Table 3 List of commonly used buffers 
 
Buffer Details 
2X SDS non-reducing sample buffer 20 ml 1M Tris, pH 6.8 
80 ml 10% SDS 
40 ml glycerol 
60 ml dH20 
4 mg Bromophenol blue 
5ml 10% -mercaptoethanol (only for 
reducing buffer) 
Antibody incubation buffer 3% BSA in PBS 
0.02% NaN3 
 
Blocking buffer (Western blot) 5% Marvel in TBS-T 
FACS buffer 0.2% BSA in TBS-T 
0.02% NaN3 
 
Complete M199 (cM199) M199 media (500 ml) 
10% FBS 
4 mM glutamine 
0.3% bovine brain extract 
90 µg/ml heparin 
100 U/ml penicillin 
100 µg/ml streptomycin 
Complete DMEM (cDMEM) DMEM media (500 ml) 
10% FBS 
4 mM glutamine 
100 U/ml penicillin 
100 µg/ml streptomycin 
Digitonin 1 % Digitonin (dissolved in methanol 10 
% w/v) 
10 mM Tris pH 7.5 
150 mM NaCl 
0.01 % NaN3 
SDS polyacrylamide resolving buffer 30.3 g Tris 
2 g SDS 
pH 8.8 




SDS polyacrylamide stacking buffer 30.3 g Tris 
2 g SDS 
pH 6.8 
500 ml dH20 
SDS-Page running buffer 15 g Tris 
72 g glycine 
50 ml 10% SDS 
5 L dH20 
TBS buffer 20 mM Tris 
137 mM NaCl 
pH 7.6 
2 L dH20 
Triton X-100 lysis buffer 250 ml 1% Triton X-100 
1 M Tris, pH 7.5 
5 M NaCl 
0.5 M EDTA pH 8.0 
0.05 g NaN3 
250 ml dH2O 
TBST buffer 20 mM Tris 
137 mM NaCl 
0.1% Tween 
pH 7.6 
5 L dH20 
TBST high salt wash buffer TBST containing 500 mM NaCl 
 
Western transfer buffer 15 g Tris 
72 g glycine 
1 L methanol 






2.3 Cellular biology methods 
 
2.3.1 Cell culture 
 
Adenocarcinoma Human Alveolar Basal Epithelial (A549) and Human Embryonic Kidney 
293T (HEK-293T) cells were obtained from laboratory stocks (Haining et al., 2012) and 
cultured in complete Dulbecco’s Modified Eagle Media (DMEM) (Table 2). ADAM10 and 
Tspan15 CRISPR/Cas9 knockout A549 and HEK-293T cells were generated previously in 
the Tomlinson lab. Human umbilical vein endothelial cells (HUVECs) were isolated from 
human umbilical cords obtained from Human Biomaterials Resource Centre (University of 
Birmingham) (09/H1010/75) by members of the Tomlinson lab. All cells were cultured in 
a humidified incubator at 37 
0
C with 5% CO2. HUVECs were used for experiments up to 
passage six and grown in 10 cm dishes pre-coated with 0.1% gelatine. The remaining cell 
lines were passaged routinely at a 1 to 10 ratio. The cell culture techniques used for 
thawing, freezing and general maintenance were performed similarly for all cell types used 
in the project. Briefly, for sub-culturing cells, the cells were washed with PBS, trypsinised 
for 1 min at 37 
0
C, resuspended in a fresh media and transferred to a new tissue culture 
dish. For freezing, a confluent monolayer of the cells was collected from 10 cm dishes, 
spun down at 270 x g for 5 min at room temperature, re-suspended in 1 ml of FBS 
supplemented with 10% dimethyl sulfoxide (DMSO) and transferred to cryo-vials. The 
cells were kept at -80
0
C for 24 hours before moving to liquid nitrogen for long-term 
storage. To thaw cells, the cells were placed in a 37
0
C water bath till completely defrosted, 




min. The supernatant was aspirated, and the cell pellet was resuspended in a fresh media 
prior to transferring to a new tissue culture vessel. 
 
2.3.2 Transfection of HEK-293T using PEI 
 
Transient transfection of all genotypes of HEK-293T cells was carried out as previously 
described by Ehrhardt et al (Ehrhardt et al., 2006). Briefly, 20 hours prior to transfection, 
the cells were seeded in 6-well plates at a density of 5 x 10
5
 cells per well in 2 ml media. 
The following day, a mix of Opti-MEM serum-free media, a plasmid DNA and 1mg/ml 
PEI was added (ratio of each are detailed in Table 4) to the cells for additional 24 hours 
(for shedding assay) or for 48 hours (for co-immunoprecipitation assay). Following the 
incubation, the cells were used for further analysis. 
 
The plasmids used for HEK-293T transfections were as follows. Human Tspan15 and 
human Tspan14 with N-terminal FLAG tag were previously described by Haining et al 
2012 and produced in pEF6-FLAG vector (a modified version of pEF6/Myc-His A from 
Invitrogen) (Haining et al., 2012). N-terminal FLAG-tagged human Tspan14/15 chimera 
series, human Tspan15 cholesterol binding mutants and human Tspan15 tailless were 
produced in the Tomlinson lab using pEF6-FLAG vector. The HA-tagged bovine 
ADAM10 in pcDNA3 was previously described (Lammich et al., 1999). The human  























6-well 5 x 10
5 




2.3.3 Transfection of HUVECs with small 
interfering RNA (siRNA) 
 
Transient transfection of HUVECs was executed as previously described (Haining et al., 
2012) using Lipofectamine RNAiMAX (Life Technologies Invitrogen Compounds), and 
pre-designed siRNA duplexes to ADAM10 and Tspan15 (Life technologies Ambion 
Compounds). The reagents and required quantities used in the experiments are shown in 
Table 5. The day prior to the transfection, cells were plated in a 6-well dish pre-coated 
with 0.1% gelatine such that the next day thery were about 80% confluent. On the day of 
the transfection, two separate vials containing siRNA duplexes and RNAiMAX, in Opti-
MEM serum free-media, were prepared, mixed and incubated at room temperature (RT) 
for 10 minutes to allow the complexes to form. While incubating, HUVECs were prepared 
by washing twice in PBS, and 800 µl of Opti-MEM was added to the cells. Following the 
incubation, the cells were treated with the siRNA/Lipofectamine mix for 3 hours at 37 
0
C 
and 5% CO2, before being replaced with appropriate antibiotic-free media for a further 48 
to 72 hours. Negative control siRNA duplex was used to account for any effects that the 




analysed proteins. Transfected cells were used in in vitro functional and biochemical 
assays.  














6 well 3.6 x 10
5 
2.5 µL 167.5 µl 3 µl 27 µl 1 ml 
 
 
2.3.4 Stable HEK-293T cell line generation 
 
Tspan15 CRISPR/Cas9 knockout (KO) HEK-293T cells were mock transfected or 
transfected with the human Tspan15 mutants and human Tspan14/15 chimeras using the 
PEI method as described above. For information about the mutants and chimera constructs, 
see figure 5.1. The plasmid vector used encodes the blasticidin-resistant gene as a 
selectable marker. Therefore at 48-hours post-transfection, the polyclonal cells were 
trypsinised, spun down at 270 x g for 5 min, the media was removed and replaced with 
complete DMEM (cDMEM) supplemented with10 µg/ml blasticidin. The cells were then 
serially diluted in a 96-well plate to isolate monoclones and cultured for 7 to 10 days to 
allow the clones to grow. The procedure for the serial dilution was as follows: 3 ml of the 
cell solution was prepared for each 96-well plate. From this, 300µl was transferred to the 
first column of the plate, while the remaining rows were filled up with 200µl the 




transferred to the second column, mixed well by pipetting up and down, thereby diluting in 
a ratio of 1:3. The action was repeated for each sequential column. After completing, 
100µl was discarded from the last column. Wells were monitored during growth and only 
those wells where colonies appeared to come from individual cells were further expanded 
and assessed for the Tspan15 expression using flow cytometry. 
 
2.4 Protein biochemistry methods 
 
2.4.1 Cell-based shedding assay 
 
The cell-based shedding assay was carried out as previously described (Haining et al., 
2012) but with the following modifications: the shedding of the endogenous N- and E-
cadherin was investigated in wild-type A549 and ADMA10- and Tspan15-KO A549 cells. 
Prior to the assay, the cells were plated at 80% confluency. The inhibition of -secretase 
activity was achieved by culturing cells for 30 minutes with 10 µM DAPT. Following this 
incubation, the cells were treated for an additional 30 minutes with 2 mM NEM, a potent 
ADAM10 agonist, or ethanol vehicle control. The cells were harvested, lysed in 1% Triton 
100-X and subjected to western blotting. An antibody to the C-terminal cytoplasmic tail 
allowed the detection of both full length and cleaved fragments of the cadherins. For 
antibody selection, see Table 2. The results were imaged using the Odyssey Infrared 
Imaging System. The intensity of resulting bands, corresponding to full length and cleaved 
fragments, were quantified, and the percentage shed protein was calculated as follows: 





A similar protocol was prepared and used for VE-cadherin shedding in HUVECs at day 3 
post-siRNA transfection. For details see section 2.6. 
 
Shedding of VE-cadherin was monitored in the wild-type HEK-293T, ADAMA10- and 
Tspan15-KO HEK-293T cells. The cells were transfected with a plasmid encoding human 
VE-cadherin, 24 hours prior to the assay, following the standard PEI transfection protocol 
detailed in section 2.5. The inducible cleavage of VE-cadherin was assessed using DAPT 
and NEM as described above. This assay was also used to study the effect of Tspan15 
monoclonal antibodies (mAbs) on VE-cadherin shedding. Here, the wild-type and 
ADAM10-KO HEK-293T cells, transfected with VE-cadherin, were pre-treated with anti-
human Tspan15 mAbs (10 µg/ml) or MOPC (10µg/ml) control mAb at the point of DAPT 
(10 µM) addition. After 30 minutes, the cells were stimulated with NEM (2 mM) for an 
additional 30 minutes. The shedding was measured, and analysis was carried out as 
aforementioned. 
 
2.4.2 Flow cytometry 
 
Surface expression of ADAM10 and TspanC8s of interest was analysed using BD 
FACSCalibur Flow Cytometer and its software CellQuest
TM 
Pro (BD Bioscience) as per 
the manufacturer’s instructions. Preceding the analysis, the cells were grown and treated as 
required for the particular experimental purpose. Briefly, 5 x 10
5
 cells were detached 
(either by scraping for HEK293T and A549 cells or trypsinised for HUVEC cells), and 
spun for 5 min at 2655 x g at room temprature. The cells were incubated on ice for 30 min 




hybridoma tissue culture supernatants, along with the appropriate isotype controls (Table 
2). Next, the cells were washed in FACS buffer to remove unbound antibodies and stained 
with species-corresponding secondary antibodies (if non-conjugated mAbs were used in 
the first stain), as described for the primary antibodies. Live cells were gated by size and 
granularity, and fluorescence of gated cells was measured. The geometric mean 
fluorescence intensity was used to assess the surface expression of proteins. The surface 
expression was calculated by dividing the geometric mean of positive staining by its 
isotype-matched negative control.  
 
2.4.3 Antibody internalisation assay using flow 
cytometry  
 
HEK-293T cells were plated in 6-well plate to 80% confluency and used in the assay. All 
the treatments were performed in duplicate. First, the cells were pre-chilled for 60 minutes 
at 4 
0
C, followed by an additional 30 min incubation in the presence of Tspan15 mAbs 
(clones 4A4, 5D4, 5F4, 1C12) or MOPC control, each at 10 µg/ml. Next, the unbound 
mAbs were washed away using ice-cold PBS, and fresh cDMEM media was added. One of 
the plates was transferred to 37 
0
C for 30 min for mAb internalisation to occur, while the 
other was kept at 4 
0
C. After the incubation time, the cells were moved to 4 
0
C and stained 
with corresponding secondary antibodies as described in section 2.4.2. The surface 
expression of Tspan15 was measured on both duplicate plates using flow cytometry. Only 
the fluorescence emitted from the live population of the cells was considered for further 
calculation. The surface expression was calculated by dividing the average geometric mean 




2.4.4 Immunoprecipitation and western 
blotting 
 
Co-immunoprecipitation and western blot experiments were conducted as previously 
described (Haining et al., 2012, Noy et al., 2016). Wild-type or transfected cells were lysed 
in either 1% Triton X-100 (for western blotting) or 1% digitonin lysis buffer (for co-
immunoprecipitation) supplemented with a 1:100 dilution of protease inhibitor cocktail for 
30 min on ice. Following centrifugation at 20817 x g for 10 min at 4 
0
C to remove 
insoluble cell derbies; a portion of the soluble lysate was removed as input control. For the 
co-immunoprecipitation experiments, the lysate was incubated for 90 min at 4 
0
C with 
primary antibody bound to protein G sepharose beads. The beads were washed four times 
with 0.1% digitonin lysate buffer and the beads were mixed with either 2x SDS non-
reducing or reducing sample buffer respectively and boiled for 5 min at 100 
0
C to elute and 
denature bounded proteins prior to gel electrophoresis. Subsequent SDS-PAGE separation 
and western blot transfer were performed according to standard protocols. For the protein 
separation, gels with a single polyacrylamide concentration were prepared in-house and 
ranged from 10 to 12 %. The samples were run at 125V until the dye front reached the 
bottom of the gel. Next, the separated proteins were transferred onto methanol-activated 
polyvinylidene difluoride (PVDF) Immobilon-FL membrane and wet-transferred for 90 
min at 30 V. Following transfer, the membrane was blocked in 5% milk in TBST for 1 
hour at room temperature and then with incubated overnight with primary antibody at 4
0
C 
on a rocker. The unbounded antibodies were removed by 3 washes for 10 min each using 
the high salt TBST wash buffer. Secondary antibodies, conjugated to infrared dye (IR dye) 




temperature. After the incubation, the membrane was washed 5 times for 5 min each using 
the high salt TBST wash buffer. The results were visualized and intensities of bands 
quantified using the Odyssey Infrared Imaging System (LI-COR Bioscience). The 
selections of the primary and secondary antibodies used in the experiments are specified in 
Table 2. 
 
2.5 Molecular biology methods 
 
2.5.1 Generation  of  Tspan15  mutant 
constructs:  point  mutations  
in  cholesterol  binding  sites  
(Q245E or Q245A)  and  truncated 
cytoplasmic N-  and  C-terminal  tails 
 
The tailless form of the human Tspan15 was constructed using a single step PCR-based 
method (Figure 2.1) in a Veriti® 96-Well Thermal Cycler (Applied Biosystems). The 
approach utilised the pEF6-FLAG-Tspan15 plasmid previously generated in the laboratory 
containing the wild-type Tspan15 as a starting template. Specific primers were designed to 
amplify Tspan15 minus the N- and C-terminal tails. These primers included the restriction 
sites BamHI and NotI (see below) to allow the resulting fragment to be cloned in-frame 
with the FLAG tag in the pEF6-FLAG plasmid; the reverse primer contained a sequence to 







fwd, 5’-TAGTAG  GGATCC  TGGCTCAAGTTTTCACTTATC-3’ (contains BamHI) 
rev, 5’-TAGTAG  GCGGCCGC  TTA  ATCAGTGACAGAGTGCTC-3’ (contains NotI 
and stop codon TTA) 
 
 
The point mutations (Q245E and Q245A) for the putative cholesterol binding site were 
introduced to human Tspan15-FLAG by a two-step PCR strategy (Figure 2.1). The 
approach required two flanking primers (MT5147 and MT4150), contained within the 
pEF6-FLAG Tspan15 plasmid, and contained BamHI and NotI restriction sites so that the 
final product could be inserted into the pEF6-FLAG vector. Also, two internal primers 
were required with complementary ends and carrying a point mutation in the middle of the 
primer, that hybridised to the region that needed to be altered. The resulting fragment was 
digested with BamHI and NotI and ligated into the pEF6-FLAG plasmid. 
 
 
Primers used were as follows:  
Q245E fwd 5’-CATCCTGCTTCCCGAGTTCCTGGGGGTG-3’ (contains Q to E mutation 
CAG -> GAG) 
Q245E rev 5’-CACCCCGAGGAACTCGGGAAGCAG-3’ (contains Q to E mutation  
CTG -> CTC) 
 
Q245A fwd 5’-CATCCTGCTTCCCGCGTTCCTGGGGGTG-3’ (contains Q to A 
mutation CAG -> GCG) 
Q245A rev 5’-CACCCCCAGGAACGCGGGAAGCAGGATG-3’ (contains Q to A 








Figure 2.1 Schematic of a PCR-based method for designing Tspan15 with cholesterol 
binding mutations.  The primers were designed and annealed to introduce point mutations 
to the full-length of Tspan15. The first two PCR reactions were used to generate fragments 
containing the desired mutation on the wild-type Tspan15 template, using primers pairs: 
MT5147/fwd mutation and MT4150/ rev mutation. The two resulting fragments were 
mixed for the second round of PCR with the flanking primers MT4150 and MT5147. 
 
2.5.2 Polymerase chain reaction (PCR) 
 
All PCR reactions were set up according to the manufacturer’s instructions. A typical 50µl 
reaction contained 25µl KAPA HiFi polymerase ReadyMix (including the polymerase at 
0.5 U per 25µl reaction, dNTPs at 0.3 mM, 2.5 mM MgCL2), 1µl DNA template (~ 20 to 
50 ng), 1 µl of each forward and reversed primer at 20µM, and 22 µl of PCR grade water. 
Typical cycling conditions were as follows: [95 
0
C, 5 min] for 1 cycle, [98 
0
C, 30 sec; 60 
0
C, 15 sec; 72 
0
C, 60 sec] for 30 cycles, [72 
0




2.5.3 Agarose gel electrophoresis 
 
A 1% gel was prepared by dissolving the agarose in 1 x TAE buffer and adding SYBR® 
Safe DNA Gel Stain (1:10.000 dilution, Invitrogen). The gel was left to set with 
appropriate combs in place. Next, the samples were mix with 6 x Orange G loading dye 
and loaded onto the gel along with a 1 kb DNA ladder. The gel was run at 100-150 V until 
appropriate separation was reached.  DNA was visualised on a UV transilluminator. 
 
2.5.4 Purification of PCR products 
 
Prior to using the products of a PCR reaction, the products were purified to remove 
primers using the QIAquick PCR purification kit (Qiagen), following the manufacturer’s 
protocol, and eluted with 50µl elution buffer (EB) buffer.  
 
2.5.5 Purification of DNA from agarose gel 
 
Prior to cloning, DNA fragments from PCR amplifications and restriction digests were 
extracted from agarose gels and purified using the GeneJet Gel Extraction Kit (Fermentas), 
following the manufacturer’s protocol, and eluted in 50 µl of EB. 
 
2.5.6 Purification of plasmid DNA 
Plasmid DNA was isolated from overnight bacterial cultures (DH5 strain of E. coli) using 




manufacturer’s protocol. The concentration of the plasmid was measured using a 
Nanodrop Spectrophotometer. 
 
2.5.7 Digestion of plasmids and PCR products 
 
The digests were set up on ice and carried out in a total volume of 60 µl, containing 48µl 
of PCR product, or 5 µg of pEF6-FLAG plasmid DNA, 6 µl of 10x NEB buffer, and 3 µl 
of specific restriction enzymes. When necessary, the remaining volume was made up to 60 




2.5.8 DNA cloning and E. coli transformation 
 
The ligations were set up on ice and incubated at room temperature for 30 min for sticky 
ends. A ligation reaction included: a digested plasmid DNA and insert DNA, combined in 
1:6 ratio, 1 µl of T4 DNA ligase and 2 µl of 10x ligase buffer. The final volume was made 
up to 20µl with molecular biology-grade water. 
 
A general E. coli transformation using DH5 cells (Invitrogen) was carried out as follows. 
For each transformation, 50 µl of the competent cells was thawed on ice and DNA was 
added to a maximum of 10% of total bacterial volume. The cells were incubated on the ice 
for 30 min, next heat shocked in a 42 
0
C water bath for 45 seconds, and placed back on the 
ice for 2 min. 200 µl of SOC media was added and the bacteria further incubated at 37 
0
C 
for 1 hour. Each batch of transformed cells was plated out on LB agar plates with 





C. A single colony of the bacteria was picked up, and a colony PCR reaction was carried 




, 23µl sterile water, 1µl of 20 µM forward and 
reverse primers. Positive colonies were chosen for plasmid prep and confirmation by DNA 
sequencing.  
 
2.5.9 DNA sequencing 
 
DNA samples for sequencing were prepared as instructed by the Functional Genomic 
Facility at the University of Birmingham. In general, 350 ng of DNA was combined with 
3.2 pmol of primers in a total reaction volume of 10 µl. The sequencing results were 
analysed using ChromasPro (Technelysium Pty Ltd) software. 
 
2.6 In vitro angiogenesis assays 
 
2.6.1 Scratch wound assay 
 
Prior to the assay, HUVECs were seeded at 90% confluency in a 96-well plate. 24 hours 
after the seeding, the monolayer was scratched using the 96-pin wound maker tool, 
followed by image acquisition using the IncuCyteZOOM System from Essen 
BioScience. Mitomycin (5 µg/ml) was included in the media to inhibit proliferation. A 
time-lapse recording was set up to scan the wounded monolayer every 6 hours until 
complete wound closure. Two experimental approaches were used to investigate the 




monolayer was incubated with ADAM10 inhibitor (GI254023X at concentrations 2.5 µM) 
or DMSO as a vehicle control. In the second approach, the ADAM10 and Tspan15 siRNA-
transfected HUVECs were used. The changes in the width of the wounded area were 
analysed over 24 to 30-hour period, using ImageJ plugin. The percentage of the wounded 
area was measured at a given time point, compared to the initial wound area for each 
sample. 
 
2.6.2 Endothelial cell proliferation assay 
 
The cell proliferation assay was used to assess the proliferative response of HUVECs to 
pharmacological inhibition or gene silencing of ADAM10 and Tspan15. The response was 
monitored by cell counting under an inverted microscope using a hemocytometer. In the 
gene silencing approach, the cells were transfected with appropriate siRNA duplexes as 
described in section 2.3.3. One day post-transfection, 2 x 10
5
 cells were seeded in a 10 cm 
plate and incubated for an additional 72-96 hours. For the pharmacological inhibition of 
ADAM10, the plated cells were maintained in the media containing ADAM10 inhibitor 
(GI254023X at 2.5 µM) for the duration of the assay alongside with a DMSO as a vehicle 
control. The cell proliferation in control and treated HUVECs was calculated as the ratio of 
the number of live cells at the end of the culture period to the number of live cells at the 
beginning of the experiment. For normalisation of the counts, the cell proliferation for the 
control was taken as 1, and fold change for the treated samples was calculated accordingly. 
Cell viability was assessed by the trypan blue exclusion method before and after the 
treatments. Briefly, 20 µl of the cell suspension was mixed with 20 µl of the trypan blue 




suspension was pipetted onto the haemocytometer. The cells were observed using 10x 
objective magnification settings. Only live cells, that did not take up the dye, were counted 
and used for the analysis. 
 
2.6.3  2D network formation on Matrigel 
 
The endothelial cell ability to form networks in vitro was measured using a 2D tube 
formation assay on Matrigel. Prior to the assay, HUVECs were transfected with ADAM10, 
Tspan15 and negative control siRNA duplexes (see section 2.3.3.). 48 hours post-
transfection, the cells were plated sparsely at a density of 1.4 x 10
5 
cells/ml into 12-well 
plates pre-coated with 70 µl of the reduced serum Matrigel. The network formation was 
observed in real-time, using the IncuCyte Imaging System (Essen BioScience), and further 
analysed using the Angiogenesis Analyser plugin for Image J, by Gilles Carpentier 
(http://imagej.nih.gov/ij/macros/toolsets/Angiogenesis% 20Analyzer.txt). For ADAM10 
pharmacological inhibition analysis, the plated cells were incubated in the presence of 2.5 
µM GI254023X or DMSO as a vehicle control. Network formation was determined based 





2.7 Statistical analysis 
 
Statistical analyses were completed using GraphPad Prism 7.0 software. All results were 
from at least 3 independent experiments. Error bars were presented as standard error of the 
mean (SEM). All relative or percentage data were transformed by arcsine of the square 
root to normalise them transform prior to parametric statistical tests. Statistical significance 
between two independent groups was analysed using unpaired two-tailed Student t-tests. 
Comparisons between multiple groups were performed using one-way or two-way analysis 
of variance (ANOVA) followed by a post hoc multiple comparison test. P-values < 0.05 










3.1 Introduction  
 
Previously, Tspan15 has been identified as a member of the group of tetraspanins, termed 
TspanC8s (Matthews et al., 2017a, Matthews et al., 2017b, Saint-Pol et al., 2017b). These 
tetraspanins comprise Tspan5, 10, 14, 15, 17 and 33. They are related by protein sequence 
and characterised by the presence of 8 cysteines in the large extracellular loop (LEL). 
Notably, Tspan15 was the first tetraspanin identified to co-immunoprecipitate with the 
‘molecular scissor’ ADAM10 in stringent detergents such as 1% digitonin, and promote its 
maturation, trafficking to the cell surface and substrate specificity (Prox et al., 2012). The 
other five TspanC8s were then shown to perform a similar function (Dornier et al., 2012, 
Haining et al., 2012) and, more recently, data has shown that different TspanC8s confer 
distinct ADAM10 substrate specificities (Jouannet et al., 2016, Noy et al., 2016, Reyat et 





The most definite example of a TspanC8 promoting ADAM10 cleavage of a specific 
substrate is for Tspan15 and the N-cadherin cell-cell adhesion molecule (Prox et al., 2012, 
Jouannet et al., 2016, Noy et al., 2016). The above findings and the notion of Tspan15 as a 
central modulator of ADAM10 were recently confirmed in vivo. Tspan15-deficient mice 
showed a substantial reduction of the mature and active form of ADAM10 within the brain 
that correlated with the reduced shedding of N-cadherin (Seipold et al., 2018). Further, 
genetic studies implicated Tspan15 in various pathological conditions. Tspan15 was 
identified as a genetic factor with a single nucleotide polymorphism (SNP) that increases 
susceptibility to S. pneumoniae infections (Salas et al., 2018) and venous thrombotic 
diseases (Germain et al., 2015), and as an oncogene that promotes oesophageal squamous 
cancer metastasis (OSCC) (Zhang et al., 2018). Indeed, as summarised by the Human 
Protein Atlas, the abundance of Tspan15 expression on epithelial cancer cells is consistent 
with its role in tumour development and progression, particular in pancreatic cancer, and 
epithelial cell biology (Uhlen et al., 2015). Therefore, the Tspan15-ADAM10 complex is 
of great interest as a potential therapeutic target.  
 
The current characterisation of Tspan15 is hindered by lack of effective monoclonal 
antibodies (mAs). To date, the majority of studies on Tspan15 functions have relied on 
over-expression of epitope-tagged proteins in various cell lines, with potential pitfalls of 
introducing false positive results. We hypothesised that the difficulty in making tetraspanin 
mAbs arises from a highly conserved sequence of the protein between the species, a small 
size of the tetraspanins and subsequent ‘masking’ effect arising from association with 
larger partner proteins like ADAM10. To address this problem, we have developed a 




mouse embryonic fibroblasts stably over-expressing human Tspan15 (Noy and Tomlinson 
unpublished). In collaboration with Abpro, a Boston-based company, we generated four 
new mouse anti-human Tspan15 mAbs to the extracellular region of Tspan15 (Figure 3.1). 
Our new mAbs, together with in-house established ADAM10 and Tspan15 CRISPR/Cas9 
knockout cell lines, were used in the investigations forming the basis of the current study 
and future work. 
 
This chapter aims to determine (1) whether ADAM10 cell surface expression requires 
Tspan15 in primary human umbilical cord endothelial cells (HUVECs), adenocarcinomic 
human alveolar basal epithelial (A549) and human embryonic kidney (HEK-293T) cells, 




















Figure 3.1 A novel method to generate Tspan15 monoclonal antibodies.  ADAM10-
deficient mouse embryonic fibroblasts stably transfected with human Tspan15 were used 
as an immunogen for the production of mouse mAbs by the company Abpro. The 
expression of Tspan15 in ADAM10 knockout mouse cells may prevent the ‘masking 
effect’ caused by ADAM10 and enable an antibody response to Tspan15. Four Tspan15 
specific mAbs were generated: clone 4A4, 1C12, 5D4 and 5F4 (Noy and Tomlinson 
unpublished). 






3.2.1 Validation of Tspan15 mAbs 
 
 
To validate that the new mAbs do indeed recognise the endogenous Tspan15, wild-type 
(WT) HEK-293T cells, in comparison with their CRISPR/Cas9 Tspan15 knockout 
(Tspan15 KO) counterparts, were used. As shown in Figure 3.2, all four Tspan15 mAbs 
were effective in recognising endogenous Tspan15 by flow cytometry. Specificity was 









Figure 3.2 Validation of new Tspan15 monoclonal antibodies.  The wild-type and 
Tspan15 CRISPR/Cas9 knockout HEK-293T cell line was stained with four clones of 
Tspan15 mAbs (clones 4A4, 1C12, 5F4 and 5D4 were used in the form of tissue culture 
supernatants) and isotype control and subjected to flow cytometry to determine the cell 















































3.2.2 Tspan15 is required for normal 
ADAM10 cell surface expression  
 
Tspan15 knockdown has previously been shown to reduce ADAM10 cell surface 
expression in a human prostate carcinoma cells (PC3) by 60% (Jouannet et at., 2016) and 
by 50% in mouse neuroblastoma cells (N2A) (Prox et al., 2012). To determine the 
requirement of Tspan15 for ADAM10 expression in HEK-293T and A549 cell lines, a 
panel of CRISPR/Cas9 KO cell lines were used, in conjunction with the new Tspan15 
mAbs. Flow cytometry revealed that in the absence of Tspan15, ADAM10 cell surface 
expression was reduced by approximately 70% in HEK-293T cells (Figure 3.3A) and by 
approximately 50% in A549 cells (Figure 3.3B). As a control, no ADAM10 was detected 
on ADAM10 KO cells (Figure 3.3A-B). To determine whether Tspan15 also affected 
ADAM10 expression in HUVECs, flow cytometry was performed following siRNA 
knockdown of Tspan15. ADAM10 cell surface expression was reduced by approximately 
30% using two different Tspan15 siRNA duplexes (Figure 3.3C). 
 
The residual ADAM10 expression in the absence of Tspan15 may be due to the expression 
of other TspanC8s. In the absence of mAbs to most TspanC8s, their expression was 
compared at the transcriptomic level using data available from the Human Protein Atlas 
(Uhlen et al., 2015). HEK-293T and A549 cells expressed substantial levels of Tspan15, 
but other TspanC8s were also expressed at various levels (Figure 3.3D). HUVECs 
expressed relatively less Tspan15, with higher levels of Tspan5, Tspan14 and Tspan17 
(Figure 3.3D). These Protein Atlas data are consistent with our published real-time PCR 




Together these data demonstrate that Tspan15 is important for normal ADAM10 cell 
surface expression, and residual expression is likely due to other TspanC8s that are 
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Figure 3.3 Tspan15 is differentially required for ADAM10 cell surface expression in 
various cell types.  [A] HEK-293T and [B] A549 wild-type (WT), ADAM10 KO and 
Tspan15 KO cells were analysed by flow cytometry using ADAM10 (green histogram) or 
MOPC negative control (filled purple histogram) mAbs. [C] HUVECs were similarly 
analysed by flow cytometry, following ADAM10 or Tspan15 knockdown with two 
different siRNA duplexes. The data in panels A-C were quantitated by dividing the 
ADAM10 geometric mean fluorescence intensity by the corresponding MOPC value, such 
that no expression has a value of 1. The bar charts represent the mean expression data from 
three to four experiments, and error bars are the standard error of the mean. Data were 
normalised by arcsine transformation of the square root and analysed by a one-way 
ANOVA and Dunnett’s multiple comparison test (
**
p < 0.01, 
***
p < 0.001, 
****
p < 0.0001). 
[D] ADAM10 and TspanC8 mRNA expression in HEK-293T, A549 and HUVECs from 
The Human Protein Atlas. The results are reported as the number of Transcripts per 





3.2.3 ADAM10 is required for normal 
Tspan15 surface expression 
 
ADAM10 knockdown has previously been shown to reduce Tspan5 cell surface expression 
in U2OS and HCT116 cell lines by 40% (Saint-Pol et al., 2017a), which indicated that 
regulation within the ADAM10/Tspan5 complex is reciprocal. In order to determine the 
requirement of ADAM10 for Tspan15 expression, flow cytometry on ADAM10 KO HEK-
293T and A549 cell lines and ADAM10 siRNA-transfected HUVEC cells were performed 
with Tspan15 mAbs. This revealed that in the absence of ADAM10, Tspan15 surface 
expression was reduced by approximately 80% in ADAM10 KO cell lines (Figure3.4 A-B) 
and by approximately 90% using two different ADAM10 siRNA duplexes in HUVEC 
upon quantitation (Figure3.4 C). 






















Figure 3.4 Tspan15 cell surface expression is reduced in the absence of ADAM10.  [A-
C] Flow cytometry was performed as described in Figure 3.3, with the exception that 
Tspan15 mAb (4A4 clone used in a form of tissue culture supernatant) was used instead of 
ADAM10. The bar charts represent the mean expression data from three to four 
experiments, and error bars are the standard error of the mean. Data were normalised by 
arcsine transformation of the square root and analysed by a one-way ANOVA and 




p < 0.01, 
***
p < 0.001, 
****







In this chapter, four new Tspan15 mAbs were used in conjunction with ADAM10- and 
Tspan15-knockout/knockdown cells to investigate the extent to which Tspan15 is required 
for ADAM10 surface expression and vice versa. Initial validation of the mAbs confirmed 
their specificity in detecting endogenous levels of Tspan15 by flow cytometry on WT 
cells, but not on Tspan15-knockout/knockdown cells. Tspan15 was found to be important 
for normal ADAM10 surface expression on HEK-293T and A549 cells lines, and 
HUVECs, since ADAM10 was reduced 70%, 50% and 30%, respectively, in the absence 
of Tspan15. Finally, the discovery that ADAM10 was required for normal Tspan15 surface 
expression, with an 80% reduction in the absence of ADAM10, was a surprising result. 
Collectively, the data presented in this chapter indicate the reciprocal relationship between 
the interacting partners which suggests that the main role of Tspan15 is to regulate 
ADAM10. 
 
There are well-characterised mAbs to several tetraspanins, in particular, those with CD 
nomenclature that is given on the basis that mAbs are available: CD9, CD37, CD63, 
CD81, CD82, CD151 and CD231. However, one problem in the tetraspanin field is the 
lack of effective antibodies to many of these proteins. Indeed, at the start of this thesis 
project, there were no mAbs, or even any effective polyclonal antibodies, to any of the 
TspanC8s. Despite considerable work to develop mAbs, to date, many efforts have failed 
(Mike Tomlinson, personal communication, following discussions with other tetraspanin 
researchers). The obstacles in tetraspanin antibody production likely arise from the high 




low expression level and/or their association with rather larger partner proteins that may 
mask a tetraspanin antibody from recognition.  
Furthermore, the four-transmembrane structure of tetraspanins, and lack of a modular 
domain structure in their extracellular regions has hindered efforts to make effective 
immunogens from soluble recombinant versions of the extracellular region. While such 
recombinant proteins have proved successful in screening for antibodies (Tomlinson et al., 
1993, Tomlinson et al., 1995), for structural studies (Kitadokoro et al., 2001, Rajesh et al., 
2012) and in a number of functional studies (Hassuna et al., 2017, Hulme et al., 2014, 
Green et al., 2011, Barreiro et al., 2008), they have not yet been validated as good 
immunogens. This is presumably because the antibody response is focussed on unfolded 
protein or novel epitopes in the recombinant proteins, that do not exist in the full-length 
protein. In contrast, successful mAb generation projects have used intact cells expressing 
tetraspanins, or immunoprecipitates of full-length tetraspanins from such cells (Rubinstein 
et al., 2013). 
In this chapter, we have reported the successful generation of four mouse anti-human-
Tspan15 mAbs, in collaboration with the antibody company Abpro, using a novel 
immunogen: ADAM10 KO mouse embryonic fibroblasts stably overexpressing human 
Tspan15. Western blotting experiments have demonstrated no cross-reactivity of the 
Tspan15 mAbs with other TspanC8s (Koo, unpublished). The new method likely 
overcomes the potential problems of low expression or masking by ADAM10, and may 
have benefited from the eight amino acid differences between human and mouse Tspan15 
in the main extracellular region. This region was shown to contain the mAb epitopes 
(Chapter 4, and Koo, unpublished). The novel immunogen strategy might be useful for 




utility of CRISPR/Cas9 genome editing would enable knockout cell lines, for tetraspanin 
partners, to be readily generated for subsequent over-expression of the tetraspanin. The 
successful mAb generation could also be attributed to Abpro’s proprietary mouse strain, on 
which the company is based. The ImmunoMax
TM
 Mouse was developed to provide an 
optimised response and a diversified repertoire of mAbs.  
 
The absence of Tspan15 was sufficient to reduce ADAM10 surface expression on HEK-
293T and A549 cells by 70% and 50%, respectively. The remaining ADAM10 is likely to 
be associated with other TspanC8s since HEK-293T cells express all six TspanC8s 
(Haining et al., 2012) and A549 express all except Tspan10 (Matthews et al., 2017b). 
Similarly, Tspan15 knockdown reduced surface ADAM10 by 30% in HUVECs, a primary 
cell type which expresses all TspanC8s except Tspan33 (Haining et al., 2012). This is in 
line with a previous study shown by Haining et al., whereby knockdown of the major 
tetraspanins expressed, such as Tspan33 in erythrocytes or Tspan14 in HUVECs, led to 
substantial reductions of ADAM10 surface levels (Haining et al., 2012). Also, Dornier et 
al. showed that ADAM10 accumulated in the ER following knockdown of the most highly 
expressed TspanC8, Tspan14, in HCT116 colon cancer cells (Dornier et al., 2012). Indeed, 
Prox et al. used pulse-chase experiments to show that Tspan15 promotes ADAM10 exit 
from the ER and its stabilisation at the cell surface (Prox et al., 2012). 
 
The most striking and surprising result in this chapter was the 80% reduction in surface 
Tspan15 observed following ADAM10 knockout in HEK-293T, A549 or HUVECs. 
However, a recent report now suggests that this could be a common feature for all 




ADAM10-associated in U2OS osteosarcoma cells and HCT116 cells and ADAM10 is 
required for normal Tspan5 expression and trafficking out of the ER (Saint-Pol et al., 
2017a). The important question is what causes the inability of Tspan15 to traffic to the 
surface? Recent unpublished work in the Tomlinson lab has shown that in the absence of 
ADAM10, the total Tspan15 protein level was reduced by 80 %, as detected by western 
blot and there was no difference in Tspan15 mRNA between WT and ADAM10 KO cells 
(Koo, unpublished). A similar observation was made by Saint-Pol et al., who showed that 
the total amount of Tspan5 decreased upon ADAM10 knockdown (Saint-Pol et al., 2017a). 
Thus, the retention of Tspan15 in the ER in the absence of ADAM10 is unlikely to be the 
mechanism, and instead, it could be that Tspan15 requires ADAM10 for protein stability. 
This stabilising effect of partners on tetraspanins has not been reported for non-TspanC8 
tetraspanins.  
 
While regulation of Tspan15 by ADAM10 is an exciting discovery, it raises the question of 
how a Tspan15-overexpressing immunogen was created in ADAM10 KO MEFs? One 
answer could be that the overexpression of Tspan15 yields a large pool of protein that 
bypasses the need for ADAM10, perhaps by causing Tspan15 clustering. Indeed, it was 
demonstrated in the Tomlinson lab that, transient over-expression of Tspan15 in WT and 
ADAM10 KO cells, achieved the same levels of Tspan15 surface expression (Koo, 
unpublished). 
 
In conclusion, the chapter describes the production of the first mAbs against Tspan15, and 
their use to characterise the expression of Tspan15/ADAM10 complexes. The data suggest 




whole when both components are present. Indeed, the formation of the complex appears 
necessary for proteins to exit the ER and be expressed on the cell surface. Moreover, the 




REGULATION OF CADHERIN 






Cadherins are homophilic cell adhesion molecules and components of cellular adherens 
junctions. They function through association with the cytoskeleton via interactions 
between their intracellular tails and -catenin, a multifunction protein with roles in cell 
adhesion and gene expression. The interaction maintains structural and functional tissue 
continuity and integrity that is essential in homeostasis (Leckband and de Rooij, 2014). 
ADAM10 has been identified as a primary sheddase for several members of the cadherin 
family (Pruessmeyer and Ludwig, 2009). Analysis of ADAM10-deficient fibroblasts, 
inhibitor studies and siRNA-mediated ADAM10 downregulation in HUVEC demonstrate 
that the protease is responsible for N-, E- and VE-cadherin shedding (Reiss et al., 2005, 
Maretzky et al., 2005, Schulz et al., 2008). ADAM10 can cleave the cadherins at the basal 
level, and this is increased upon cell stimulation. Shedding of the full-length protein leaves 
a membrane-bound C-terminal fragment that is a target for intracellular cleavage by the -






 loosening of cell-cell junctions to promote cell motility and vessel permeability and signal 
transduction by release of -catenin to translocate to the nucleus and regulate gene 
transcription (Reiss et al., 2005, Maretzky et al., 2005, Schulz et al., 2008). The importance 
of cadherin cleavage is not fully understood. In the brain, ADAM10 cleavage of N-
cadherin induces neuronal progenitor cell migration to promote myelin repair following 
brain injury (Klingener et al., 2014). Inflammation-induced VE-cadherin shedding is 
implicated in endothelial barrier disruption and severe increase in sepsis pathogenesis 
(Flemming et al., 2015). Also, S. aureus -toxin targets ADAM10 to weaken epithelial 
junctions and promote bacterial spread through a mechanism involving E-cadherin 
shedding (Inoshima et al., 2011).  
 
Existing evidence in the tetraspanin field indicates that different TspanC8/ADAM10 
complexes can cut different cadherins. We and others have reported the effect of Tspan15 
specifically on the promotion of N-cadherin shedding in epithelial cell lines. (Prox et al., 
2012, Jouannet et al., 2016, Noy et al., 2016). Also, we have shown that Tspan5 and 
Tspan17 regulate VE-cadherin surface expression and promote T cell transmigration in an 
inflammatory model while Tspan15 has no effect (Reyat et al., 2017). This study suggested 
that Tspan5/ADAM10 and Tspan17/ADAM10 were the scissors for VE-cadherin, but only 
VE-cadherin expression was assessed, not its cleavage (Reyat et al., 2017). The role of 
TspanC8s in E-cadherin shedding has not been reported. The aim of this chapter was to 
determine whether Tspan15 is required for N-, E- and VE-cadherin cleavage and to 







4.2.1 Tspan15 is required for endogenous  
N- and E-cadherin shedding in A549  
cells and VE-cadherin shedding  
in transfected HEK-293T cells 
 
To determine the effect of Tspan15 on cadherin cleavage, a panel of CRISPR/Cas9 
ADAM10 and Tspan15 KO cell lines were used, all previously generated in the Tomlinson 
lab. Both constitutive and NEM-stimulated cleavage was investigated for endogenous N- 
and E-cadherin in A549 cells, and transfected human VE-cadherin in HEK-293T cells, 
because the latter do not express VE-cadherin. The alkylating agent NEM was chosen to 
trigger the enzymatic activity of ADAM10, because it is a robust activator, although the 
mechanism of action is not clear (Gardiner, 2018). Cleavage of the cadherins was 
determined by western blotting of whole cell lysates with an antibody against the C-
terminal tail of the cadherins, to allow detection of both the full length and the truncated 
transmembrane fragment.  
 
NEM induced a striking increase in N-cadherin cleavage in WT A549 cells, but not in 
ADAM10- or Tspan15-knockout cells (Figure 4.1A-B). Basal cleavage in the absence of 
NEM was relatively weak but was also reduced in the absence of ADAM10 or Tspan15 
(Figure 4.1A-B). E-cadherin cleavage was similarly dependent on ADAM10 and Tspan15 
in A549 cells (Figure 4.1C-D). Furthermore, transfected VE-cadherin cleavage in HEK-
293T cells also required ADAM10 and Tspan15 (Figure 4.1E-F). Importantly, Tspan15-




surface ADAM10 (Figure 3.3A-B). Together these data suggest that Tspan15/ADAM10 is 




















































Figure 4.1 ADAM10 and Tspan15 are required for N- and E-cadherin shedding in 
A549 cells and VE-cadherin shedding in transfected HEK-293T cells.  [A-B] N-
cadherin and [C-D] E-cadherin shedding were measured in A549 cells, and [E] transfected 
VE-cadherin shedding was measured in HEK-293T cells. The cells were first treated with 
DAPT (10µM), to prevent post-ADAM10 proteolysis by γ-secretase, followed by NEM 
(2mM) to activate ADAM10. Cells were lysed in 1% Triton X-100 and lysates blotted with 
antibodies against the C-terminal fragments of the cadherins. Representative blots are 
shown in panels A, C and E, and quantitation of percentage cleavage in panels B, D and F. 
Error bars represent the standard error of the mean (SEM) of three independent 
experiments. Before statistical analysis, data were transformed by arcsine of the square 
root and statistically analysed by a one-way ANOVA followed by Dunnett’s multiple 
comparison test, compared to WT (**p<0.01, ***p<0.001, ****p<0.0001). [E] The blot 
and quantitation of the E-cadherin shedding without NEM stimulation was done and kindly 





4.2.2 Tspan15 has a minor role in VE-cadherin 
shedding on HUVEC cells 
 
We have previously reported that Tspan5 and Tspan17, but not other TspanC8s, affect VE-
cadherin expression on HUVECs and might promote VE-cadherin cleavage, but the latter 
was not formally tested (Reyat et al., 2017). Since Tspan15/ADAM10 appears to be the 
scissor for transfected VE-cadherin in HEK-293T cells (Figure 4.1E-F), we speculated that 
Tspan15 might be required for VE-cadherin cleavage in HUVECs. To test this, western 
blotting of endogenous VE-cadherin was performed following siRNA knockdown of 
Tspan15 and ADAM10. As shown in Figure 4.2A-B, NEM treatment induced VE-cadherin 
cleavage in an ADAM10-dependent manner, but knockdown of Tspan15 had only a minor 
effect in reducing cleavage by approximately 30%. The slight reduction in the cleavage 
could result from the 30% decrease in ADAM10 surface expression after the Tspan15 
knockdown, as shown in Figure 3.3. The efficiency of the knockdown was confirmed by 
flow cytometry and found to be at least 85% (Figure 4.3C-D). 


















































































































































































































































































































Figure 4.2 ADAM10 is required for VE-cadherin cleavage in HUVEC, but Tspan15 
has a minor role.  [A] HUVECs were transfected with Tspan15, ADAM10 and negative 
control siRNAs and cleavage assays were done by western blotting as described in Figure 
4.1. [B]The percentage cleaved VE-cadherin was calculated based on the intensities of 
intact and cleaved fragments of the cadherin. [C-D] Efficiency of ADAM10 and Tspan15 
knockdowns were measured by flow cytometry. The blue lines represent isotype control 
staining and the green lines represent ADAM10 or Tspan15 staining. Tspan15 mAb (clone 
4A4) was used in a form of tissue culture supernatant. Error bars represent standard error 
of the mean for three to four independent experiments. Statistical significance of arcsine-
transformed data was analysed by one-way ANOVA followed by Dunnett’s multiple 






4.2.3 Tspan15 mAbs 4A4 and 1C12 inhibit 
cleavage of transfected VE-cadherin  
in HEK-293T  
 
A mAb to Tspan5 was reported to inhibit Notch activation (Saint-Pol, 2017). To 
investigate whether the new Tspan15 mAbs, validated in the previous chapter, might also 
affect substrate cleavage, VE-cadherin-transfected HEK-293T cells were selected as a 
model because of the complete Tspan15 dependence in this system (Figure 4.1E-F).  
As shown in Figure 4.3A-B, the cells pre-treated with Tspan15 mAb clone 4A4 or 1C12 
had inhibited NEM-induced VE-cadherin cleavage as compared to the WT. The phenotype 
was the most pronounced at a concentration of 10 µg/ml of the mAbs used. Also, the 
antibody’s titration revealed that the cleavage was concentration dependent, and gradually 
increased as the concentration of the antibodies decreased. In contrast, Tspan15 mAb 




































Figure 4.3. Tspan15 mAb clones 4A4 and 1C12 inhibit transfected VE-cadherin 
cleavage in HEK-293T cells, but clones 5F4 and 5D4 do not.  VE-cadherin-transfected 
HEK-293T cells were treated with Tspan15 mAbs or MOPC control mAb for 30 minutes 
followed by NEM stimulation for an additional 30 minutes. The cleavage of VE-cadherin 
was detected by western blotting as described in Figure 4.1E. The data are presented in the 
form of a representative western blot and quantitation for [A] clone 4A4, [B] 1C12, [C] 
5F4 and [D] 5D4. Tspan15 mAbs were used in a form of purified antibodies. Error bars 
represent SEM for three independent experiments. Statistical significance was measured on 
arcsine-transformed data using one-way ANOVA and a Dunnett’s multiple comparison 
test as compared with WT control (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 




4.2.4 Evidence that the four Tspan15 mAbs 
share a common epitope   
 
Since two of the Tspan15 mAbs (4A4 and 1C12) appear to be inhibitory, but the other two 
(5F4 and 5D4) do not this could be due to the recognition of different epitopes. Epitope is 
likely to be within the main extracellular region of Tspan15 since this is the target for most 
other tetraspanin mAbs that have been epitope mapped. A previously reported method for 
tetraspanin mAb epitope mapping used chimeras of two different species of CD53, given 
that the mAbs recognised one species but not the other (Tomlinson et al., 1993, Tomlinson 
et al., 1995). The four mouse anti-Tspan15 mAbs western blot human but not mouse 
Tspan15 (Tomlinson lab, unpublished). Sequence analysis showed that human and mouse 
Tspan15 orthologues share 95% sequence homology (Figure 4.4A). The main difference 
falls within the main extracellular region and contains eight amino acids that vary between 
mouse and human which were divided into four regions for chimera generation (Figure 
4.4B). Each of the four chimeras comprised human Tspan15 with the designated mouse 
sequences introduced (Figure 4.5A); these were generated as expression constructs by 
project student Mike Sykes with the help of Eleanor Cull and Neale Harrison. 
  
To investigate the Tspan15 mAbs epitopes the four FLAG-tagged chimeras were 
transfected into Tspan15 KO HEK-293T cells alongside WT mouse and human Tspan15 
controls. The cells were lysed using 1% Triton X-100 lysis buffer and lysates were western 
blotted under non-reducing condition (the non-reducing conditions preserves reactivity of 




Tspan15 and FLAG mAbs respectively. Each mAb detected chimeras 1, 3 and 4, but not 
chimera 2, and as expected WT human but not mouse was detected (Figure 4.5B-C).  
These results suggest the existence of a common epitope for the four Tspan15 mAbs, 










Figure 4.4 Alignment of human (h) and mouse (m) Tspan15 sequences.  The amino 
acid sequences comparison was performed using Clustal Omega. (A) The alignment of the 
full-length sequences. In light blue are highlighted the N-terminal tyrosine-based (YLWL) 
and C-terminal dileucine-based (LL) motifs, respectively. The putative N-glycosylation 
conserved residues are in pink. The four transmembrane regions are indicated in yellow. 
(B) The alignment of the large extracellular region only. The amino acids are grouped into 























































































Figure 4.5 Tspan15 epitope mapping suggests a common epitope for the four Tspan15 
mAbs.  [A] Schematic of human/mouse Tspan15 chimeras. The eight amino acid residues 
in the large extracellular region of human Tspan15 were divided into four regions (1-4) 
and substituted with the corresponding residues of mouse Tspan15. Chimeric constructs 
were generated by Neale Harrison, Michael Sykes and Eleanor Cull. [B] Tspan15 KO 
HEK-293T cells were transfected with FLAG-tagged WT human and mouse Tspan15 and 
human/mouse Tspan15 chimeras. The cells were lysed in 1% Triton X-100 lysis buffer and 
lysates western blotted under non-reducing conditions with each Tspan15 mAbs (used 
clones were in a form of purified antibodies) or FLAG mAb. [C] Tspan15 mAb data from 
panel B were quantified relative to FLAG blotting and relative to the WT human Tspan15 
which was set to 100. Data were arcsine transformed and statistically analysed using a one-
way ANOVA with Dunnett’s multiple comparison test compared to WT human Tspan15 
(*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Error bars represent standard error of 





To investigate whether the human FSV sequence was sufficient for recognition by any of 
the Tspan15 mAbs, a chimera was generated in which FSV was introduced into mouse 
Tspan15 (Figure 4.6A). Western blotting was performed as described in the previous 
figure, but no detection of the chimera was observed for any of the mAbs, despite clear 
detection by FLAG blotting (Figure 4.6B-C). This indicates, that in the context of mouse 
Tspan15, the human FSV region is not sufficient to restore the binding and recognition by 
the Tspan15 antibodies. Therefore, while individual mAbs differed in their functional 





























































Figure 4.6 The human FSV sequence not sufficient to restore binding of Tspan15 
mAbs to mouse Tpan15.  [A] Schematic of the mouse Tspan15 chimera. The three amino 
acid residues in the large extracellular region of the mouse Tspan15 were substituted with 
the corresponding residues of human Tspan15, and the FLAG-tagged chimeric construct 
was generated by Neale Harrison. The substitutions were as follow mouse leucine, 
asparagine and alanine to human phenylalanine, serine and valine. [B-C] Western blotting 
was performed as described in Figure 4.5. Data were arcsine transformed and statistically 
analysed using a one-way ANOVA with Dunnett’s multiple comparison test compare to 
WT human Tspan15 (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). Error bars 





 4.2.5 Tspan15 mAbs induce similar level of 
Tspan15 internalisation  
 
It is well established that mAbs to cell surface proteins commonly induce their 
internalisation (Latysheva et al., 2006, Xu et al., 2009, de Goeij et al., 2016, Li et al., 
2015). To evaluate whether Tspan15 mAbs might differentially induce internalization, and 
thus potentially explain their different inhibitory effects, the four Tspan15 mAbs were used 
in conjunction with flow cytometry to measure a potential antibody internalisation effect. 
The Tspan15 mAbs were added directly to the HEK-293T cells at 4
0
C for 30 min to allow 
mAb recognition. Next, the unbound mAbs were washed away. Internalization of Tspan15 
and mAbs was enabled by incubating the cells at 37 
0
C for an additional 30 min. Following 
potential internalization, the remaining surface-bound mAbs were detected using anti-
mouse-FITC and analysed by flow cytometry. As shown in Figure 4.7 A-B, the mAbs 
induced partial internalisation of Tspan15. However, the expression levels, post-
internalisation, did not differ between the clones studied. Therefore, differential 








































































































Figure 4.7 Tspan15 mAbs each cause a partial reduction in Tspan15 surface 
expression.  [A] HEK-293T cells were treated with Tspan15 mAbs for 30 min (Tspan15 
mAbs four clones were used in a form of purified antibodies). Tspan15 surface expression 
was measured by flow cytometry before (at 4
0
C) and after (at 37
0
C) the internalisation. 
Representative histograms of Tspan15 fluorescence intensities are plotted. The blue line 
represents isotype control staining while the green line represents Tspan15 staining ( the 
cells were stained with four clones of Tspan15 mAbs in a form of tissue culture 
supernatants). [B] The average geometric mean of Tspan15 fluorescence intensities was 
quantified relative to the negative control and presented as a relative Tspan15 surface 
expression for each condition tested, such that a value of 1 represents no specific staining. 
The data were arcsine transformed before being statistically analysed using a two-way 
ANOVA with Sidak's multiple comparisons test (*p<0.05, **p<0.01, ***p<0.001, 





The effect of Tspan15 mAbs on ADAM10 surface expression was also investigated since 
this could potentially explain the differential inhibitory effects on VE-cadherin cleavage. 
However, as shown in Figure 4.8, incubation with the Tspan15 mAbs did not alter the 
surface level of ADAM10.  
Taken together, the inhibitory effects of Tspan15 mAbs 4A4 and 1C12, versus the non-
inhibitory effects of 5F4 and 5D4, cannot be explained by different mAb epitopes, 





















































































































Figure 4.8 ADAM10 surface expression is not affected by Tspan15 mAbs.  [A] HEK-
293T were incubated with Tspan15 mAbs at 37
0
C for 30 min and analysed by flow 
cytometry for ADAM10 surface expression using ADAM10-conjugated mAbs. The blue 
lines represent isotype control staining, and green lines represent ADAM10 staining. [B] 
The average geometric mean fluorescence intensities of the samples were measured, and 
data were presented as a relative ADAM10 surface expression, as described for Figure 4.7. 
Data was arcsine transformed and statistically analysed using one-way ANOVA with 
Dunnett’s multiple comparison test as compared with the control; no significant difference 








The data in this chapter confirmed published reports suggesting that Tspan15/ADAM10 is 
the specific scissor for N-cadherin (Jouannet 2016; Noy 2016; Prox 2012), and extended 
these to show that Tspan15 was also required for E- and VE-cadherin cleavage. The latter 
was cell type dependent, because Tspan15 was required for cleavage in VE-cadherin-
transfected HEK-293T cells, but not for the endogenous protein in HUVECs. Two of the 
Tspan15 mAbs, 1C12 and 4A4, impaired VE-cadherin cleavage in transfected HEK-293T 
cells by 50%, but 5D4 and 5F4 had not effect. No evidence was obtained to suggest that 
these differences are due to different mAb epitopes, because epitope mapping indicated 
epitopes dependent on the same three-amino acid sequence for all mAbs. The differences 
could also not be explained by differential internalisation of Tspan15, which was similar 
for all mAbs, or by loss of surface ADAM10, which was not induced by any of the mAbs. 
 
In the absence of Tspan15 in A549 cells, the cleavage of endogenous N- and E-cadherin, 
respectively, was almost completely abolished, similar to ADAM10-KO cells. The 
cleavage of VE-cadherin in transfected HEK-293T cells was similarly abolished in the 
absence of Tspan15. Cleavage was induced in these experiments by the alkylating agent 
NEM, a powerful activator of ADAM10 (Loechel et al., 1999, Gardiner, 2018). These 
findings are consistent with a previous study from the Tomlinson lab, which showed that 
Tspan15 was unique amongst TspanC8s in being able to promote N-cadherin cleavage 
when over-expressed in HEK-293T cells (Noy et al., 2016). Two other groups have made 
observations consistent with this in different epithelial cell lines, using over-expression and 
siRNA knockdown of Tspan15 (Jouannet et al., 2016, Prox et al., 2012). More recently, the 




but the main phenotype reported was a 75-85% reduction in cleaved N-cadherin in the 
brain, despite only a 25-50% reduction in mature ADAM10; the variation was due to 
increases in effect size with age of the mice (Seipold et al., 2018). Taken together, this 
evidence implies that the cleavage of cadherins on epithelial cells is likely to rely on the 
regulation of ADAM10 by Tspan15. It remains to be determined how exactly the cleavage 
is affected by the complex. Whether it is an explicit structural conformation that ADAM10 
adopts in association with Tspan15, or cellular localisation of the complex in close 
proximity with the cadherins, or capacity for Tspan15 to interact with cadherins, remains 
to be determined. In the absence of a consensus sequence for proteolytic cleavage by 
ADAM10, the specific cleavage of the cadherins could be caused by a distinct 
conformation change of ADAM10 in complex with Tspan15, which is supported by the 
Tomlinson lab’s previous report that the 26 amino acid membrane-proximal stalk region of 
ADAM10 is sufficient for co-immunoprecipitation with Tspan15, but not other TspanC8s 
(Noy et al., 2016). Accordingly, the position of Tspan15 could be sufficient to ‘lock’ 
ADAM10 in the conformation that allows cleavage of the cadherins but not many other 
surface proteins such as Notch proteins which are preferentially cleaved and activated by 
Tspan5 and Tspan14 (Dornier et al., 2012, Jouannet et al., 2016, Saint-Pol et al., 2017). 
The role of Tspan15 in the cleavage of the cadherins could be further explained by 
Tspan15’s preferential localization to the plasma membrane, where the cadherins are also 
predominantly localised. The relatively strong Tspan15 plasma membrane localisation, 
versus other TspanC8s, was apparent in transfected HeLa cells (Dornier et al., 2012) and 





In contrast, to the observations in A549 and HEK-293T cells, Tspan15 knockdown in 
HUVECs had only a minor effect on endogenous VE-cadherin cleavage in response to 
NEM, as opposed to that seen in the ADAM10 knockdown cells where cleavage was 
reduced more profoundly. Indeed, the 30% reduction in cleavage following Tspan15 
knockdown correlated with a 30% reduction in surface ADAM10 expression, suggesting 
that Tspan15/ADAM10 is not a specific scissor for VE-cadherin in primary endothelial 
cells. Previously, Haining et al. showed that knockdown of Tspan14, the major TspanC8 
present in HUVECs, also caused a partial reduction (30%) in basal VE-cadherin cleavage, 
accompanied by an incomplete reduction (50%) in ADAM10 expression, which argues 
that Tspan14/ADAM10 is also not a specific scissor for VE-cadherin. More likely 
candidates are Tspan5 and Tspan17, which are the two most highly related TspanC8s, with 
72% amino acid identity. As shown by a combination knockdown approach, the presence 
of either Tspan5 or Tspan17, with the other five TspanC8s knocked down, was sufficient 
to reduce basal surface levels of VE-cadherin by 30-40%, without affecting surface 
ADAM10 expression (Reyat et al., 2017). However, the mechanism by which Tspan5 and 
Tspan17 affect VE-cadherin expression remains unclear because no cleavage data was 
presented (Reyat et al., 2017). Indeed, experiments conducted during this thesis found that 
knockdown of Tspan5 and Tspan17 in HUVECs, either singly or in combination, had no 
effect on NEM-induced VE-cadherin cleavage (data not shown). Finally, it remains unclear 
why Tspan15/ADAM10 is the scissor for transfected VE-cadherin in HEK-293T cells, but 
not for endogenous VE-cadherin in HUVECs. A possible explanation is that HUVECs lack 





Tetraspanin mAbs have a history of being used to gain functional insights and have often 
initiated a programme of work on particular tetraspanins. For example, CD81 was 
originally identified as the target of an anti-proliferative antibody (TAPA-1) in one of the 
earliest tetraspanin publications (Oren et al., 1990). More recently, a CD151 mAb was 
reported which disrupted the interaction of CD151 with integrin α3β1, to render CD151-
free integrin less able to bind laminin (Nishiuchi et al., 2005). Of additional therapeutic 
interest is a mAb to Tspan12, which suppresses signalling through its Frizzled-4 partner 
and has therapeutic benefit in a mouse model of vasoproliferative retinopathy (Bucher et 
al., 2017). Of direct relevance to TspanC8s, a Tspan5 mAb inhibits Notch signalling in a 
cell line model (Saint-Pol et al., 2017a). In this chapter, two of the Tspan15 mAbs, clones 
4A4 and 1C12, inhibited NEM-induced VE-cadherin cleavage in transfected HEK-293T 
cells by approximately 50%. In contrast, 5D4 and 5F4 mAbs had no such effect. The 
inhibitory effect was not due to any obvious difference in epitopes for these mAbs, which 
could enable ADAM10 inhibition by disruption of the Tspan15/ADAM10 complex or by 
steric hindrance of the ADAM10 active site. Indeed, the use of human/mouse chimeric 
Tspan15 constructs showed that all four mAbs require the FSV amino acid triplet, which is 
likely to be positioned near the top of the main extracellular region since its mutation to the 
LNA sequence of mouse Tspan15 prevented mAb recognition by western blotting. In more 
recent work by the Tomlinson group, this data was strengthened by a mAb competition 
experiment, in which all four mAbs competed with each other for Tspan15 binding by flow 
cytometry (Koo, unpublished). Furthermore, it does not appear likely that the mAbs can 
disrupt the Tspan15/ADAM10 interaction, because each co-immunoprecipitate ADAM10 
effectively (Koo, unpublished). Also, the mAb differences are unlikely be to be due to 




caused Tspan15 to be only partially internalised, and to a similar extent, while ADAM10 
levels remained unchanged. It is possible that different affinities might explain the 
different functional effects of the mAbs, which has been established for other mAbs 
(Mortensen et al., 2012, Zhou et al., 2012). Alternatively, they might have epitopes that are 
overlapping, but distinct in terms of the way in which the bound mAb is orientated relative 
to ADAM10, thus allowing two to inhibit ADAM10 activity and two to have no effect. 











5.1 Introduction  
 
In the previous chapter it was shown that ADAM10 activity towards cadherins on HEK-
293T and A549 cells was specifically promoted by Tspan15. The underlying molecular 
mechanism by which Tspan15 promotes cadherin cleavage is not known. Indeed, the 
mechanism by which any TspanC8 promotes specificity in ADAM10 substrate recognition 
is unknown. This chapter starts with the hypothesis that Tspan15 promotes cadherin 
shedding by affecting ADAM10 conformation and/or cellular localisation. TspanC8s have 
been previously shown to have distinct localisations (Dornier et al., 2012) and to interact 
with ADAM10 through different mechanisms that could regulate the structural 
conformation of ADAM10 (Noy et al., 2016). Therefore, the chapter aims to extend these 
findings, using Tspan15-knockout cells stably reconstituted with various mutant forms of 
Tspan15 and the Tspan15/14 chimeric constructs (Figure 5.1). The information gathered in 









Figure 5.1 Schematic of Tspan15 chimeric and mutant constructs.  From the left: 
human Tspan14 chimera with the extracellular region (EC) of human Tspan15 
(Tspan14/EC15); Tspan15 chimera with EC of Tspan14 (Tspan15/EC14); Tspan15 with a 
glutamine (Q) to glutamic acid (E) point mutation at the predicted cholesterol-binding site 
at amino acid position 245 in the transmembrane region (Tspan15 Q/E); Tspan15 with a 
glutamine (Q) to alanine (A) point mutation at amino acid position 245 (Tspan15 Q/A); 
Tspan15 mutant with truncations in both N- and C- cytoplasmic tails (Tspan15 cyto). 
TspanC8 N-glycosylations are indicated by filled ovals. The putative ’open’ conformation 
is shown for the Q/A mutant, based on structural analysis of CD81; the Q/E mutation may 


























5.2 Results  
 
5.2.1 The Tspan15 transmembrane and 
cytoplasmic regions are sufficient  
for promoting ADAM10 surface 
localisation, but the extracellular region 
is required for N-cadherin shedding 
 
Noy et al have previously shown that different TspanC8s have distinct binding 
requirements for ADAM10; albeit, the requirements involve the extracellular region of 
TspanC8s and specific extracellular domains of ADAM10. Tspan15 is distinctive among 
TspanC8s in requiring only the 26 amino acid membrane-proximal “stalk” of ADAM10 
for its interactions (Noy et al., 2016). To determine whether the extracellular region of 
Tspan15 confers its capacity to promote ADAM10-mediated shedding of N-cadherin, two 
Tspan15/14 chimeric constructs (Figure 5.1) were generated; Tspan14 was arbitrarily 
chosen as a representative TspanC8 that does not promote N-cadherin cleavage.  
 
To confirm that the Tspan15/14 chimeras were functional in terms of interaction with 
ADAM10, HEK-293T cells were co-transfected with the FLAG-tagged chimeras and HA-
tagged ADAM10. The cells were lysed in 1% digitonin lysis buffer, which has previously 
been used to demonstrate TspanC8 interactions with ADAM10 (Haining et al., 2012, Noy 
et al., 2016), and the tetraspanins were immunoprecipitated with an anti-FLAG antibody, 
separated by SDS-PAGE and probed with anti-HA and anti-FLAG for ADAM10 and 
tetraspanins respectively. As shown in Figure 5.2A Tspan14, 15 and chimeras co-




lower molecular weight of ADAM10, which corresponds to the mature form of the 
protease, and their expression promoted ADAM10 maturation as reported previously 
(Haining et al., 2012). The cells co-transfected with the Tspan14/15 chimeras appeared to 
express less ADAM10, as detected by anti-HA blotting of the whole cell lysate. A possible 
explanation is that the chimeras are unstable, and thus the chimera-ADAM10 complex is 
unstable. The data presented suggest that the chimeric constructs act like WT TspanC8s in 
binding to ADAM10.  
 
Since the overexpression of the chimeras promoted ADAM10 maturation, the process that 
precedes ADAM10 trafficking to the cell surface, the effect of the chimeras on ADAM10 
surface expression was investigated by flow cytometry. Previous studies from the 
Tomlinson lab showed that over-expression of Tspan15, but not Tspan14, promotes 
localisation of ADAM10 to the cell surface in HEK-293T cells (unpublished). Because 
mAbs were not available for both of the TspanC8s tested, they were co-expressed with 
GFP, to label transfected cells. As shown in Figure 5.2B, only Tspan15 and the 
Tspan15/EC14 chimera significantly increased ADAM10 surface expression. This data 
suggested that the transmembrane and/or cytoplasmic regions of Tspan15 are important in 
promoting ADAM10 surface expression. 
 
The functional role of the chimeras in promoting N-cadherin cleavage was next 
investigated using a well-established cleavage assay (Noy et al., 2016). HEK293T cells 
were transfected with the chimeric constructs, and the WT tetraspanins and western blotted 
with an antibody to the cytoplasmic tail of N-cadherin to measure the cleavage (as 




cleavage; only Tspan15 promoted cleavage. This data suggests that the extracellular region 
of Tspan15 is required but not sufficient to promote ADAM10 cleavage of N-cadherin, in 
the context of the chimera with Tspan14. When considered alongside the localisation data, 
it can be concluded that the capacity of Tspan15 to promote ADAM10 cleavage of N-
cadherin cannot be explained simply by its capacity to promote ADAM10 surface 
localisation. It is possible that the extracellular region of Tspan15 is important for inducing 














































































Figure 5.2 Tspan15 transmembrane and cytoplasmic regions are sufficient for 
promoting ADAM10 surface localisation, but the extracellular region is required for 
N-cadherin shedding.  [A] Tspan14, 15, Tspan14/EC15 and Tspan15/EC14 co-
immunoprecipitate mature ADAM10 in transfected HEK-293T cells. Co-
immunoprecipitation was performed from 1% digitonin lysates of HEK-293T cells co-
transfected with expression constructs for FLAG-tagged TspanC8s, chimeras and HA-
tagged ADAM10. The amount of immunoprecipitated ADAM10 was quantified and 
showed as a relative amount of co-immunoprecipitated ADAM10 to the amount of 
ADAM10 present in the whole cell lysates. ADAM10 from whole cell lysate was 
measured and quantified as a percentage of mature ADAM10 detected in the presence of 
the tetraspanins. [B] The expression of WT Tspan15 and the Tspan15/EC14 chimera 
increases the surface expression of ADAM10. HEK-293T cells were transfected with the 
indicated TspanC8s, chimeras and GFP expression constructs. Cells were stained with 
APC-conjugated ADAM10 antibodies and analysed by flow cytometry. The geometric 
mean fluorescence intensities of ADAM10 from GFP-positive transfected populations of 
cells were quantified and presented as the relative ADAM10 surface expression. [C] The 
Tspan15 extracellular region is required for N-cadherin cleavage. HEK-293T cells were 
transiently transfected with the expression construct for FLAG-tagged WT Tspan14, 15 
and the chimeras. The cells were lysed in 1% Triton X-100 lysis buffer, and western 
blotted with the antibodies against the cytoplasmic tail of N-cadherin and a FLAG-tagged 
epitope of the tetraspanins. The graph represents % cleaved N-cadherin calculated based 
on the intensities of the full-length and cleaved fragments. Error bars represent SEM for 
three independent experiments for shedding assay and flow cytometry; six independent 
experiments for co-i.p. The data was arcsine transformed and statistically analysed by one-
way ANOVA with Dunnett’s multiple comparison test, compared to the WT control for 
the flow cytometry and shedding assays, or to the ADAM10-HA transfection in the co-i.p 
experiment and whole cell lysates (*p<0.05, ***p<0.001, ****p<0.0001). 
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5.2.2 Mutation of the putative cholesterol-
binding sites or truncation of cytoplasmic 
tails do not affect the ability of Tspan15 
to interact with ADAM10  
 
The previous section suggested the cytoplasmic tails and/or transmembranes are important 
for Tspan15 localisation. The cytoplasmic tails are the most divergent regions in sequence 
between TspanC8s but highly conserved between species of the same TspanC8 (Matthews 
et al., 2017b). Therefore, they are good candidates for regulating localisation and hence 
function. Through the generation of the Tspan15 tailless mutant construct (Figure 5.1), a 
suitable model was created for testing the tail truncations in the regulation of Tspan15. The 
recent structural characterisation of tetraspanin CD81 suggested that cholesterol binding 
within a transmembrane cavity is important for regulating conformational change and 
function (Zimmerman et al., 2016). To investigate this possibility, mutations in the 
putative cholesterol-binding sites of Tspan15 transmembranes were generated (Figure 5.1). 
It is expected that Q/E mutation would enhance a closed conformation, while Q/A would 
promote an open conformation.  
  
To test whether Tspan15 mutants are functional in terms of ADAM10 binding,  
the co-transfection and immunoprecipitation approaches in 1% digitonin were used as 
previously described in section 5.2. As shown in Figure 5.3A, Tspan15 and the mutants  
co-immunoprecipitated with mature ADAM10, and each promoted the relative amount of 
this form versus immature. Next, the Tspan15 mutants were tested for their ability to 
promote endogenous ADAM10 surface expression. HEK-293T cells were mock 




ADAM10 mAbs and analysed by flow cytometry as previously described in section 5.2. 
As shown in Figure 5.3B, all the mutants increased ADAM10 surface expression by 
approximately two-fold on average, similar to WT Tspan15, and Tspan15 expression level 
correlated with that of ADAM10. None of these reached statistical significance from the 
five experiments, but the data suggests that the mutants are comparable to WT regarding 



















Figure 5.3 Mutation of the putative cholesterol-binding site or truncations of 
cytoplasmic tails do not affect the ability of Tspan15 to interact with ADAM10.  [A] 
Tspan15 mutants interact with and promote ADAM10 maturation. HEK293T cells were 
mock transfected (-), transfected with FLAG-tagged Tspan15, the mutants and HA-tagged 
ADAM10. Cells were lysed in 1% digitonin and subjected to anti-FLAG 
immunoprecipitation (upper and lower panel) and anti-HA western blotting (middle panel). 
The co-precipitated immature and mature forms of ADAM10 were detected and quantified 
as a relative amount of ADAM10 co-immunoprecipitated to the amount of ADAM10 
present in the whole cell lysate. ADAM10 in a whole cell lysate was quantified as a 
percentage of mature ADAM10 detected in the presence of the tetraspanins. [B] Tspan15 
mutants retain the ability to traffic ADAM10 to the cell surface. HEK293T cells were 
transfected with FLAG-tagged Tspan15 constructs. Cells were stained with APC-
conjugated ADAM0 antibody and Tspan15 mAbs (4A4 clone was used in a form of tissue 
culture supernatant) to identify transfected cells. The fluorescence intensities for ADAM10 
surface expression, gated on live and positively transfected cells, for each construct were 
measured. [A, B] Data were arcsine transformed, and statistical significance was 
determined using one-way ANOVA with a Dunnett’s multiple caparison test compare to 
WT control for flow cytometry or to ADAM10-HA for co-i.p (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001). The data are representative for three independent 





5.2.3. Transfection of WT Tspan15 restores 
VE-cadherin cleavage in Tspan15 KO 
HEK-293T cells 
 
As demonstrated in chapter 4.1, the cleavage of transfected VE-cadherin in Tspan15 KO 
HEK-293T cells was almost completely abrogated, and this was comparable to the extent 
observed in ADAM10 KO cells, suggesting a critical role for Tspan15 in the ADAM10-
mediated shedding of this substrate. This VE-cadherin assay was more robust than the 
previously used N- and E-cadherin cleavage assays. Therefore, this assay was selected to 
functionally assess the Tspan15 chimeric and mutant constructs. To first confirm that 
Tspan15 could rescue VE-cadherin cleavage in Tspan15 KO cells, WT Tspan15 and VE-
cadherin were co-transfected into WT, ADAM10 KO and Tspan15 KO cells, the latter of 
which served as a control. The cleavage assay used NEM stimulation (2 mM) for 30 min, 
followed by lysis in 1% Triton 100-X lysis buffer and Western blotting for VE-cadherin. 
VE-cadherin cleavage was rescued by over-expressed Tspan15 in Tspan15 KO HEK-293T 
cells, which was comparable to observations in WT (Figure 5.4).  
Moreover, the percentage of cleaved VE-cadherin was significantly higher when Tspan15 
was overexpressed in WT cells. As previously shown, VE-cadherin cleavage was minimal 
in ADAM10 and Tspan15 KO cells. It was noted in the experiment the appearance of some 
bands in the control samples in the FLAG blot. The weak band in the negative control (line 
1) was most likely a result of non-specific binding of anti-FLAG mAb. The band in the 
positive control (line 2) was most likely caused by a strong signal of VE-cadherin in one 
channel that bled through to the other FLAG channel. As the VE-cadherin expression was 
always at relatively high levels in these experiments, this could be minimised in the future 




transfected construct. Nevertheless, the presence of the relatively weak background bands 
did not affect the VE-cadherin cleavage quantitation.  
These data suggest that this VE-cadherin cleavage assay will be useful for testing the 










Figure 5.4 The reintroduced Tspan15 can rescue VE-cadherin cleavage in Tspan15 
KO HEK-293T cells.  WT, Tspan15 and ADAM10 KO HEK-293T cells were co-
transfected with the FLAG-tagged WT Tspan15 and VE-cadherin. 2 mM of NEM was 
added to the cells for 30 min to induce cleavage. Cells were lysed in 1% Triton X-100 lysis 
buffer, and Western blotted with anti-VE-cadherin and anti-FLAG mAbs. The percentage 
of cleaved VE-cadherin was calculated based on fluorescence intensities of the cleaved 
fragment and full-length of VE-cadherin. The data was transformed by arcsine of the 
square root transformed, and statistical significance was determined by one-way ANOVA 
with Dunnett’s multiple comparison test, as compared to Tspan15 KO HEK-293T cells. 






5.2.4 Overexpression of cholesterol-binding 
mutants and tailless Tspan15, but not  
the  Tspan15/EC14  chimera, rescues 
NEM-induced VE-cadherin cleavage  
in Tspan15-KO HEK-293T cells  
 
Tspan15 KO HEK-293T cells were co-transfected with VE-cadherin and Tspan15/14 
chimeras or Tspan15 mutant constructs, and NEM-induced VE-cadherin cleavage assay 
performed as described in the previous section. The Q/E and Q/A cholesterol-binding 
mutants, and the tailless Tspan15, were each able to rescue VE-cadherin cleavage like WT 
Tspan15 (Figure 5.5). In contrast, the two Tspan15/14 chimeras failed to rescue VE-
cadherin cleavage, similar to WT Tspan14. However, expression of the Tspan14/EC15 
chimera was not detected in these experiments (Figure 5.5), for reasons that are not clear, 
despite detectable expression previously (Figure 5.2A). Therefore, conclusions cannot be 
made for this chimera. The FLAG blotting showed that each construct was expressed at 
different levels. It was noted that Tspan14, chimera Tspan14/15 and mutant Q/A had 
considerably stronger expression levels than the other TspanC8s. However, this was 
















Figure 5.5 Over-expression of cholesterol-binding mutants and tailless Tspan15, but 
not the Tspan15/EC14 chimera, rescues NEM-induced VE-cadherin cleavage in 
Tspan15-KO HEK-293T cells.  HEK-293T WT and Tspan15 KO cells were co-
transfected with the Tspan15 mutant constructs FLAG-tagged and VE-cadherin. 2 mM 
NEM was added to the cells to induce the cleavage. Cells were lysed in 1% Triton X-100 
lysis buffer, and Western blotted with anti-VE-cadherin and anti-FLAG mAbs. The 
percentage shed VE-cadherin was calculated based on fluorescence intensities of cleaved 
fragment and full-length of the cadherin. The data was transformed by arcsine of the 
square root and statistical significance was determined by one-way ANOVA with 
Dunnett’s multiple comparison test as compared Tspan15 KO. The error bars represent 





5.2.5 Generation of Tspan15-KO HEK-293T 
cell lines stably expressing mutant 
Tspan15 constructs  
 
The overexpression system used to this point might not be an ideal model for determining 
the consequences of the mutations on ADAM10 activity. As all mutants were expressed at 
a much higher level than endogenous Tspan15, the overexpression may mask any defects 
in the mutants. Also, the level of over-expression differed between mutants. Therefore, the 
aim of this section was to generate Tspan15-knockout cell lines stably expressing Tspan15 
mutants at the endogenous level. 
 
To generate stable cell lines, Tspan15 WT, mutants and chimeras were first transiently 
expressed in Tspan15 KO and WT HEK-293T cells. The transfected cells were enriched 
by blasticidin selection, and clonal populations were isolated from a heterogeneous pool by 
serial dilution to one cell per well on 96-well plate. Only clones that appeared to originate 
from a single cell were expanded. The expression of the constructs was assessed by flow 
cytometry using mAbs against Tspan15 or Tspan14, for Tspan15/14EC construct; the 
Tspan14 mAb was recently made by the Tomlinson lab but may be a low affinity mAb 
because it only detects transfected Tspan14 by flow cytometry, not endogenous levels of 
the protein (Koo, unpublished). Two clones with a Tspan15 expression that resembled 





5.2.6 Tspan15 tailless and Q245A mutants 
support normal surface expression of 
ADAM10, but Q245E and Tspan15/14 
chimeras do not 
 
In order to determine whether stable expression of the Tspan15 mutants and chimeras 
could restore normal expression of surface ADAM10 in the Tspan15 KO cells, they were 
analysed by flow cytometry for ADAM10. As shown in Figure 5.6C-D, none of the stable 
Tspan15 KO clones expressing WT or mutant Tspan15 constructs had a significant 
increase in surface ADAM10 expression, compared to Tspan15 KO cells; ADAM10 was 
only significantly increased in the WT cells in which Tspan15 was stably expressed. 
However, when each pair of clones was grouped, the Tspan15 tailless and Q/A mutant 
reconstituted cells did show a significant increase in ADAM10 expression (Figure 5.6D), 
suggesting that individual clones would have reached significance if more repeats had been 
done. In contrast, the Tspan15 Q/E mutant and the two Tspan15/14 chimeras, when 
grouped, failed to show any significant rescue of ADAM10 expression (Figure 5.6D). The 
WT Tspan15 reconstituted cells did not reach significance for restoration of ADAM10 
expression when grouped, but these probably would have reached significance with more 
repeats, because they were not significantly different from WT. These data demonstrate the 
importance of assessing Tspan15 mutants at endogenous expression levels, because all of 
these constructs, with the exception of the Tspan14/15 chimera, rescued ADAM10 



































































































































































Figure 5.6 Validation of Tspan15 stables HEK-293T cell lines.  WT and Tspan15 KO 
HEK-293T stably expressing Tspan15 WT, mutants and chimeric constructs were 
subjected to flow cytometry with mAbs against Tspan15 (clone 4A4 used in a form of 
tissue culture supernatant) and ADAM10. The surface expression of Tspan15 [A] and 
ADAM10 [C] was detected in the selected clones. [B, D] Data from panel A and C were 
normalised by arcsine transformation of the square root and analysed by a one-way 
ANOVA and Dunnett’s multiple comparison test as compared to WT cells for Tspan15 
expression or to Tspan15 KO cells for ADAM10 surface expression. The error bars 






5.2.7 Tspan15 tailless and Q245A mutants support 
NEM-induced VE-cadherin cleavage, but 
Q245E and Tspan15/14 chimeras do not 
 
 
In order to determine whether stable expression of the Tspan15 mutants and chimeras 
could restore normal VE-cadherin cleavage, the reconstituted cell lines were analysed in 
the NEM-induced cleavage assay. As shown in Figure 5.7A-D, VE-cadherin cleavage was 
rescued by the tailless and Q/A Tspan15 mutants and WT Tspan15. In contrast, the Q/E 
Tspan15 mutant and chimeric constructs did not rescue VE-cadherin cleavage (Figure 
5.7A-D), which is consistent with their inability to rescue ADAM10 surface expression 
(Figure 5.6). The expression of distinct Tspan15 mutants was not detectable in anti-FLAG 
blotting of the whole cell lysates, which was to be expected given that endogenous 
Tspan15 cannot be detected by Western blotting in these cells (data not shown).  
 
Taken together, these data show that the tails of Tspan15 are not required for NEM-
induced cleavage of VE-cadherin, and similarly the Q/A mutation of the Tspan15 putative 
cholesterol binding site does not affect NEM-induced VE-cadherin cleavage. In contrast, 
the Q/E mutation and Tspan15/14 chimera fail to rescue VE-cadherin cleavage, probably 

















Figure 5.7 The cleavage of VE-cadherin is differentially affected by the stable 
expression of distinct Tspan15 mutants.  [A-C] The NEM-induced cleavage assay was 
performed on the stable cell lines (two seperate clones for each cell line used) transfected 
with VE-cadherin as previously described. The cells were western blotted with VE-
cadherin mAb and the percentage cleaved VE-cadherin was plotted [B-D]. Data were 
normalised by arcsine transformation of the square root and analysed by a one-way 
ANOVA and Dunnett’s multiple comparison test as compared to Tspan15 KO cells. Error 
bars represent the standard error of the mean for three independent experiments (**p<0.01, 






5.3 Discussion  
 
In this chapter, the first structure/function analyses on Tspan15 were carried out in WT and 
Tspan15-knockout HEK-293T cells using a range of Tspan15 mutant constructs to 
investigate the functions of the extracellular region, the putative cholesterol binding site 
and the cytoplasmic tails. Experiments with chimeric Tspan15/Tspan14 constructs, in 
which the extracellular regions were exchanged, showed that they could not function like 
WT Tspan15 in supporting ADAM10 surface expression and VE-cadherin cleavage, 
despite their co-immunoprecipitation with ADAM10. This indicates that the trafficking 
and function of Tspan15/ADAM10 complexes is dependent on the full Tspan15 molecule. 
In contrast, tail-less Tspan15 and a Q245A mutation in the putative cholesterol binding site 
supported ADAM10 surface expression and VE-cadherin cleavage following NEM 
stimulation. However, a Q245E mutation in the cholesterol binding site failed to support 
ADAM10 expression and VE-cadherin cleavage in response to NEM. These data suggest a 
potential functional role for the Tspan15 cholesterol binding site, but no role for the 
cytoplasmic tails, at least for NEM activation of the Tspan15/ADAM10 complex. 
 
The Tomlinson lab previously showed that large extracellular region of TspanC8s is 
important for interaction with ADAM10 and for enabling its maturation and localisation to 
the cell surface (Noy et al., 2016). These experiments were conducted in HeLa cells with 
Tspan14 as a model TspanC8 (Noy et al., 2016). However, in the HEK-293T cells used in 
this chapter, Tspan15 over-expression promoted ADAM10 surface expression but Tspan14 
did not, despite both being able to promote ADAM10 maturation (Haining et al., 2012). 




proteins in the two cell types, such that Tspan14 is predominantly intracellularly-localised 
in HEK-293T cells. Nevertheless, the difference between Tspan15 and Tspan14 in HEK-
293T cells allowed experiments to be conducted with chimeric forms of these proteins, in 
which the entire extracellular regions were exchanged. In initial over-expression studies, 
both chimeras co-immunoprecipitated with ADAM10 and promoted its maturation, 
demonstrating their correct folding and functionality as TspanC8s. However, only the 
construct with transmembrane/cytoplasmic regions of Tspan15 significantly increased 
ADAM10 surface expression, suggesting that these regions are driving localisation, 
possibly by interaction with as yet unidentified trafficking proteins. Candidates include 
Rab14 and its effector FAM116, which were reported to be required for ADAM10 
trafficking to the cell surface in A549 cells (Linford et al., 2012). In Tspan15-knockout 
cells stably reconstituted with the two chimeras, neither restored normal ADAM10 surface 
expression, and neither supported cleavage of transfected VE-cadherin in response to 
NEM. This suggests that normal trafficking and shedding function of Tspan15/ADAM10 
complexes is critically dependent on the entire Tspan15 protein, which cannot be 
substituted with either extracellular or transmembrane/cytoplasmic regions of Tspan14. 
This work also underscores the importance of working with stably reconstituted cell lines 
with endogenous levels of the mutant proteins, because 50-100-fold over-expression of the 
chimeras promoted ADAM10 surface expression, but endogenous-level expression did not. 
The former is likely to be an over-expression artefact. 
 
Recent publication of the full-length structure of CD81 suggested that the tetraspanin-
partner interactions may be regulated by cholesterol-mediated conformational state of the 




glutamic acid residue in transmembrane 4 (E219), which formed hydrogen bonds with the 
hydroxyl group of the cholesterol molecule. In molecular dynamics simulations, loss of 
cholesterol was predicted to cause a dramatic conformational change, in which the main 
extracellular region swings upwards (Zimmerman et al., 2016). Thus, CD81 may act as a 
‘molecular switch’ to regulate partner proteins by inducing their conformational change. 
E219Q and E219A mutations, predicted to impair cholesterol binding, did indeed reduce 
cholesterol binding by 40%, in an experiment using immunoprecipitated CD81 and 
tritiated cholesterol (Zimmerman et al., 2016). Moreover, cell surface expression of 
transfected WT CD19, a CD81 partner, was increased two-fold in a HEK-293T model 
system overexpressing the mutants. Therefore, to investigate whether these observations 
hold true for the Tspan15/ADAM10 complex, Tspan15 Q245E and Q245A constructs 
were generated. Like most tetraspanins, Tspan15 lacks the glutamic acid residue in the 
precise location of that in CD81 (Zimmerman et al., 2016), but does have a conserved 
polar glutamine (Q245) on the preceding helix of the fourth transmembrane. Therefore, the 
Q245E mutant may interact with cholesterol more strongly than Q245A or WT Tspan15. 
The two mutant constructs were functional in terms of co-immunoprecipitation with 
ADAM10 and each promoted ADAM10 surface expression when over-expressed. In stably 
transfected Tspan15-knockout cells, the Q245A mutant restored ADAM10 surface 
expression and NEM-induced VE-cadherin cleavage, but the Q245E mutant did not, 
despite similar expression levels of each mutant at the cell surface that were similar to 
endogenous levels. Thus, the cleavage phenotype correlates with the ADAM10 trafficking 
phenotype. It is possible that Tspan15 Q245E, like for WT CD81 (E219) and CD19, binds 
cholesterol more strongly, cannot readily adopt an open conformation, and poorly traffics 




mutants E219Q or E219A and CD19, may weakly bind cholesterol and be more prone to 
adopt an open conformation and promote ADAM10 trafficking. Further experiments, 
including cholesterol-binding and subcellular localisation using fluorescence microscopy, 
are required to investigate this further. 
 
Tspan15 is particularly efficient in promoting ADAM10 trafficking to the cell surface, as 
was shown in this chapter in comparison with Tspan14, and by fluorescence microscopy 
experiments that compared all TspanC8s (Dornier et al., 2012). To date the mechanism 
that controls the process remains unknown. As revealed by sequence line-ups of a full 
length of TspanC8s, the cytoplasmic tails are found to be relatively divergent in the 
sequence and length, but are highly conserved between species of a single TspanC8 
(Matthews et al., 2017). Moreover, Tspan15 and Tspan10 possesses tyrosine- and 
dileucine-based motifs respectively, which can potentially engage to adaptor proteins 
capable of controlling subcellular localisation (Berditchevski and Odintsova, 2007). 
Therefore, the cytoplasmic tails are strong candidates for regulation of TspanC8 
subcellular localisation. Indeed, this is a plausible scenario, as tail swaps between Tspan15 
and Tspan10 were shown to be sufficient to alter the localisation of the respective 
TspanC8s (Matthews and Tomlinson, unpublished data). Thus, the importance of Tspan15 
cytoplasmic tails in the regulation of ADAM10 activity was addressed in this study. Using 
Tspan15 tailless mutant stable transfectants in Tspan15-knockout cells, it was shown that 
interactions between Tspan15 and ADAM10 are not mediated by the cytoplasmic regions. 
In fact, neither NEM-induced cleavage of VE-cadherin nor surface expression of 
ADAM10 and Tspan15 were affected by the truncations. Therefore, the Tspan15 tails are 




caveat to the cleavage data is that ADAM10 was activated with NEM, which is likely to 
directly activate ADAM10 via alkylation. Any requirement for the Tspan15 tails in, for 
example, growth factor- or Ca
2+
-induced ‘inside-out’ ADAM10 activation, would not be 
determined using NEM. This will be discussed in Chapter 7 in the context of a proposed 
model for physiological ADAM10 activation.  
 
Finally, it is interesting to note that in the overexpression system, the total expression level 
of the tailless mutant detected by western blot (Figure 5.5A) was relatively low compared 
to WT Tspan15, but its surface expression measured by flow cytometry was relatively high 
(Figure 5.3B). This could suggest that the tailless mutant, once trafficked to the cell 
surface, is not being degraded or recycled back as efficiently. Therefore, the Tspan15 tails 
may be important for endocytosis, potentially via the tyrosine-based motif in the N-
terminus, as mentioned earlier. Future fluorescent microscopy experiments, or 
internalisation experiments similar to that used in the previous chapter, will help to address 
this interesting possibility.   
 
In summary, this chapter has established Tspan15-knockout HEK-293T cells, stably 
reconstituted with Tspan15 mutants at endogenous expression levels, as a robust system to 
perform structure/function analyses. The data indicate that the capacity for Tspan15 to 
promote ADAM10 surface expression and activity towards a specific substrate is 
dependent on the extracellular region in combination with the transmembrane/cytoplasmic 
region, and that the putative cholesterol binding site may regulate ADAM10 trafficking in 




for promoting ADAM10 trafficking to the cell surface and its activity in response to NEM, 




ROLE OF ADAM10 AND TSPAN15 IN 






The previous chapters have (1) characterised the first Tspan15 mAbs and shown that this 
TspanC8 requires ADAM10 for its expression, (2) shown that Tspan15 promotes cadherin 
shedding in cell lines and that two of the four mAbs have inhibitory function, and (3) 
initiated a structure-function analysis by stably reconstituting Tspan15-knockout cell lines 
with Tspan15 mutants. This chapter aimed to functionally characterise the 
Tspan15/ADAM10 scissor in primary cells. HUVECs were selected as an in vitro model 
system because siRNA knockdown is highly efficient in these cells, ADAM10 is known to 
be important for endothelial function in vivo (Alabi et al., 2018), and Tspan15 is largely 
unstudied in endothelial cells. 
 
The molecular scissor ADAM10 is involved in many pathophysiological processes 
including angiogenesis. Through the proteolytic processing of growth factors, adhesion 
molecules and cytokines, it regulates many cellular functions relevant to the process. The 




 Notch signalling that is required for vascular development, removal of VE-cadherin to 
increase vascular permeability, and the release of transmembrane receptors VEGFR2 and 
Nrp-1 to direct angiogenesis by suppressing vessel sprouting and cell migration (van der 
Vorst et al., 2012, Mehta et al., 2018). The importance of ADAM10 in angiogenesis is 
underlined by the findings from knockout mice studies. Global ADAM10 inactivation is 
lethal at the embryonic stage due to developmental defects in the cardiovascular system 
(Hartmann et al., 2002), while its endothelial cell-specific deletion leads to abnormal 
vasculature sprouting and density (Caolo et al., 2015), and defects in multiple organs in 
both developing and adult mice (Glomski et al., 2011, Farber et al., 2018). These are 
similar to phenotypes observed by Notch deletion (Hartmann et al., 2002, Alabi et al., 
2016), for which ADAM10 is essential for providing the initial cleavage event in the 
ligand-induced shedding of Notch proteins (van Tetering et al., 2009).  
 
The role of TspanC8s in angiogenesis has not been previously investigated. However, 
HUVECs express five TspanC8s at the mRNA level and knockdown of the most highly 
expressed TspanC8, Tspan14, leads to a 30% decrease in basal VE-cadherin cleavage, 
which is most likely explained by a 50% decrease in surface expression of ADAM10 
(Haining et al., 2012). Moreover, in a global study of HUVEC TspanC8s, Tspan5 and 
Tspan17 were found to negatively regulate VE-cadherin cell surface expression and to 
promote lymphocyte transmigration in an inflammatory model (Reyat et al., 2017). 





The objectives of this chapter were firstly, to establish in vitro HUVEC assays in which 






6.2.1 Inactivation of ADAM10, but not 
Tspan15, promotes HUVEC migration  
in an in vitro scratch wound assay 
 
To assess the functional importance of ADAM10 on HUVEC migration, initially in vitro 
scratch wound assays were performed in the presence or absence of ADAM10 inhibitor 
(GI254023X). The concentration of 2.5 µM was chosen as it is commonly used at the 
similar concentration in the other studies (Hundhausen et al., 2003, Moss et al., 2007, 
Caolo et al., 2015, Mullooly et al., 2015). A confluent monolayer of the cells was wounded 
and immediately treated with the inhibitor or DMSO as vehicle control, and mitomycin (5 
µg/ml) to inhibit proliferation. The images were taken every 6 hours until complete wound 
closure. As shown in Figure 6.1A-B, inhibition of ADAM10 promoted cell migration. The 
differences in the wounded area started to be apparent at the 6-hour time point and reached 
approximately 50% at 18 hours post-wounding, while at 24 hours the wound was 
completely closed for inhibitor-treated cells but not yet closed for DMSO controls. 
 
To determine whether ADAM10 knockdown would yield a similar phenotype to the 




ADAM10. As shown in Figure 6.1C-D, ADAM10 transfected cells were more motile as 
indicated by complete wound closure at 24 hours. Similar to the inhibitor, the effect was 
subtle but significant. Having shown that ADAM10 inhibitor and knockdown promoted 
cell migration, the assay was performed with Tspan15 siRNA knockdown to identify the 
effect of the tetraspanin on cell migration. As shown in Figure 6.1F-G, Tspan15 
knockdown had no effect on cell migration, as no differences in the area covered by the 
cells were recorded at any time point. The efficiency of ADAM10 and Tspan15 
knockdown was subsequently measured by flow cytometry and was found to be 80-90% 
(Figure 6.1E-H). 
 
Taken together, these data suggest that ADAM10 is a negative regulator of cell migration 



























































































































































Figure 6.1 Inactivation of ADAM10, but not Tspan15, promotes HUVEC migration 
in an in vitro scratch wound assay.  Migratory phenotypes of HUVEC cells treated with 
[A-B] 2.5 µM ADAM10 inhibitor (GI254023X), [C-D] ADAM10 siRNA duplexes and [F-
G] Tspan15 siRNA duplexes were analysed using an in vitro scratch wound assay. The 
representative images of the wounded monolayer were taken using the IncuCyte Imaging 
System. The percentage of the wounded area for each time point was quantified by 
dividing the area at a given time point by the original area. The initial area was arbitrarily 
set as 100. Scale bar - 300 µm. [E, H] The ADAM10 and Tspan15 knockdown efficiencies 
were analysed by flow cytometry. Tspan15 mAb (4A4 clone) was used in a form of tissue 
culture supernatant. The bar charts represent the mean values from four to six independent 
experiments, and error bars are the standard error of the mean. Data were normalised by 
arcsine transformation of the square root and analysed by one-way ANOVA and Dunnett’s 
multiple comparison test as compared to the control of each time point (*p < 0.05, **p < 

























































6.2.2 Inactivation of ADAM10, but not 
Tspan15, impairs HUVEC network 
formation in an in vitro assay on 
Matrigel 
 
To determine whether ADAM10 and Tspan15 affect the ability of HUVECs to form two-
dimensional networks, cells were cultured on reduced growth factor gel matrix, Matrigel, 
in the presence of the ADAM10 inhibitor or after being transfected with ADAM10 or 
Tspan15 siRNA duplexes as previously described. Formation of characteristic networks of 
orderly branching structures was monitored every 6 hours until its complete 
decomposition. The stage of network formation was quantified by measuring the number 
of meshes. ADAM10 inhibition (Figure 6.2A-B) and siRNA-mediated knockdown (Figure 
6.2C-D) impaired endothelial network formation. Efficient ADAM10 knockdown was 
confirmed by flow cytometry (Figure 6.2E). In contrast, Tspan15 knockdown had no 
significant effect on the network integrity (Figure 6.2F-G); knockdown was confirmed by 
flow cytometry (Figure 6.2H).  
 
Together this data demonstrates that ADAM10 is required for normal endothelial tube 
formation in vitro. Tspan15 knockdown is not sufficient to mimic the phenotype seen 

































































































































































Figure 6.2 Inactivation of ADAM10, but not Tspan15, impairs endothelial network 
formation in an in vitro assay on Matrigel.    HUVEC cells cultured on Matrigel were 
treated with 2.5 µM of ADAM10 inhibitor [A-B], ADAM10 siRNA duplexes [C-D] or 
Tspan15 siRNA duplexes [F-G]. The changes in the network were monitored every 6 
hours, and representative images are shown. Scale bar - 300 µm. The bar charts represent 
the average number of meshes for four to six independent experiments, and error bars are 
the standard error of the mean. Data were normalised by arcsine transformation of the 
square root and analysed by one-way ANOVA and Dunnett’s multiple comparison test as 
compared to the control (*p<0.05, **p<0.01, ***p < 0.001, ****p < 0.0001). The 
efficiency of ADAM10 and Tspan15 knockdown was analysed by flow cytometry [E, H]. 



























































6.2.3 HUVECs proliferate faster upon 
inactivation of ADAM10, but not 
Tspan15, in an in vitro proliferation 
assay 
 
A role of ADAM10 and Tspan15 on HUVEC proliferation was measured by direct 
counting of viable cells (determined by the trypan blue exclusion method) following 
treatments with ADAM10 inhibitor or ADAM10 or Tspan15 siRNA duplexes for a 72-94-
hour period. As shown in Figure 6.3A, inhibition of ADAM10 promoted cell proliferation, 
as did the ADAM10 knockdown (Figure 6.3B). In contrast, Tspan15 knockdown had no 
effect (Figure 6.3C). Efficient knockdown efficiency was confirmed by flow cytometry 
(Figure 6.3D-E). 
 
In summary, ADAM10 appears to be a negative regulator of endothelial cell proliferation 
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Figure 6.3 HUVECs proliferate faster upon inactivation of ADAM10, but not 
Tspan15, in an in vitro cell proliferation assay.  HUVECs were treated with [A] 
ADAM10 inhibitor at 2.5 µM, [B] ADAM10 siRNA duplexes and [C] Tspan15 siRNA 
duplexes and cultured for an additional 72-94 hours. The difference in the cell number at 
the start and at the end of the time course was calculated and presented as a relative fold of 
proliferation relative to the control sample. The bar charts represent the mean fold of the 
proliferation from three to four independent experiments, and the error bars are the 
standard error of the mean. Data were normalised by arcsine transformation of the square 
root and analysed by a one-way ANOVA and Dunnett’s multiple comparison test as 
compared to the control (*p<0.05, **p<0.01). The knockdown efficiency for ADAM10 
and Tspan15 was determined by flow cytometry [D-E]. Tspan15 mAb (clone 4A4) was 





6.3 Discussion  
 
 
In this chapter, three in vitro angiogenesis assays were used to investigate the role of 
ADAM10 and Tspan15 in endothelial cell functions. In the assays, HUVEC cells were 
used as a model system and tested for their in vitro migration, proliferation and network 
formation. The results revealed that pharmacological inhibition, as well as siRNA 
knockdown, of ADAM10 promoted HUVEC proliferation and migration, but impaired 
their ability to form and maintain networks on Matrigel. In contrast, the inhibition of 
Tspan15 had no obvious effects in any of the functions studied.  
 
The phenotypes observed following ADAM10 inhibition or knockdown are clear but not 
dramatic. The promotion of proliferation and migration were approximately two-fold and 
the impairment of network formation was about 50%. The latter is consistent with siRNA 
knockdown of ADAM10 in human microvascular endothelial cells (Isozaki et al., 2013). 
Therefore, ADAM10 appears to have a modulatory, not essential, role in these in vitro 
assays. Analysis of the in vitro endothelial cell literature suggests that impaired Notch 
activation is the mechanism responsible. For example, Williams et al showed that over-
expression of DLL4 in HUVECs promotes Notch activation and decreases proliferation 
and migration (Williams et al., 2006), which is consistent with the opposite effects 
observed in this chapter following ADAM10 inhibition/knockdown to inhibit Notch 
signalling. Mechanistically, the Williams et al data could be explained by effects on gene 
expression of VEGFR2 and NRP1, since both were down-regulated following Notch 
activation (Williams et al., 2006). In agreement with the Williams et al study, Noseda et al 




NICDs, decreases proliferation (Noseda et al., 2004). In an earlier paper by Taylor et al, 
expression of dominant negative Notch3 or dominant negative Jagged 1 in HUVECs was 
found to decrease network formation on Matrigel (Taylor et al., 2002). 
 
In addition to Notch, VE-cadherin may partially explain the defects observed in network 
formation. Following ADAM10 knockdown, we have found VE-cadherin surface 
expression to increase by approximately 50% (Reyat et al., 2017). In a study by Abraham 
et al, a partial knockdown or antibody blockade of VE-cadherin increased HUVEC 
network formation on Matrigel (Abraham et al., 2009). Furthermore, VE-cadherin 
antibody blockade promoted tube formation in a HUVEC tube formation assay on 
fibroblasts, and VE-cadherin morpholino knockdown promoted vessel sprouting in a 
zebrafish model. The proposed mechanism was impaired VE-cadherin signalling, thus 
impaired Rho-kinase-dependent myosin light-chain 2 phosphorylation, and impaired 
actomyosin contractility at cell junctions, allowing sprouting to occur (Abraham et al., 
2009). 
 
This chapter includes the first functional analysis of Tspan15 in endothelial cells. No effect 
of Tspan15 knockdown was detected for HUVEC migration, proliferation or network 
formation, suggesting that one or more of Tspan5/ADAM10, Tspan10/ADAM10, 
Tspan14/ADAM10 or Tspan17/ADAM10 complexes are regulating these aspects of 
endothelial cell function. It is likely that Tspan15 regulates N-cadherin shedding in 
endothelial cells, given its clear role in other cell types (Jouannet et al., 2016, Noy et al., 
2016, Prox et al., 2012). This was not examined in this study, but an approximate 50% 




cadherin data (Reyat et al., 2017). Generation of endothelial-specific N-cadherin knockout 
mice demonstrated the importance of N-cadherin in endothelial cells, since the mice are 
embryonic lethal at about day 9.5, due to severe defects in the vasculature, and this is 
accompanied by a dramatic reduction in VE-cadherin expression, for reasons that are not 
clear (Luo and Radice, 2005). However, any potential endothelial phenotype in mice with 
increased N-cadherin expression, due to defective shedding, may be subtle. Indeed, no 
endothelial cell phenotype was reported in the recent characterisation of Tspan15-knockout 
mice (Seipold et al., 2018). 
 
In conclusion, this chapter indicates that HUVECs are not a suitable model system to 
investigate the functional effects of Tspan15/ADAM10 complexes. In future studies, it 
would be interesting to assess Tspan5, Tspan10 and Tspan14 in HUVECs, using single and 
combinatorial knockdowns, since they are reported to promote ADAM10-induced Notch 
signalling in other cell types (Dornier et al., 2012, Jouannet et al., 2016, Saint-Pol et al., 
2017(Zhou et al., 2014). It is tempting to speculate that knockdown of one or more of these 
TspanC8s would impair Notch signalling, and would phenocopy the effects of ADAM10 









7.1 Project overview 
 
The ubiquitously expressed ‘molecular scissor’ ADAM10 can be regarded as a master 
regulator of health and disease through its role as a sheddase for over 40 proteins, some of 
which are life-essential (Dreymueller et al., 2015). As such, therapeutic targeting of 
ADAM10 has a vast potential. However, unlocking that potential is at present impossible 
because of toxicity which would result from the inactivation of ADAM10 on every cell in 
the body. The recent identification of the TspanC8 tetraspanins as crucial regulators of 
ADAM10 has opened the possibility to overcome this problem. The association of 
ADAM10 with TspanC8s is providing a further understanding of the molecular mechanism 
behind ADAM10 function on human cells (Saint-Pol et al., 2017b, Matthews et al., 
2017b). Therefore, targeting of specific ADAM10/TspanC8 complexes could provide a 
substrate- and disease-specific therapeutic intervention in diseases where ADAM10’s 
proteolytic activity is driving disease, or when its activity could be exploited to prevent 
disease. However, the mechanisms by which ADAM10 is regulated by specific TspanC8s 





 reagents to investigate the endogenous function of specific TspanC8s and their role in 
affecting ADAM10.  
 
The major aim of the study was to provide new insights into TspanC8/ADAM10 function, 
using Tspan15 as a model TspanC8. To investigate the function of Tspan15 in regulating 
ADAM10 activity, mAbs to Tspan15 were generated and validated in-house. In addition, 
the function of Tspan15 was interrogated using Tspan15 CRISPR/Cas9 knockout cells and 
siRNA, in epithelial-like cell lines and primary endothelial cells, respectively. Finally, 
various Tspan15 mutants and chimeric constructs were stably expressed in Tspan15-
knockout HEK-293T cells at endogenous levels for structure/function analyses. The main 
findings showed:  
(1) A reciprocal requirement for the regulation of Tspan15 and ADAM10 surface 
expression exists with the complex (Chapter 3, section 3.2.2). 
(2) Tspan15 is required for cleavage of N-, E- and VE-cadherin in epithelial-like cell lines 
(Chapter 4.1, 4.2). 
(3) Two of the four anti-Tspan15 mAbs have inhibitory activity, but this cannot be 
explained by different epitopes or differential effects on Tspan15 internalisation or 
ADAM10 expression (Chapter 4.3).  
(4) The cytoplasmic tails of Tspan15 are not required for promotion of ADAM10 cell 
surface localisation and capacity to cleave VE-cadherin following activation by NEM. The 
Tspan14/15 chimeras appear not to support Tspan15 surface localization or cleavage of 
VE-cadherin, while mutation of the putative cholesterol binding site has effects that 




position 245 does not support ADAM10 surface expression or VE-cadherin cleavage 
capacity, but substitution to alanine does (Chapter 5).  
(5) Loss of ADAM10 in primary human endothelial cells promotes cell migration, 
increases proliferation and impairs network formation, but loss of Tspan15 has no effect in 
these assays. 
 
Due to the fundamental role of ADAM10 and tetraspanins in cell biology, these findings 
offer a starting point for future studies in exploring the specific purpose of 
TspanC8/ADAM10 complexes, and their potential therapeutic targeting in a substrate and 
cell-specific context.  
 
7.2 The Tspan15/ADAM10 molecular 
scissor  
 
The existing information regarding ADAM10 paints a complex picture, where a single 
protease is the primary regulator for a broad spectrum of cell surface proteins, giving a 
wide range of diverse functional consequences in a tissue and substrate-specific manner 
(Kuhn et al., 2016). Due to the biological importance of substrates cleaved by ADAM10, 
this protease has essential developmental and tissue-maintenance functions and represents 
an attractive therapeutic target. ADAM10 targeting could give rise to significant benefits 
for disease prevention, for instance its ability for non-amyloidogenic -secretase activity 




of neurotoxic A species and amyloid plaque formation that are responsible for 
Alzheimer’s disease pathology. ADAM10 is also an attractive therapeutic target for a host 
of other diseases including, but not limited to, cancer, bacterial infections and 
inflammatory disease (Wetzel et al., 2017). However, so far, direct targeting of ADAM 
family members for therapeutic benefit remains a challenge. This failure appears to be a 
consequence of the ubiquitous nature of any ADAM proteases, and their redundancy, in 
addition to the physiological importance of the cleaved substrates. Also, global ADAM10 
inhibition is likely to result in severe toxicity and may only be useful in topical 
applications to the skin (Andreas Ludwig, personal communication). To be able to apply 
ADAM10/protease-based therapies, it is first necessary to successfully discriminate 
between, or target, a particular protease. In particular, an in-depth understanding of the 
substrate-specific regulation of ADAM10 is required.  
 
Previous studies have demonstrated that the interaction of ADAM10 with TspanC8 
tetraspanins could potentially lead to selective proteolytic processing of different substrates 
(Matthews et al., 2017b, Saint-Pol et al., 2017). The concept of the ‘six molecular 
scissors’, where ADAM10 is regarded as a distinct protease when partnered with each of 
the TspanC8s, could be applied in therapy design to overcome problems associated with 
global targeting of ADAM10 (Matthews et al., 2017b). Thus, targeting specific TspanC8s 
may offer a way to modify ADAM10 functions in more subtle ways, with less likelihood 
of disrupting vital physiological functions and less unwanted toxic side-effects. In this 
study, the role of TspanC8s in determining ADAM10 substrate specificity was evaluated 
using a model of N-cadherin shedding by Tspan15/ADAM10. Tspan15 is of particular 




of APP, Notch and N-cadherins, all involved in various pathologies (Prox et al., 2012, Noy 
et al., 2016, Dornier et al., 2016, Jouannet et al., 2016).  
N-cadherin shedding by ADAM10/Tspan15 is a well-recognised phenomenon in vitro and 
in vivo. This was confirmed by multiple groups independently and in various cell line 
models, indicating that a particular relationship exists between the components of the 
complex that drives the shedding (Prox et al., 2012, Noy et al., 2016, Dornier et al., 2016, 
Jouannet et al., 2016). Tspan15 was chosen as the focus of this thesis because it is of 
particular interest in the Tomlinson lab due to its importance as a biomarker and potential 
therapeutic target for many pathologies (Germain et al., 2015, Seipold et al., 2018, Zhang 
et al., 2018). 
 An important question that arises from the present study concerns the mechanism by 
which the Tspan15/ADAM10 molecular scissor cleaved cadherins and why is it so 
efficient in the process?  
 
7.2.1 The main role of Tspan15 is to regulate 
ADAM10 
 
Direct association between ADAM10 and Tspan15 was previously confirmed in multiple 
cell lines, reviewed in Matthews et al., 2017b and Saint-Pol et al., 2017b. Importantly, the 
interaction is specific to ADAM10, as its close relative, ADAM17 does not associate with 
TspanC8s. In fact, ADAM17 associates with inactive rhomboids 1 and 2 (Adrain et al., 
2012, Matthews et al., 2017b). Furthermore, Tspan15 was shown to have a positive effect 




cadherin when over-expressed (Prox et al.,2012, Noy et al., 2016, Jouannet et al., 2016). 
Interestingly, Saint-Pol et al have also shown the reciprocal effect whereby ADAM10 also 
contributes to Tspan5 trafficking and surface localisation, therefore implying that complex 
formation is a prerequisite for determining activity of the molecular scissor towards Notch 
(Saint-Pol et al., 2017a). Thus, the current study aimed to test the possible reciprocal 
dependency between Tspan15 and ADAM10 and investigate how this relationship affects 
the shedding specificity towards N-cadherin. The ADAM10 and Tspan15 KO cell lines, 
provided suitable model systems to investigate the reverse impact on ADAM10 and 
Tspan15 trafficking distributions. While ADAM10 surface expression was partially 
reduced in Tspan15 KO cells, a significant reduction in Tspan15 surface expression was 
observed in ADAM10 KO cells, which was also associated with almost complete loss of 
N-cadherin shedding in both cell lines (section 3.2 and 4.1). This data strongly implies that 
the primary function of Tspan15 is to regulate ADAM10 surface expression. Indeed, 
Jouannet et al have suggested that Tspan15 has a strong ‘affinity’ towards ADAM10, 
which appears to take priority over the interactions of the protease with other tetraspanins. 
This was established by the observation that the overexpression of Tspan15 inhibited to 
some extent the interaction of ADAM10 with other constituents of the tetraspanin web 
(Jouannet et al., 2016). More recently, the Tomlinson and Lichtenthaler groups have 
combined to show that in proteomic analyses of endogenous Tspan15 immunoprecipitates 
in the relatively stringent detergent 1% digitonin, ADAM10 was the only significant 
protein to be identified (unpublished). High levels of Tspan15 have been found in cancer 
cells (Zhang et al., 2018). Thus, Tspan15 may act, at least in cancer, to enhance the 
ADAM10-mediated shedding of N- and E-cadherin, as a tumour becomes metastatic 




Therefore, the regulation of the epithelial cadherins by Tspan15/ADAM10 could provide a 
potential therapeutic strategy. 
 
7.2.2 Tspan15 localises ADAM10 to  
N-cadherin 
 
Tspan15 has both positive and negative effect on APP cleavage expressed on different 
cells (Prox et al., 2012, Jouannet et al., 2016). However, the shedding of N-cadherin seems 
to be explicitly regulated by Tspan15 regardless of the cell type (Prox et al., 2012, 
Jouannet et al., 2016, Noy et al., 2016). The reason behind this is unknown, but a direct 
association between Tspan15 and N-cadherin could occur. Indeed, Jouannet et al have 
shown that N-cadherin was within the repertoire of proteins that were present in the 
membrane compartments within which Tspan15 resides (Jouannet et al., 2016). CD82 was 
also able to co-immunoprecipitate N-cadherin in mild detergent, suggesting that the protein 
is present in tetraspanin microdomains. The fact that CD82 could regulate N-cadherin was 
evidenced by the reduction of N-cadherin surface expression in CD82-deficient acute 
myeloid leukaemia (AML) cells (Marjon et al., 2016). Also, E-cadherin was found to 
interact with tetraspanins, since co-immunoprecipitation revealed that E-cadherin is 
associated with Tspan8 in colon carcinoma cells (Greco et al., 2010). These data suggest 
that preferential binding of the tetraspanins to the substrate could contribute to the 
substrate specificity of the TspanC8/ADAM10 complex.  
 
The subcellular localisation of TspanC8/ADAM10 complexes has been analysed 




of the individual molecules has shown the most striking difference between Tspan15, 
which had plasma membrane localisation, and Tspan10, which was mostly intracellular 
(unpublished data). Therefore, it could be speculated that as N-cadherin shedding takes 
place at the plasma membrane, Tspan15 specific surface localisation may contribute to the 
competence of ADAM10 for its processing. The fact that Tspan15 could bring ADAM10 
to close proximity to N-cadherin is further evidenced in the current study utilising chimeric 
constructs generated by exchanging the extracellular regions between Tspan14 and 
Tspan15 (Chapter 5.2). The surface expression of the chimeras showed that the 
transmembrane and cytoplasmic regions of Tspan15 promoted expression of ADAM10 at 
the surface, and the extracellular regions were necessary for cadherin cleavage. The 
importance of the cytoplasmic tails was previously shown for CD9 in supporting 
tetraspanin functions, molecular organisation at the plasma membrane and assembly of its 
interacting partners into CD9 complexes (Wang et al., 2011). Additionally, the cytoplasmic 
tail structural determinants of tetraspanins, such as palmitoylation and binding/sorting 
motifs, turned out to also have a vital impact. For example, the palmitoylation of CD151 
had the functional consequence of recruiting and sorting integrin 31 within the 
tetraspanin web and contributed to integrin signalling (Berditchevski et al., 2002). As 
Tspan15 cytoplasmic tails do not share sequence similarity with other TspanC8s 
(Matthews et al., 2017b), it may engage with unique intracellular trafficking proteins 
which may account for why the ADAM10/Tspan15 complex localises to N-cadherin. 
Indeed, it was shown that specific motifs, like the PDZ-binding motifs in CD151, CD81 
and CD9, were essential for controlling their subcellular localisation and protein-protein 
interactions by as yet unknown interactions (Cao et al., 1999, Hemler, 2005). CD63, 




complexes that mediate its intracellular transport (Berditchevski and Odintsova, 2007). 
Amino acid sequence analysis of the TspanC8s cytoplasmic tails showed the presence of 
characteristic motifs containing dileucine (LL) and/or leucine repeats (LX6L) in Tspan10, 
or tyrosine-based like for Tspan15 (Berditchevski and Odintsova, 2007). The leucine-
containing motifs have been shown to be recognised by Rab effectors, that function as 
regulators of intracellular trafficking pathways (Evans et al., 2002). Therefore, it may be 
speculated that the cytoplasmic tail of Tspan15 might engage with an intracellular 
trafficking protein to direct ADAM10 to N-cadherin at the plasma membrane. This could 
be supported by the observation that Rab14 was required for ADAM10 localisation at the 
plasma membrane in A549 cells, similar to TspanC8s (Linford et al., 2012). It is worth 
noting that different Rabs in different cells might be involved in Tspan15/ADAM10 
trafficking.   
 
The results presented in Chapter 5.3 and 5.4, using the Tspan15 mutants lacking 
intracellular N- and C-termini, showed that the tails are actually dispensable for trafficking 
of the complex and are not a driving factor in the interaction of Tspan15 and ADAM10. 
This could suggest that additional regulatory mechanisms are involved, presumably at the 
plasma membrane and independent of trafficking. Jouannet et al have indicated that the 
composition of the plasma membrane and lateral diffusion of the proteins within the 
nanoclusters could be an essential driving factor in regulating protease specificity. Using 
co-immunoprecipitation followed by proteomic identification of interacting proteins, it was 
found that the nanodomain formed by Tspan15 differs to that of Tspan5 in terms of the 
composition of auxiliary proteins (Jouannet et al., 2016). This may in return change the 




holding the intended substrate. Similarly, the physical properties of tetraspanin 
nanoclusters was shown to be modulated by cholesterol content. Cholesterol depletion 
from the nanoclusters was shown to enhance ADAM10 substrate accessibility and 
cleavage, probably due to disruption of the tetraspanin nanoclusters and/or increased 
fluidity of the membrane (Charrin et al., 2003, Reiss and Bhakdi, 2017). All of the above 
could contribute to different actions of ADAM10/Tspan15; when proximal to N-cadherin it 
promotes the shedding, but when near to Notch shedding is inhibited. 
 
7.2.3 Tspan15 may induce a distinct ADAM10 
conformation to promote N-cadherin 
shedding 
 
Extracellular regions of ADAM10 and TspanC8 have been found to mediate interactions 
with each other, but the individual TspanC8s require distinct binding domains on 
ADAM10. In this regard, Tspan15 is unique by requiring a relatively short ‘stalk’ domain 
of ADAM10 for its interaction (Noy et al., 2016). Therefore, it was hypothesised that 
preferential substrate cleavage is dictated by the particular conformational state of 
ADAM10 induced by a specific TspanC8 (Matthews et al., 2017b). In the current work, it 
was shown (Chapter 5.2) that the Tspan15/EC14 chimeric contract, which has the 
localisation properties of Tspan15 but presumably the ADAM10 interaction of Tspan14, 
was not able to cut N-cadherin, as compared to WT Tspan15. Importantly, the study 
showed that the involvement of the extracellular regions in regulating ADAM10 activity 
was analogous to that previously reported for CD151 and 31 integrin (Yauch et al., 




and the related CD9 and CD81 (Montpellier et al., 2011). This type of interaction is well 
established to be a general feature within the tetraspanin family. The analysis of the 
TspanC8-specific motifs in the main extracellular region of Tspan5 provided new insight 
into the functionality of this domain. Indeed, Saint-Pol et al identified two conserved 
motifs that not only determined the specificity of the interactions mediated by the major 
extracellular region, but also contributed to ER exit and proper folding of the tetraspanin 
(Saint-Pol et al., 2017a).  
 
In the recently proposed model by Zimmerman et al, the tetraspanins were suggested to be 
‘molecular switches’ that regulate partner protein activity via conformational change 
(Zimmerman et al., 2016). In the study, the authors used molecular dynamic simulations to 
show the effect of cholesterol removal on CD81 conformational change, from a ‘closed’ to 
‘open’ state, and its effect on the partner protein CD19 trafficking. Therefore, a similar 
strategy was employed with Tspan15 in this thesis, mutating the cholesterol-binding sites 
within the transmembrane regions. In section 5.8 it was shown that Q245E mutation of the 
Tspan15 putative cholesterol binding site impairs NEM-induced VE-cadherin cleavage, 
whereas Q245A mutation has no effect. This data indicates that the putative 
conformational change in the major extracellular region of Tspan15 could be a driving 
factor for ADAM10 proteolytic activity towards cadherins through cholesterol depletion.  
ADAM10 substrate cleavage sites vary in their position from the plasma membrane, for 
example 5 amino acids for GPVI (Gardiner et al., 2007), 9 and 10 amino acids for E- and 
N-cadherin (Uemura et al., 2006, Marambaud et al., 2002), respectively, and 15 amino 
acids for Notch (van Tetering et al., 2009). It is possible that Tspan15 constrains the 




amino acids from the plasma membrane, such as the cadherins. Similarly, Tspan5 and 
Tspan14 may constrain ADAM10 into a slightly different position for optimal cutting of 
Notch at 15 amino acids from the plasma membrane. Future experiments could investigate 
whether changing the distance of the cleavage site on N-cadherin, relative to the plasma 
membrane, affects shedding by Tspan15/ADAM10. In particular, could N-cadherin be 
converted into a Tspan5/ADAM10 or Tspan14/ADAM10 substrate by extending the cut 
site by 5 amino acids? Riethmueller et al have suggested that cleavage site localisation 
regulates substrate proteolysis (Riethmueller et al., 2016). Therefore, this experiment could 
begin to investigate if distinct modes of interactions within ADAM10/TspanC8 complexes 
indeed contribute to substrate specificity. 
 
In the present study, the regulatory function of the Tspan15 mutants on ADAM10-
mediated VE-cadherin cleavage was tested following NEM stimulation to activate 
ADAM10 (Chapter 5.7). However, NEM is thought to directly activate ADAM10 by 
alkylation of cysteine residues, so bypassing the intracellular signalling events, including 
Ca
2+
 elevation, that activate ADAM10 under physiological conditions. The cytoplasmic 
tails of Tspan15 were found not to be required for Tspan15/ADAM10 cleavage of VE-
cadherin in response to NEM, but the use of NEM may have failed to reveal the true 
importance of the Tspan15 cytoplasmic tails in inducing ADAM10 activity. A hypothetical 
model for Tspan15 triggering of ADAM10 activity is shown in Figure 7.1A. The general 
idea behind the regulation could be that growth factors, for example VEGF, induce 
signalling to activate phospholipase C (PLC), which results in elevation of intracellular 
Ca
2+
. This could activate serine/threonine kinases that phosphorylate serine and threonine 




conformational change in Tspan15, which in turn causes a conformational change in the 
ADAM10 ectodomain, hence activating it. In contrast, NEM stimulation would bypass this 
activation mechanism (Figure 7.1B). This hypothesis offers a starting point for future 
studies where the function of Tspan15 mutants could be tested by the use of 
physiologically relevant inducers of ADAM10 activity, such as growth factors.  
 
 
Figure 7.1 Speculative model of ADAM10 triggering by Tspan15 through 
intracellular signal activation [A] versus NEM stimulation [B].  [A-1] In the 
unstimulated state, ADAM10 and Tspan15 are expressed on the cell surface, but the 
constitutive sheddase activity is low. [A-2] Stimulation with growth factors or Ca
2+
 influx 
induces intracellular signalling that may lead to phosphorylation of serine/threonine 
residues in cytoplasmic tails of Tspan15. This may cause a conformational change in the 
tails that is transmitted to the transmembranes to slightly open the cholesterol-binding 
cavity and compromises cholesterol binding. [A-3] Loss of cholesterol changes the 
Tspan15 conformation from the closed to the open state. The open structure of Tspan15 
induces a conformational change in ADAM10 that relieves the partial obscuring of the 
active site by the cysteine-rich region, so allowing it to cut substrate. [B-1 and B-2] 
Stimulation of ADAM10 with the alkylating agent NEM directly activates the 
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7.3 What does the future hold for 
Tspan15? 
 
7.3.1 Tspan15 and cancer 
 
Tspan15 is substantially upregulated in cholangio carcinoma, pancreatic adenocarcinoma 
and ovarian serous cystadenocarcinoma, and Tspan15 expression is associated with poor 
patient survival in liver, kidney and pancreatic cancer (Tang et al., 2017). In addition, over-
expression of Tspan15 was recently reported in oesophageal squamous cell carcinoma, 
which was associated with metastasis and poor survival. Indeed, Tspan15 over-expression 
in oesophageal cancer cell lines increased their migration in vitro and promoted their 
tumour formation in mice. Complementary to this, Tspan15 knockdown reduced in vivo 
tumour formation (Zhang et al., 2018). The authors presented evidence suggesting that the 
E3 ubiquitin ligase BTRC interacts with Tspan15 to promote NF-κB activation and drive 
tumour progression. However, these experiments were not definitive, as explained in 
section 1.4.2. It would informative in future to test whether Tspan15 interacts specifically 
with BTRC using Tspan15-knockout cells as the ideal control. In addition, both Tspan15-
knockout and ADAM10-knockout cancer cell lines could be tested for tumour formation in 
mouse models; if both have reduced tumour formation it would suggest that Tspan15 
exerts its oncogenic effects through ADAM10. Further experiments could then investigate 
which Tspan15/ADAM10 substrates are responsible. Potential candidates include E- and 
N-cadherin, due to their roles in epithelial-to-mesenchymal transition (EMT), and the 
growth factors EGF and betacellulin, which the Tomlinson lab have shown to be 




7.3.2 Tspan15 and bacterial infection 
 
ADAM10 is activated by pore-forming bacterial toxins, including pneumolysin from 
Streptococcus pneumoniae and α-haemolysin from Staphylococcus aureus, the latter of 
which can interact with ADAM10. This causes ADAM10 cleavage of E-cadherin on 
epithelial cells and VE-cadherin on endothelial cells to weaken cell-cell junctions and 
promote bacterial spread (Berube and Bubeck Wardenburg, 2013, Powers et al., 2015, 
Thomer et al., 2016). 
 
The data in this thesis suggest that Tspan15/ADAM10 is a critical mediator of bacterial 
toxin-induced cadherin shedding, at least for E-cadherin. Indeed, an exome sequencing 
project recently implicated a Tspan15 SNP as a susceptibility factor in Streptococcus 
pneumoniae infection (Salas et al., 2018).  Future experiments could assess the Tspan15 
knockout mouse (Seipold et al., 2018) for susceptibility to bacterial infection; a prediction 
is that they will be protected to a similar extent as ADAM10-knockout mice. If so, the 
Tspan15 mAbs 1C12 and 4A4, which this thesis has shown to impair Tspan15/ADAM10 
activity towards cadherins, could be tested for a capacity to reduce bacterial infection. This 
could initially be done in A549, a lung epithelial cell line model that is used in the 
Streptococcus pneumoniae field, and our existing ADAM10- and Tspan15-knockout cells 
would provide useful confirmatory data. Ultimately a mouse infection model would be 
ideal to test the mAbs, but since they recognise mouse Tspan15 relatively weakly, a 





7.4 Concluding remarks 
 
Overall, the results presented in this thesis contribute to the broader understanding of the 
regulation of ADAM10 by the TspanC8s. Each results chapter opens new avenues for 
future research into the potential therapeutic targeting of Tspan15. This may provide novel 
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